0001213900-20-016186.txt : 20200708 0001213900-20-016186.hdr.sgml : 20200708 20200629185625 ACCESSION NUMBER: 0001213900-20-016186 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200629 DATE AS OF CHANGE: 20200629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American BriVision (Holding) Corp CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-91436 FILM NUMBER: 20998770 BUSINESS ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 510-668-0881 MAIL ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 FORMER COMPANY: FORMER CONFORMED NAME: Ecology Coatings, Inc. DATE OF NAME CHANGE: 20070711 10-Q 1 f10q0320_americanbrivision.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number 333-91436

 

American BriVision (Holding) Corporation.

(Exact name of Registrant as specified in its charter)

 

Nevada   26-0014658

State or jurisdiction of

incorporation or organization

  

IRS Employer

Identification Number

 

44370 Old Warm Springs Blvd.

Fremont, CA 94538

Tel: (510) 668-0881

(Address and telephone number of principal executive offices)

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of June 26, 2020, there were 19,488,168 shares of common stock, par value per share $0.001, issued and outstanding.

 

Securities registered pursuant to Section 12(b) of the Act: None

 

 

 

  

 

 

TABLE OF CONTENTS

 

PART I FINANCIAL INFORMATION 1
     
Item 1. Financial Statements (Unaudited) 1
  Unaudited Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 1
  Unaudited Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019 2
  Unaudited Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 3
  Unaudited Consolidated Statement of Changes in Equity (Deficit) for the Three Months Ended March 31, 2020 and 2019 4
  Notes to Unaudited Consolidated Financial Statements 5 - 31
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 32
Item 3. Quantitative and Qualitative Disclosures About Market Risk 48
Item 4. Controls and Procedures 48
     
PART II OTHER INFORMATION 49
     
Item 1. Legal Proceedings 49
Item 1A. Risk Factors 49
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49
Item 3. Defaults Upon Senior Securities 49
Item 4. Mine Safety Disclosures 49
Item 5. Other Information 49
Item 6. Exhibits 49
Signatures   50

 

  

 

 

CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” which discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” and negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements.

 

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Risks Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K and its amendment filed with the Securities and Exchange Commission (the “SEC” OR “Commission”); in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Report, and information contained in other reports that we file with the SEC. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

 

There are important factors that could cause actual results to vary materially from those described in this report as anticipated, estimated or expected, including, but not limited to: the effects of the COVID-19 outbreak, including on the demand for our products; the duration of the COVID-19 outbreak and severity of such outbreak in regions where we operate; the pace of recovery following the COVID-19 outbreak; our ability to implement cost containment and business recovery strategies; the adverse effects of the COVID-19 outbreak on our business or the market price of our ordinary shares; competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins, volatility in the securities market due to the general economic downturn; SEC regulations which affect trading in the securities of “penny stocks,” and other risks and uncertainties. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward- looking statements, even if new information becomes available in the future. Depending on the market for our stock and other conditional tests, a specific safe harbor under the Private Securities Litigation Reform Act of 1995 may be available. Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. Because we may from time to time be considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.

 

As used in this Report, the terms “we”, “us”, “our”, and “our Company” and “the Company” refer to American BriVision (Holding) Corporation and its subsidiaries, unless otherwise indicated.

 

i

 

 

EXPLANATORY NOTE

 

On May 13, 2020, American BriVision Holding Corporation (the “Company”) furnished to the Commission a report on Form 8-K to report that the Company relied on an order issued by the Commission on March 4, 2020 (Release No. 34-88318), as modified on March 25, 2020 (Release No. 34-88465) (the “Order”), and availed itself a 45-day extension for filing of its interim financial statements on Form 10-Q for the fiscal quarter ended March 31, 2020. This Form 10-Q is being filed in reliance on the Order. 

 

ii

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   March 31,
2020		   December 31,
2019		 
ASSETS  (Unaudited)     
Current Assets        
Cash and cash equivalents  $123,645   $144,295 
Restricted cash and cash equivalents   16,148    16,148 
Accounts receivable, net   110,217    163,566 
Accounts receivable - related parties, net   143,677    143,278 
Due from related parties   337,778    333,682 
Inventory, net   -    - 
Prepaid expense and other current assets   71,026    77,269 
Total Current Assets   802,491    878,238 
           
Property and equipment, net   505,408    520,930 
Operating lease right-of-use assets   449,683    524,445 
Goodwill, net   -    - 
Long-term investments   3,264,200    3,364,619 
Deferred tax assets   1,487,364    1,460,033 
Prepaid expenses – noncurrent   112,173    135,443 
Security deposits   43,890    44,103 
Total Assets  $6,665,209   $6,927,811 
           
LIABILITIES AND EQUITY          
Current Liabilities          
Accounts payable  $20,363   $23,995 
Short-term bank loans   1,910,250    1,918,500 
Short-term loan   100,000    - 
Long-term bank loans - current portion   3,332    13,403 
Notes payable   99,300    100,200 
Accrued expenses and other current liabilities   2,502,749    2,007,573 
Advance from customers   13,089    13,085 
Operating lease liabilities – current portion   282,715    304,248 
Due to related parties   715,303    425,689 
Convertible notes payable – current portion   820,000    820,000 
Convertible notes payable - related parties, current portion   1,187,500    1,187,500 
Total Current Liabilities   7,654,601    6,814,193 
           
Tenant security deposit   2,880    2,880 
Operating lease liability – noncurrent portion   179,994    235,555 
Total Liabilities   7,837,475    7,052,628 
           
Equity          
Preferred stock, $0.001 par value, 20,000,000 authorized,          
           nil shares issued and outstanding   -    - 
Common stock, $0.001 par value, 100,000,000 authorized,          
           19,488,168 and 19,478,168 shares issued and outstanding   19,488    19,478 
Additional paid-in capital   28,222,862    28,180,348 
Stock subscription receivable   (3,837,580)   (4,063,320)
Accumulated deficit   (17,098,761)   (15,851,223)
Other comprehensive income   657,302    663,753 
Treasury stock   (9,100,000)   (9,100,000)
Total Stockholders’ deficit   (1,136,689)   (150,964)
Noncontrolling interest   (35,577)   26,147 
Total Equity (Deficit)   (1,172,266)   (124,817)
           
Total Liabilities and Equity (Deficit)  $6,665,209   $6,927,811 

 

1

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

 

   March 31,
2020		   March 31,
2019		 
         
Revenues  $78,786   $212,242 
           
Cost of revenues   3,959    1,499 
           
Gross profit   74,827    210,743 
           
Operating expenses          
Selling, general and administrative expenses   1,152,889    510,803 
Research and development expenses   92,790    421,956 
Stock-based compensation   525    8,550 
Total operating expenses   1,246,204    941,309 
           
Loss from operations   (1,171,377)   (730,566)
           
Other income (expense)          
Interest income   10,720    189 
Interest expense   (131,517)   (129,886)
Rental income   5,231    (4,291)
Rental income – related parties   1,200    400 
Gain/Loss on foreign exchange changes   2    (3)
Gain/Loss on investment in equity securities   (70,411)   (66,205)
Other income (expense)   6,322    (500)
Total other expenses   (178,453)   (200,296)
           
Loss before provision income tax   (1,349,830)   (930,862)
           
Provision for income tax   (40,568)   (57,545)
           
Net loss   (1,309,262)   (873,317)
           
Net loss attributable to noncontrolling interests   (61,724)   (81,646)
           
Net loss attributed to ABVC and subsidiaries   (1,247,538)   (791,671)
Foreign currency translation adjustment   (6,451)   (86,786)
Comprehensive loss  $(1,253,989)  $(878,457)
           
Net loss per share:          
Basic and diluted  $(0.06)  $(0.05)
           
Weighted average number of common shares outstanding:          
Basic and diluted   19,484,542    14,965,665 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTH ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

 

   2020   2019 
         
Cash flows from operating activities        
Net loss  $(1,309,262)  $(873,317)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   11,174    13,940 
Stock based compensation for nonemployees   525    8,550 
Gain/Loss on investment in equity securities   70,411    66,205 
Other non-cash income and expenses   (2,333)   (553)
Deferred tax   (40,568)   (48,028)
Changes in operating assets and liabilities:          
Decrease (increase) in accounts receivable   52,950    (116,334)
Decrease (increase) in prepaid expenses and deposits   27,834    29,237 
Decrease (increase) in other receivable   -    39,005 
Decrease (increase) in due from related parties   (7,536)   1,252 
Decrease (increase) in inventory   -    797 
Increase (decrease) in accounts payable   (3,632)   (37,353)
Increase (decrease) in accrued expenses and other current liabilities   500,743    305,214 
Increase (decrease) in due to related parties   68,750    11,857 
Net cash used in operating activities   (630,944)   (599,528)
           
Cash flows from investing activities          
     Long-term equity investment   -    (17,801)
          Net cash used in investing activities   -    (17,801)
           
Cash flows from financing activities          
Issuance of common stock for acquisition   267,740    531,147 
Proceeds from short-term bank loan   -    1,000,000 
Proceeds from short-term borrowing from third parties   280,940      
Borrowings from related parties   71,688    312,660 
Repayment of borrowings from related parties   -    (460,000)
Repayment of long-term bank loans   (9,981)   (10,016)
Net cash provided by financing activities   610,387    1,373,791 
           
Effect of exchange rate changes on cash and cash equivalents   (93)   (1,809)
           
Net increase (decrease) in cash and cash equivalents   (20,650)   754,653 
           
Cash and cash equivalents          
Beginning   160,443    242,781 
Ending  $139,793   $997,434 
           
Supplemental disclosure of cash flows          
Cash paid during the year for:          
Interest expense paid  $10,446   $26,592 
Income taxes paid  $-   $1,250 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

 

   Common Stock   Stock   Additional           Treasury Stock   Non   Stockholders’ 
   Number of
shares		   Amounts  

Subscription

Receivable

   Paid-in
Capital		   Accumulated
Deficit		   Comprehensive
Income		   Number of
shares		   Amounts   controlling
Interest		   Equity
(Deficit)		 
Balance at December 31, 2018   11,885,468   $11,885   $    -   $14,983,714   $(12,209,446)  $655,851    (275,347)  $(9,100,000)  $317,610   $(5,340,386)
Issuance of common shares   1,642,291    1,642    -    692,577    -    -    -    -    -    694,219 
Effects of restructuring   4,166,530    4,167    -    (4,167)   -    -    -    -    -    - 
Stock based compensation   -    -    -    8,550    -    -    -    -    -    8,550 
Net loss for the period   -    -    -    -    (791,671)   -    -    -    (81,646)   (873,317)
Cumulative transaction adjustments   -    -    -    -    -    (15,412)   -    -    -    (15,412)
Balance at March 31, 2019   17,694,289   $17,694   $-   $15,680,674   $(13,001,117)  $640,439    (275,347)  $(9,100,000)  $235,964   $(5,526,346)

 

   Common Stock   Stock   Additional           Treasury Stock   Non   Stockholders’ 
   Number of
shares		   Amounts  

Subscription

Receivable

   Paid-in
Capital		   Accumulated
Deficit		   Comprehensive
Income		   Number of
shares		   Amounts   controlling
Interest		   Equity
(Deficit)		 
Balance at December 31, 2019   19,478,168   $19,478   $(4,063,320)  $28,180,348   $(15,851,223)  $663,753    (275,347)  $(9,100,000)  $26,147   $(124,817)
Issuance of common shares   10,000    10    225,740    41,989    -    -         -    -    267,739 
Stock based compensation                  525                             525 
Net loss for the period   -    -    -    -    (1,247,538)   -         -    (61,724)   (1,309,262)
Cumulative transaction adjustments   -    -    -    -    -    (6,451)        -    -    (6,451)
Balance at March 31, 2020   19,488,168   $19,488   $(3,837,580)  $28,222,862   $(17,098,761)  $657,302    (275,347)  $(9,100,000)  $(35,577)  $(1,172,266)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4

 

 

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.

 

Reverse Merger

 

On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock (the “Common Stock”) of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).

 

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”).

 

Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company’s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision had become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

Upon the consummation of the Share Exchange, BriVision became our wholly owned subsidiary of the Company.

 

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and explore global markets.

 

Accounting Treatment of the Reverse Merger

 

For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

 

Merger

 

On February 8, 2019, the Company, BioLite Holding, Inc. (“BioLite”), BioKey, Inc. (“BioKey”), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent (“Merger Sub 1”), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (“Merger Sub 2”) (collectively referred to as the “Parties”) completed the business combination pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.

 

Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.

 

5

 

 

BioLite Holding, Inc. (the “BioLite Holding”) was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the “BioLite BVI”), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.

 

BioLite, Inc., (the “BioLite Taiwan”) was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.

 

In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the “BioLite Share Purchase / Exchange Agreement”). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.

 

BioKey, Inc. was incorporated on August 9, 2000 in the State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.

 

Accounting Treatment of the Merger

 

The Company adopted ASC 805, “Business Combination” to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang’s common control, the transaction is accounted for as a restructuring transaction. All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding’s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

 

Fiscal Year 

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Inventory

 

Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.

 

6

 

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock Split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

Stock Reverse Split

 

On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the “Reverse Split”) of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company’s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company’s articles of incorporation (the “Amendment”) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (“FINRA”) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

 

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements” defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:

 

  ● Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.
     
  ● Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  ● Level 3 – Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.

 

The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company’s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company’s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.

 

7

 

 

Cash and Cash Equivalents 

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company’s cash and cash equivalents amounted $123,645 and $144,295, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

Restricted Cash Equivalents 

 

Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company’s restricted cash equivalents amounted $16,148 and $16,148, respectively.

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.

 

Revenue Recognition

 

During the fiscal year 2018, the Company adopted Accounting Standards Codification (“ASC”), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company’s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company’s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company’s revenue during all periods presented.

 

Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

 

The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.

 

Merchandise Sales — The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company’s products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or “transaction price,” which includes applicable reserves for variable consideration, including discounts, allowances, and returns.

 

Trade discount and allowances: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.

 

Product returns: The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company’s customers have the right to return unopened packages, subject to contractual limitations.

 

To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.

 

Collaborative Revenues — The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.

 

8

 

 

As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success.

 

The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company’s deliverables requires the use of management’s judgment. Significant factors considered in management’s evaluation of the estimated performance periods include, but are not limited to, the Company’s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.

 

(i)       Nonrefundable upfront payments

 

If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.

 

(ii)       Milestone payments

 

The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company’s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company’s obligations under the collaborative agreement with collaboration partners.

 

The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.

 

(iii)       Multiple Element Arrangements

 

The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).

 

9

 

 

The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company’s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company’s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.

 

At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.

 

(iv)       Royalties and Profit Sharing Payments

 

Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.

 

Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.

 

If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.

 

The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company’s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.

 

The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.

 

10

 

 

Property and Equipment

 

Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:

 

   Estimated Life
in Years
Buildings and leasehold improvements  5 ~ 50
Machinery and equipment  5 ~ 10
Office equipment  3 ~ 6

 

Impairment of Long-Lived Assets

 

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

 

Long-term Equity Investment 

 

The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:

 

●Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.

 

●Non-marketable cost method investments when the equity method does not apply.

 

Significant judgment is required to identify whether an impairment exists in the valuation of the Company’s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee’s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees’ revenue, costs, and discount rates. The Company’s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.

 

Other-Than-Temporary Impairment

 

The Company’s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:

 

●       Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee’s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.

 

●       Non-marketable equity investments based on the Company’s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee’s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three month ended March 31, 2020 and 2019.

 

11

 

 

Goodwill

 

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

 

The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

 

For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification (“ASC”) 730, Research and Development (“ASC 730”). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.

 

Post-retirement and post-employment benefits

 

The Company’s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the “Act”) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker’s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees’ salaries to the employees’ pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.

 

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.

 

12

 

 

The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 “Compensation-Stock Compensation” and FASB ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.

 

Beneficial Conversion Feature

 

From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.

 

Valuation of Deferred Tax Assets

 

A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.

 

13

 

 

Loss Per Share of Common Stock

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share”. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

Foreign-currency Transactions

 

For the Company’s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (“NTD”) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders’ Equity (Deficit).

 

Translation Adjustment

 

The accounts of the Company’s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (“NT$”). Such financial statements were translated into U.S. Dollars (“$” or “USD”) in accordance ASC 830, “Foreign Currency Matters”, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder’s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders’ equity (deficit).

 

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

 

14

 

 

3. COLLABORATIVE AGREEMENTS

 

Collaborative agreements with BHK

 

(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

 

  ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

 

  ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment

 

  ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment

 

  ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment

 

  ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment

 

In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.

 

In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK’s net sales related to BLI-1401-2 Products. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Co-Development Agreement.

 

(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the “BHK Collaborative Agreements”), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for “Targeting Major Depressive Disorder” (BLI-1005 Products) and BLI-1006 for “Targeting Inflammatory Bowel Disease” (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.

 

15

 

 

In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.

 

Co-Development agreement with Rgene Corporation, a related party

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 11). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company has determined to fully write off this investment based on the Company’s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene’s ability to remain in business. However, all projects that have been initiated and scheduled will be continuously managed and supported by the Company and Rgene.

 

Collaborative agreement with BioFirst Corporation, a related party

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 11).

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

 

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

 

On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the “Purchase Agreement”) with BioFirst Corporation (“BioFirst”). Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company’s common stock (the “Shares”) to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the “Total Payment”) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the “Collaborative Agreement”). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.

 

On August 5, 2019, BriVision entered into a Stock Purchase Agreement (the “Purchase Agreement”) with BioFirst Corporation (“BioFirst”). Pursuant to the Purchase Agreement, the Company issued 414,702 shares of the Company’s common stock (the “Shares”) to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst (the “Total Payment”) in connection with a sunk payments that were due to related party prior to the conversion.

 

16

 

 

4. INVENTORY

 

Inventory consists of the following:

 

   March 31,
 2020		   December 31,
 2019		 
   (Unaudited)     
Finished goods  $94,508   $94,727 
Work-in-process   20,491    20,676 
Raw materials   57,384    57,904 
Allowance for inventory valuation and obsolescence loss   (172,383)   (173,307)
Inventory, net  $-   $- 

 

5. PROPERTY AND EQUIPMENT

 

Property and equipment as of March 31, 2020 and December 31, 2019 are summarized as follows:

 

   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Land  $367,861   $371,195 
Buildings and leasehold improvements   2,224,270    2,225,386 
Machinery and equipment   986,237    987,234 
Office equipment   176,861    178,409 
    3,755,229    3,762,224 
Less: accumulated depreciation   (3,249,821)   (3,241,294)
Property and equipment, net  $505,408   $520,930 

  

Depreciation expenses were $11,174 and $13,940 for three months ended March 31, 2020 and 2019, respectively.

 

6. LONG-TERM INVESTMENTS

  

(1) The ownership percentages of each investee are listed as follows:

 

   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2020   2019   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   7.13%   7.13%  Cost Method
BioFirst Corporation   15.89%   15.89%  Equity Method
Rgene Corporation   31.61%   31.61%  Equity Method

 

(2) The extent the investee relies on the company for its business are summarized as follows:

 

Name of related party  The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Loaned from the investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs

  

(3) Long-term investment mainly consists of the following:

 

   March 31,
2020		   December 31,
2019		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,301   $7,367 
Genepharm Biotech Corporation   22,291    22,493 
BioHopeKing Corporation   1,980,361    1,998,310 
Sub total   2,009,953    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   1,254,247    1,336,449 
Rgene Corporation   -    - 
Total  $3,264,200   $3,364,619 

  

17

 

 

(a) BioFirst Corporation (the “BioFirst):

 

The Company holds an equity interest in BioFirst Corporation, (the “BioFirst”), accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 15.89% and 15.89% common stock shares of BioFirst, respectively.

 

Summarized financial information for the Company's equity method investee, BioFirst, is as follows:

 

Balance Sheet

 

   March 31,
 2020		  

December 31,
2019

 
   (Unaudited)     
Current Assets  $1,235,043   $1,350,701 
Noncurrent Assets   7,238,415    7,450,032 
Current Liabilities   2,105,938    2,060,460 
Noncurrent Liabilities   65,847    78,888 
Shareholders' Equity   6,301,673    6,661,385 

 

Statement of operation

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $12,110   $10,334 
Gross profit   1,578    1,882 
Net loss   (325,652)   (307,034)
Share of losses from investments accounted for using the equity method   (70,411)   (66,205)

 

(b) Rgene Corporation (the “Rgene”)

 

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the Company. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 31.61% and 31.61% Common Stock shares of Rgene, respectively.

  

Summarized financial information for the Company’s equity method investee, Rgene, is as follows:

 

Balance Sheets

 

   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $136.936   $82,254 
Noncurrent Assets   161,255    62,768 
Current Liabilities   462,667    312,950 
Noncurrent Liabilities   62,801    - 
Shareholders’ Deficit   (227,277)   (167,928)

 

18

 

 

Statement of operations

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $      $   
Gross Profit          
Net loss   (21,889)   (22,662)
Share  of loss from investments accounted for using the equity method   -    - 

 

(4) Disposition of long-term investment

 

During the year ended December 31, 2018, the Company sold 552,000 shares of common stock of BioHopeKing Corporation (the “BHK”) at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period.

 

On October 15, 2018 and November 2, 2018, the Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.

 

(5) Losses  on Equity Investments

 

The components of losses on equity investments for each period were as follows:

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(70,411)  $(66,205)

 

7. CONVERTIBLE NOTES PAYABLE

 

On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the “Yu and Wei Note”) in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the “Yu and Wei”), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $2.00 per share (the “Fixed Conversion Price”), subject to adjustment or (ii) 80% of the per share offering price (the “Alternative Conversion Price”) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note as of December 31, 2019 and 2018. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new “Yu and Wei” Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with “Yu and Wei”. The aggregate principal amount plus accrued interest expenses are $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company’s common stock, and warrants to purchase 192,784 shares of the Company’s common stock.

 

On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the “Keypoint Note”) in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. (“Keypoint”), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $2.00 per share (the “Fixed Conversion Price”), subject to adjustment or (ii) 80% of the per share offering price (the “Alternative Conversion Price”) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note as of December 31, 2019 and 2018. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new “Keypoint” Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with “Keypoint”. The aggregate principal amount plus accrued interest expenses are $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company’s common stock, and warrants to purchase 159,145 shares of the Company’s common stock.

19

 

 

On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the “Odaira Note”) in the aggregate principal amount of $250,000 to Yoshinobu Odaira. (“Odaira”), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $2.00 per share (the “Fixed Conversion Price”), subject to adjustment or (ii) 80% of the per share offering price (the “Alternative Conversion Price”) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaria Note as of December 31, 2019. On January 21, 2020, Odiara entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new “Odaira” Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with “Odaira”. The aggregate principal amount plus accrued interest expenses are $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company’s common stock, and warrants to purchase 154,368 shares of the Company’s common stock.

 

On May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the “KSL Note”) in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the “KSL”), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to the KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020,. At any time from the date hereof until this KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company has received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 month.

 

On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the “NEA Note”) in an aggregate principal amount of $250,000 to New Eastern Asia (the “NEA”), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note as of March 31, 2020.

 

On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the “KLS Note”) in an aggregate principal amount of $200,000 to Kuo Li Shen (the “KLS”), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses are $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company’s common stock, par value $0.001 per share, and warrants to purchase 126,530 shares of Common Stock.

 

20

 

 

On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the “C.L.L. Note”) in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the “C.L.L.”), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses are $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company’s common stock, par value $0.001 per share, and warrants to purchase 162,908 shares of Common Stock.

 

On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the “Lee Note”) in an aggregate principal amount of $250,000 to Hawlin Lee (the “Lee”), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020 , and the company has not received any indication from NEA that it wants to claim the repayment of loan for 12 month. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company’s common stock at a conversion price (the “Conversion Price”) equal to the lower of (i) $.50 per share (the “Fixed Conversion Price”), subject to adjustment, or (ii) 70% of the per share offering price (the “Alternative Conversion Price”) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the “Public Offering”), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note as of March 31, 2020.

 

As of March 31, 2020 and December 31, 2019, the aggregate carrying values of the convertible debentures were $2,007,500 and $2,007,500, respectively; and accrued convertible interest was $277,066 and $181,852, respectively.

 

Total interest expenses in connection with the above convertible note payable were $95,214 and $16,000 for the three months ended March 31, 2020 and 2019, respectively.

 

8. BANK LOANS

 

(1) Short-term bank loan consists of the following:

 

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $248,250   $250,500 
CTBC Bank   662,000    668,000 
Cathay Bank   1,000,000    1,000,000 
Total  $1,910,250   $1,918,500 

 

Cathay United Bank

 

On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the “Cathay United Loan Agreement”) in an amount of NT$7,500,000, equivalent to $248,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $248,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which is due on September 6, 2020. As of March 31, 2020 and 2019, the effective interest rates per annum were 2.22%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company’s chairman.

 

Interest expenses were $1,378 and $1,330 for the three months ended March 31, 2020 and 2019, respectively.

 

21

 

 

CTBC Bank

 

On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the “CTBC Loan Agreements”) in an amount of NT$10,000,000, equivalent to $331,000, and NT$10,000,000, equivalent to $331,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on July 19, 2020. The loan balances bear interest at a fixed rate of 1.63% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan is also personal guaranteed by the Company’s chairman and BioFirst.

 

Interest expenses were $2,755 and $2,604 for the three months ended March 31, 2020 and 2019, respectively.

 

Cathay Bank

 

On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the “Bank”) pursuant to a business loan agreement (the “Loan Agreement”) entered by and between the Company and Bank on January 8, 2019 and a promissory note (the “Note”) executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the “Maturity Date”) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the “Regular Interest Rate”) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the “Index”) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate. After the completion of Merger, the Company had updated relevant documents with the state of California and is working with the Bank to revise its internal records and reviewing the Company’s request for loan extension.

 

In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the “Guaranty”) to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned subsidiary of the Company effective by operation of law on or about February 5, 2019.

 

In addition, on January 8, 2019, each of the Company and BriVision, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the “Security Agreement”) to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BriVision (each, a “Grantor”, and collectively, the “Grantors”) granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020.

 

Interest expenses were $13,740 and $9,527 for the three months ended March 31, 2020 and 2019, respectively.

 

(2) Long-term bank loan consists of the following:

 

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $3,332   $13,403 
Less: current portion of long-term bank loan   (3,332)   (13,403)
Total  $-   $- 

 

On April 30, 2010, BioLite Taiwan entered a seven-year bank loan of NT$8,900,000, equivalent to $288,360, with Cathay United Bank. The term started April 30, 2010 with maturity date at April 30, 2017. On April 30, 2017, BioLite Taiwan extended the original loan agreement for additional three years with the new maturity date at April 30, 2020. The loan balance bears interest at a floating rate of prime rate plus variable rates from 0.77% to 1.17%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. As of March 31, 2020 and 2019, the actual interest rates per annum were 2.24%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company’s chairman.

 

Interest expenses were $56 and $284 for the three months ended March 31, 2020 and 2019, respectively. 

 

22

 

 

9. NOTES PAYABLE

 

On December 27, 2018, BioLite Taiwan issued a promissory note of NT$450,000, equivalent to $14,715, to Taipei Veterans General Hospital to repay the clinical experiment costs. The note has been paid in full on January 2, 2019.

 

On March 27, 2018, BioLite Taiwan and two individuals entered into a promissory note, (the “Hsu and Chow Promissory Note”), for borrowing an aggregate amount of NT$4,660,000, equivalent to $155,800, for the period from March 27, 2018 to June 26, 2018. On September 26, 2018, BioLite Taiwan extended the original loan agreement through December 26, 2018. On September 26, 2019, BioLite Taiwan renewed and amended the contract with the “Hsu” only and extend the maturity date to December 26, 2019. The principal of the Hsu new Promissory Note bears interest at 13.6224% per annum. This Note was secured by common stock shares of ABVC and was also personal guaranteed by the Chairman of BioLite Taiwan. Interest expense was $5,269 and $5,085 for the three months ended March 31, 2020 and 2019, respectively.

 

In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $99,300, for working capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of the unsecured loans. Interest expense was $2,988 and $2,916 for the three months ended March 31, 2020 and 2019, respectively.

 

10. SHORT-TERM LOAN

 

On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020.

  

11. RELATED PARTIES TRANSACTIONS 

 

The related parties of the company with whom transactions are reported in these financial statements are as follows:

  

Name of entity or Individual  Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)  Entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)  Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the “Yuangene”)  Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)  Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang  Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)  The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)  Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)  Director of the Company
GenePharm Inc. (the “GenePharm”)  Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)  Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)  Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)  Shareholder of the Company
Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the “Jiangs”)  Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst
 
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc.
 
Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
 
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.
 
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)   An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc

 

23

 

 

Accounts receivable – related parties

 

Accounts receivable due from related parties consisted of the following as of the periods indicated:

 

 

   March 31,   December 31, 
   2020   2019 
GenePharm Inc.  $142,225   $142,225 
Rgene   1,052    1,053 
Amkey   400    - 
Total  $143,677   $143,278 

 

Due from related parties

 

Amount due from related parties consisted of the following as of the periods indicated:

 

   March 31,   December 31, 
   2020   2019 
Rgene  $36,903   $36,332 
AsiaGene   3,645    3,578 
BioFirst   141,650    137,151 
BioFirst (Australia)   40,000    40,000 
BioHopeKing Corporation   114,905    115,946 
LBG USA   675    675 
Total  $337,778   $333,682 

 

(1) As of March 31, 2020, and December 31, 2019, the Company has advanced an aggregate amount of $36,903 and $36,332 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the contract has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $28,953 and $29,194, and accrued interest was $7,950 and $7,138, respectively.

 

(2) On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,310, to meet its working capital needs.  Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the agreement has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $3,310 and $3,340, and accrued interest was $335 and $238, respectively.

 

(3) On July 12, 2019, the Company had an aggregate amount of loan with BioFirst of $150,000 to meet its working capital needs, pursuant to which the interest bears at 12% per annum. The Company paid back $21,317 in 2019. The remaining loan balance was $128,683 as of December 31, 2019. This loan is matured on July 11, 2020 and bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $128,683, and accrued interest was $12,967 and $8,468, respectively.

 

(4) On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and December 31, 2019, the outstanding loan balances were $40,000.

 

(5) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2020 and 2019, due from related parties was $114,905 and $115,946, respectively.

 

(6) On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and 2019, the outstanding advance balances were $675.

  

24

 

 

Due to related parties

 

Amount due to related parties consisted of the following as of the periods indicated:

 

   March 31,   December  31, 
   2020   2019 
LionGene Corporation  $10,481   $10,275 
BioFirst Corporation   218,261    24,182 
AsiaGene   24,017    24,017 
YuanGene   9,205    9,205 
The Jiangs   58,503    40,031 
Kimho   55,000    21,500 
Euro Asia   12,000    12,000 
Due to shareholders   233,832    284,479 
Due to employees   94,004    - 
Total  $715,303   $425,689 

 

(1) In September, 2018, BioLite Taiwan has borrowed an aggregate amount of NT$2,950,000, equivalent to $94,990, from LION ARTS for working capital purpose. These loans bear interest at fixed rates at 12% per annum with various maturity dates through April 14, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert all of the remaining balance of $97,864 to 13,981 shares of the Company’s common stock at a conversion price of $7.00 per share (see Note 11). As such, no balance is due as of March 31, 2020 and December 31, 2019.

 

(2)

In November 2018, BioLite Taiwan has borrowed an aggregate amount of NT$13,295,000, equivalent to $430,817 from LionGene for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the all of remaining balance of $428,099, to 61,157 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

On October 15, 2019, LionGene has advanced funds to the Company for working capital purpose in an aggregate amount of NTD $300,000, equivalent to $9,930, The advances bear 1% interest rate and as of March 31, 2020, the accrued interest rate is $551.

 

(3)

On January 26, 2017, BriVision and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. On February 2, 2019, BriVision and BioFirst agreed to extend the remaining loan balance of $693,000 for one year matured on February 1, 2020. Under the terms of the loan agreement, the loan bears interest at 12% per annum. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

Since 2017, BioLite Taiwan and BioFirst entered into several loan agreements for an aggregate amount of NT$19,430,000, equivalent to $625,646, to meet its working capital needs. Under the terms of the loan agreements, the loans bear interest at 12% per annum. The term of the loans has various maturity dates through May 27, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $625,646 to 89,378 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

Since 2017, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

On April 12, 2017, BioLite BVI and BioFirst entered into a loan agreement for NT$30,000,000, equivalent to $987,134 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). BioLite BVI and BioFirst extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2019. On May 12, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company’s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.

 

Since 2019, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2020, the aggregate amount of outstanding balance and accrued interest is $218,261.

 

(4)

In September 2017, AsiaGene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

Since 2018, AsiaGene has advanced the Company an aggregate amount of $24,017 for working capital purpose. This advance bears 0% interest rate and is due on demand.

25

 

 

(5)

On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 19, 2019. On January 20, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on January 19, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $50,000 to 7,143 shares of the Company’s common stock at a conversion price of $7.00 per share. 

 

In January 2018, YuanGene Corporation has advanced an aggregate amount of $42,690 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company’s common stock at a conversion price of $7.00 per share. 

 

Since 2018, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.

 

(6)

Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company’s common stock at a conversion price of $7.00 per share.

 

As of March 31, 2020, the Jiangs has advanced an aggregate amount of $58,503, to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

 

(7) On July 2, 2019, the Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of March 31, 2020 and December 31, 2019, the outstanding services charge was $55,000 and $21,500, respectively.

 

(8) As of March 31, 2020 and December 31, 2019, Euro Asia has advanced of $12,000 and $12,000, respectively, to the Company for working capital purpose. The advances bear 0% interest rate.

 

(9) During the three months ended March 31, 2020, for working capital purpose, the Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum. As of March 31, 2020 and 2019, the aggregate amount of outstanding advance balance and accrued interest was $233,832 and $284,479, respectively.

 

(10) During the three months ended March 31, 2020, the Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of March 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $22,316 as of March 31, 2020. This loan bears zero interest rate and is due on demand.

 

12. EQUITY

 

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

 

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People’s Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s Common Stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s Common Stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

26

 

 

On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the “Forward Stock Split”) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company’s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s Common Stock, par value $0.001 (the “Offering”) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company’s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company’s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).

 

On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (“FINRA”). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company’s common stock were exchanged for 17,693,625 shares of the Company’s Common Stock. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

 

On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s Common Stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $28,800 and $5,400 for the years ended December 31, 2018 and 2017, respectively. On March 28, 2018, the Company issued 4,828 shares of the Company’s common stock at $1.60 per share in a total of $7,725 to Kameyama in connection with this consulting agreement.

 

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. And the Company entered into a service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $60,000 in connection with the terms in the Euro-Asia Agreement, respectively. On March 28, 2018, the Company issued 50,000 shares of the Company’s common stock at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.

 

On January 1, 2017, Kimho Consultants Co., Ltd. And the Company entered into a service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $90,000 in connection with the terms in the Kimho Agreement, respectively. On March 28, 2018, the Company issued 75,000 shares of the Company’s common stock at $1.60 per share in a total of $120,000 to Kimho in connection with the Kimho Agreement.

 

Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

 

On March 28, 2018, the Company also issued an aggregate of 50,000 shares of the Company’s common stock at $1.60 per share for salaries in a total of $80,000 to three officers.

 

27

 

 

On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.

 

As stated in Note 10, in August 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of “due to related parties” in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company’s common stock at a price of $7.00 per share.

 

   Amount of Debt
Converted		   Number of Shares
Issued		 
         
Lion Arts Promotion Inc   97,864    13,981 
LionGene Corporation   428,099    61,157 
BioFirst Corporation   2,902,911    414,702 
AsiaGene Corporationoo   160,000    22,858 
YuanGene Corporation   92,690    13,242 
The Jiangs   1,190,776    170,111 
Total  $4,872,340   $696,051 

 

On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company’s Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.

 

13. LOSS PER SHARE

 

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31, 2020 and 2019. 

 

   For the Three Month Ended 
   March 31,
2020		   March 31,
2019		 
Numerator:        
Net loss attributable to ABVC’s common stockholders  $(1,247,538)  $(791,671)
           
Denominator:          
Weighted-average shares outstanding:          
Weighted-average shares outstanding - Basic   19,484,542    14,965,665 
Stock options        - 
Weighted-average shares outstanding - Diluted   19,484,542    14,965,665 
           
Loss per share          
-Basic  $(0.06)  $(0.05)
-Diluted  $(0.06)  $(0.05)

 

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.

 

14. LEASE

 

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 840.

 

The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:

 

  ● Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.

 

  ● Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.

 

28

 

 

  ● Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.

 

  ● Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.

 

  ● Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.

 

The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months as of January 1, 2019. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities.

 

The adoption of ASC 842 had a substantial impact on the Company’s consolidated balance sheets. The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $577,830 and operating lease liabilities of $598,937 comprised of $301,105 of current operating lease liabilities and $297,832 of non-current operating lease liabilities on the consolidated balance sheet as of January 1, 2019. The adoption of ASC 842 also resulted in a cumulative-effect adjustment of $(21,107) to the opening balance of accumulated deficit.

 

In addition, the adoption of the standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

 

The Company has no finance leases. The Company’s leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company’s operating leases have remaining lease terms of up to approximately four years.

 

ASSETS  March 31,
2020		   December 31,
2019		 
Operating lease right-of-use assets  $449,683   $524,445 
LIABILITIES          
Operating lease liabilities (current)  282,715   304,248 
Operating lease liabilities (noncurrent)  179,994   235,555 

 

Supplemental Information

 

The following provides details of the Company’s lease expenses:

 

   Three Months Ended
March 31,		 
   2020   2019 
Operating lease expenses  $77,527   $73,802 

 

Other information related to leases is presented below:

 

   Three Months Ended
March 31,		 
   2020   2019 
Cash paid for amounts included in the measurement of operating lease liabilities  $77,527   $73,802 

 

   March 31,
2020		   December 31,
2019		 
Weighted Average Remaining Lease Term:        
Operating leases    2.79 years     3.08 years 
           
Weighted Average Discount Rate:          
Operating leases   1.21%   0.55%

 

29

 

 

The minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as follows:

 

    Operating leases  
2020 ((excluding the three months ended March 31, 2020)   $ 232,438  
2021     92,101  
2022     49,805  
2023     49,805  
2024      49,805  
Total future minimum lease payments, undiscounted     473,954  
Less: Imputed interest     11,245  
Present value of future minimum lease payments   $ 462,709  

  

15. BUSINESS COMBINATION

 

On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, “Business Combination” to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey’s results of operations were included in the Company’s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:

 

Purchase consideration:    
Common Stock (*)  $44,341,847 
Allocation of the purchase price:     
Cash and cash equivalents  $531,147 
Accounts receivable, net   188,550 
Property and equipment, net   56,075 
Operating lease right-of-use assets   485,684 
Security deposits   10,440 
Total assets acquired   1,271,896 
Accounts payable   (56,204)
Accrued expenses and other current liabilities   (251,335)
Operating lease liability   (267,256)
Tenant security deposit   (2,880)
Total liabilities assumed   (577,675)
Total net assets acquired   694,221 
Goodwill as a result of the Merger  $43,647,626 

 

* 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.

 

On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company’s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.

 

30

 

 

16. SUBSEQUENT EVENTS

 

On April 5, 2020, the Company entered into certain exchange agreements separately with certain U.S. and non-U.S. holders of certain convertible promissory notes issued by the Company on January 21, 2020. The non-U.S. holders are qualified as “non-U.S. Persons” as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”). The U.S. holder is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D. Pursuant to the Exchange Agreements, the holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $931,584.07, and the Company agreed to issue to the holders an aggregate of 506,297 shares of the Company’s common stock, par value $0.001 per share, and warrants to purchase 506,297 shares of Common Stock.

 

On April 20, 2020, the Company entered into certain exchange agreements separately with additional non-U.S. holders of certain convertible promissory notes issued by the Company on August 28 and September 4, 2019. The non-U.S. holders are qualified as “non-U.S. Persons” as defined in Regulation S of the Securities Act. Pursuant to the Exchange Agreements, the holders agreed to deliver such notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $515,195.84, and the Company agreed to issue to the holders an aggregate of 289,438 shares of the Company’s common stock, par value $0.001 per, and warrants to purchase 289,438 shares of Common Stock.

 

In May 2020, the Company received capital contributions of approximately $1,602,040 in cash from 40 investors through private placements of the sale of certain number of Common Stocks for the purchase price of $2.25 per share of Common Stock and a free warrant attaches with each Common stock that was purchased. The exercise price of the warrant will be at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants.

 

The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2020 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”  

 

31

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our unaudited consolidated financial statements for the three months ended March 31, 2020 and 2019, and notes thereto contained elsewhere in this Report, our annual report on Form 10-K for the twelve months ended December 31, 2019 and 2018. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements.”

 

Overview

 

Our Business

 

American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.

 

On February 8, 2019, the Company, BioLite Holding, Inc. (“BioLite”), BioKey, Inc. (“BioKey”), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent (“Merger Sub 1”), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (“Merger Sub 2”) (collectively referred to as the “Parties”) completed the business combination pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.

 

Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.

 

BioLite Holding, Inc. (the “BioLite Holding”) was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the “BioLite BVI”), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.

 

BioLite, Inc., (the “BioLite Taiwan”) was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.

 

In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the “BioLite Share Purchase / Exchange Agreement”). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.

 

32

 

 

BioKey, Inc. was incorporated on August 9, 2000 in the State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.

 

Business Objectives

 

The Company is operating its core business based on 2 main activities that can generate current and future revenues, merchandise sales and collaborative revenues. The following are examples of both how/when the Company recognizes revenue based on the types of payments the Company receives and examples of collaborative agreement that we have executed with strategic partners.

 

Merchandise Sales — The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company’s products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or “transaction price,” which includes applicable reserves for variable consideration, including discounts, allowances, and returns.

 

Trade discount and allowances: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.

 

Product returns: The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company’s customers have the right to return unopened packages, subject to contractual limitations.

 

To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.

 

Collaborative Revenues — The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.

 

As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success.

 

The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company’s deliverables requires the use of management’s judgment. Significant factors considered in management’s evaluation of the estimated performance periods include, but are not limited to, the Company’s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.

 

33

 

 

(i) Nonrefundable upfront payments

 

If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.

 

(ii) Milestone payments

 

The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company’s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company’s obligations under the collaborative agreement with collaboration partners.

 

The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.

 

(iii) Multiple Element Arrangements

 

The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).

 

34

 

 

The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company’s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company’s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.

 

At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.

 

(iv) Royalties and Profit Sharing Payments

 

Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.

 

Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.

 

If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.

 

The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company’s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.

 

35

 

 

The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.

 

Collaborative agreements with BHK

 

(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

 

  ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

 

  ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment

 

  ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment

 

  ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment

 

  ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment

 

In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.

 

In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK’s net sales related to BLI-1401-2 Products. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Co-Development Agreement.

 

(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the “BHK Collaborative Agreements”), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for “Targeting Major Depressive Disorder” (BLI-1005 Products) and BLI-1006 for “Targeting Inflammatory Bowel Disease” (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

36

 

 

In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.

 

In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.

 

Co-Development agreement with Rgene Corporation, a related party

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 11). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company has determined to fully write off this investment based on the Company’s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene’s ability to remain in business. However, all projects that have been initiated and scheduled will be continuously managed and supported by the Company and Rgene.

 

Collaborative agreement with BioFirst Corporation, a related party

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 11).

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

 

37

 

 

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

 

On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the “Purchase Agreement”) with BioFirst Corporation (“BioFirst”). Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company’s common stock (the “Shares”) to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the “Total Payment”) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the “Collaborative Agreement”). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.

 

On August 5, 2019, BriVision entered into a Stock Purchase Agreement (the “Purchase Agreement”) with BioFirst Corporation (“BioFirst”). Pursuant to the Purchase Agreement, the Company issued 414,702 shares of the Company’s common stock (the “Shares”) to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst (the “Total Payment”) in connection with a payment that were due to related party prior to the conversion.

 

Seasonality of Business

 

Our CDMO business is affected by seasonal trends, with higher levels of sales in our first, second and third quarters. These trends primarily result from the timing of seasonal activities from customers and holiday periods slow donw in the forth quarter.

 

Global Economic Uncertainty

 

Due to the COVID-19, our revenue of the first quarter had been impacted significantly and with a continue of shelter-in-place order during the second quarter, our business’s overall revenue stream may be impacted further until the restrictions of COVID-19 can be released, so the company can start operating normally.

 

Summary of Critical Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

 

Fiscal Year 

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

38

 

 

Inventory

 

Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock Split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

Stock Reverse Split

 

On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the “Reverse Split”) of both the authorized Common Stock and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company’s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company’s articles of incorporation (the “Amendment”) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (“FINRA”) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

 

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements” defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:

 

  ● Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.
     
  ● Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  ● Level 3 – Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.

 

39

 

 

The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company’s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company’s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.

 

Cash and Cash Equivalents 

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company’s cash and cash equivalents amounted $123,645 and $144,295, respectively. Some of the Company’s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

Restricted Cash Equivalents 

 

Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company’s restricted cash equivalents amounted $16,148 and $16,148, respectively.

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.

 

Revenue Recognition

 

During the fiscal year 2018, the Company adopted Accounting Standards Codification (“ASC”), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company’s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company’s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company’s revenue during all periods presented.

 

Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

 

40

 

 

Property and Equipment

 

Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:

 

    Estimated Life
in Years
Buildings and leasehold improvements   5 ~ 50
Machinery and equipment   5 ~ 10
Office equipment   3 ~ 6

 

Impairment of Long-Lived Assets

 

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

 

Long-term Equity Investment 

 

The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:

 

  ● Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.

 

  ● Non-marketable cost method investments when the equity method does not apply.

 

Significant judgment is required to identify whether an impairment exists in the valuation of the Company’s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee’s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees’ revenue, costs, and discount rates. The Company’s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.

 

41

 

 

Other-Than-Temporary Impairment

 

The Company’s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:

 

●       Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee’s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.

 

●       Non-marketable equity investments based on the Company’s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee’s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three months ended March 31, 2020 and 2019.

 

Goodwill

 

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

 

The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company’s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

 

42

 

 

For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification (“ASC”) 730, Research and Development (“ASC 730”). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.

 

Post-retirement and post-employment benefits

 

The Company’s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the “Act”) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker’s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees’ salaries to the employees’ pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.

 

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.

 

The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 “Compensation-Stock Compensation” and FASB ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.

 

Beneficial Conversion Feature

 

From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

43

 

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.

 

Valuation of Deferred Tax Assets

 

A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.

 

Loss Per Share of Common Stock

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share”. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

44

 

 

Foreign-currency Transactions

 

For the Company’s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (“NTD”) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders’ Equity (Deficit).

 

Translation Adjustment

 

The accounts of the Company’s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (“NT$”). Such financial statements were translated into U.S. Dollars (“$” or “USD”) in accordance ASC 830, “Foreign Currency Matters”, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder’s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders’ equity (deficit).

 

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

 

Estimates and Assumptions

 

In preparing our consolidated financial statements, we use estimates and assumptions that affect the reported amounts and disclosures. Our estimates are often based on complex judgments, probabilities and assumptions that we believe to be reasonable, but that are inherently uncertain and unpredictable. We are also subject to other risks and uncertainties that may cause actual results to differ from estimated amounts.

 

45

 

 

Results of Operations — Three Months Ended March 31, 2020 Compared to Three Months Ended March 31, 2019.

 

The following table presents, for the three months indicated, our consolidated statements of operations information.

 

    March 31,
2020		     March 31,
2019		  
             
Revenues   $ 78,786     $ 212,242  
                 
Cost of revenues     3,959       1,499  
                 
Gross profit     74,827       210,743  
                 
Operating expenses                
Selling, general and administrative expenses     1,152,889       510,803  
Research and development expenses     92,790       421,956  
Stock-based compensation     525       8,550  
Total operating expenses     1,246,204       941,309  
                 
Loss from operations     (1,171,377 )     (730,566 )
                 
Other income (expense)                
Interest income     10,720       189  
Interest expense     (131,517 )     (129,886 )
Rental income     5,231       (4,291 )
Rental income – related parties     1,200       400  
Gain/Loss on foreign exchange changes     2       (3 )
Gain/Loss on investment in equity securities     (70,411 )     (66,205 )
Other income (expense)     6,322       (500 )
Total other expenses     (178,453 )     (200,296 )
                 
Loss before provision income tax     (1,349,830 )     (930,862 )
                 
Provision for income tax     (40,568 )     (57,545 )
                 
Net loss     (1,309,262 )     (873,317 )
                 
Net loss attributable to noncontrolling interests     (61,724 )     (81,646 )
                 
Net loss attributed to ABVC and subsidiaries     (1,247,538 )     (791,671 )
Foreign currency translation adjustment     (6,451 )     (86,786 )
Comprehensive Income (Loss)   $  (1,253,989 )   $  (878,457 )
                 
Net loss per share:                
Basic and diluted   $ (0.06 )   $ (0.05 )
                 
Weighted average number of common shares outstanding:                
Basic and diluted     19,484,542       14,965,665  

 

Revenues. We generated $78,786 and $212,242 in revenues for the three months ended March 31, 2020 and 2019, respectively; and incurred $3,959 and $1,499 in cost of sales for the three months ended March 31, 2020 and 2019, respectively. The decrease in revenues was mainly due to the impact of COVID-19 onto our CDMO business sector.

  

Operating Expenses.  Our operating expenses have increased by $304,895, or 32%, to $1,246,204 for the three months ended March 31, 2020 from $941,309 for the three months ended March 31, 2019. Such increase in operating expenses was mainly due to the increase in selling, general and administrative expenses.

 

Our selling, general and administrative expenses increased by $642,086, or 126%, mainly due to the increase in salary expenses.

 

Our research and development expenses decreased by $329,167 or approximately 78% primarily because there were no major milestone payments during the three months ended March 31, 2020.

  

46

 

 

Other Income (Expense). Our other expense was $178,453 for the three months ended March 31, 2020 as compared to $200,296 for the three months ended March 31, 2019, representing an increase of $21,843, or (11%). The increase was principally caused by the increase in overall interest income, rental incomes, and other income, partially offset by the increase in interest expense and loss on investment in equity securities.

 

Interest income was $10,720 for the three months ended March 31, 2020 as compared to $189 for the three months ended March 31, 2019. The increase of $10,531, or approximately 5,572%, was primarily due to the interest income for various related-party loans.

 

Rental income, including related parties, was $6,431 for the three months ended March 31, 2020 as compared to ($3,891) for the three months ended March 31, 2019. The increase of $10,322, or approximately 265%, was primarily contributed by our CDMO’s customers for their dedicatedly operational needs.

 

Other income was $6,322 for the three months ended March 31, 2020 as compared to ($500) for the three months ended March 31, 2019. The increase of $6,822, or approximately 1,364%, was primarily due to the adjustments of income tax regarding salaries.

 

Loss on investment in equity securities was $70,411 for the three months ended March 31, 2020 as compared to $66,205 for the three months ended March 31, 2019, representing an increase of $4,206, or 6%. The increase in loss on investment in equity securities was mainly due to less share of losses from investments in BioFirst accounted for using the equity method during the three months ended March 31, 2020.

 

Net Loss. As a result of the above factors, our net loss was $1,309,262 for the three months ended March 31, 2020 compared to $873,317 for the three months ended March 31, 2019, representing an increase of $435,945, or 50%.

 

Liquidity and Capital Resources

 

Working Capital

 

    As of 
March 31,
2020		     As of December 31,
2019		  
      (Unaudited)    
Current Assets   $ 802,491     $ 878,238  
Current Liabilities   $ 7,654,601     $ 6,814,193  
Working Capital (deficit)   $ (6,852,110 )   $ (5,935,955 )

 

Cash Flow from Operating Activities

 

During the three months ended March 31, 2020 and 2019, the net cash used in operating activities were $630,944 and $599,528, respectively. The increase in the amount used in operating activities of $31,416 was primarily due to the increased net loss and decrease in other receivable, partially offset by the increase in accrued expense and other current liabilities, and increase in due to related parties during the three months ended March 31, 2020.

 

Cash Flow from Investing Activities

 

During the three months ended March 31, 2020, the net cash used in investing activities was $0, compared to the net cash used in investing activities was $17,801 for the three months ended March 31, 2019. The increase in net cash provided by investing activities in the amount of $17,801 was primarily because there were no payments from long-term investment during the three months ended March 31, 2020.

 

Cash Flow from Financing Activities

 

During the three months ended March 31, 2020 and 2019, the net cash provided by financing activities were $610,387 and $1,373,791, respectively. The net cash provided by financing activities decreased by $763,404 during the compared periods mainly because we obtained less funding from short-term bank loans and related parties during the three months ended March 31, 2020.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2020, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

 

47

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.

 

Based on their evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2020. 

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures is also based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Management Plan to Remediate Material Weaknesses 

 

We expect to implement the following measures in 2020 to continue to remediate the material weaknesses identified:

 

●To continue providing applicable training for our financial and accounting staff to enhance their understanding of U.S. GAAP and internal control over financial reporting.

 

●To expand involvement of qualified external consultants to supervise and review our financial reporting process.

 

Changes in Internal Control Over Financial Reporting 

 

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal year to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

 

48

 

 

PART II. - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

Nil. 

 

ITEM 1A. RISK FACTORS.

 

As of the date of this Report, there have been no material changes to the risk factors disclosed in our annual report on Form 10-K filed with the SEC on May 15, 2020.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

Nil.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

  

ITEM 6. EXHIBITS

 

The following exhibits are filed herewith:

 

        Incorporated by reference to   Filed
Exhibit No.   Description   Form   Exhibit   Filing Date   herewith
                     
2.1   Share Exchange Agreement, dated February 8, 2016   8-K   10.1   February 16, 2016    
3.1   Articles of Incorporation of the Company   SB-2   3.01   June 28, 2002    
3.2   Bylaws of the Company   SB-2   3.01   June 28, 2002    
3.3   Certificate of Amendment to Articles of Incorporation   8-K   4.1   March 28, 2016    
3.4   Certificate of Amendment to Articles of Incorporation   S-1   3.4   September 13, 2016    
3.5   Certificate of Amendment to Articles of Incorporation   8-K   3.1   April 7, 2020    
4.1   Form of Warrant   8-K   4.1   April 24, 2020    
10.1   Collaboration Agreement dated December 29, 2015   8-K   10.2   February 16, 2016    
10.2   Collaborative Agreement and Milestone Payment Agreement dated June 9, 2016   8-K   99.1   June 9, 2016    
10.3   Employment Agreement with Kira Huang   10-K   10.3   January 12, 2017    
10.4   Addendum to the Collaboration Agreement dated January 12, 2017   8-K   99.1   February 22, 2017    
10.5   Collaboration Agreement with BioFirst dated July 24, 2017   8-K   10.1   July 24, 2017    
10.6   Co-Deve Agreement with Rgene dated May 26, 2017   8-K   99.1   May 39, 2017    
10.7   Employment Agreement with Dr. Howard Doong   8-K   10.1   September 20, 2017    
10.8   Employment Agreement with Dr. Chi-Hsin Richard King   8-K   10.3   September 20, 2017    
10.9   Employment Agreement with Chihliang An   10-K   10.9   May 15, 2020    
10.10   Business Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation   8-K   10.1   February 1, 2019    
10.11   Promissory Note entered by American BriVision (Holding) Corporation   8-K   10.2   February 1, 2019    
10.12   Form of Commercial Security Agreement   8-K   10.3   February 1, 2019    
10.13   Form of Exchange Agreement entered into by and between the Company and non-US person   8-K   10.1   April 24, 2020    
10.14   Form of Exchange Agreement entered into by and between the Company and non-US person   8-K   10.2   April 14, 2020    
10.15   Form of Securities Purchase Agreement entered into by and between the Company and U.S. investors   10-K   10.15   May 15, 2020    
10.16   Form of Securities Purchase Agreement entered into by and between the Company and non-U.S. investors   10-K   10.16   May 15, 2020    
14.1   Code of Ethics   S-1/A   14.1   November 14, 2016    
21.1   List of subsidiaries   S-1   21.1   September 13, 2016    
31.1   Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               X
31.2   Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               X
32.1   Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.               X
32.2   Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.               X

49

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  American BriVision (Holding) Corporation
     
Dated: June 29, 2020 By: /s/ Howard Doong 
    Howard Doong
    Chief Executive Officer
(Principal Executive Officer)

 

 

50

 

 

 EX-31.1 2 f10q0320ex31-1_american.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Howard Doong, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of American BriVision (Holding) Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4 The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5 The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
   
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 29, 2020 By: /s/ Howard Doong
   

Howard Doong

Chief Executive Officer

(Principal Executive Officer)

 

 EX-31.2 3 f10q0320ex31-2_american.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Chihliang An, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of American BriVision (Holding) Corporation;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4 The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5 The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
   
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 29, 2020 By: /s/ Chihliang An
   

Chihliang An

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 EX-32.1 4 f10q0320ex32-1_american.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

SECTION 906 OF SARBANES-OXLEY ACT OF 2002

 

I, Howard Doong, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

1.The Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of American BriVision (Holding) Corporation (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 29, 2020 By: /s/ Howard Doong
    Howard Doong
   

Chief Executive Officer

(Principal Executive Officer)

 

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

 EX-32.2 5 f10q0320ex32-2_american.htm CERTIFICATION

EXHIBIT 32.2

 

Certification Pursuant To

Section 906 of Sarbanes-Oxley Act of 2002

 

I, Chihliang An, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

1.The Quarterly Report on Form 10-Q for the three months ended March 31, 2020 of American BriVision (Holding) Corporation (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 29, 2020 By: /s/ Chihliang An
    Chihliang An
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

 

 EX-101.INS 6 abvcd-20200331.xml XBRL INSTANCE FILE 0001173313 2020-03-31 0001173313 abvcd:CodevelopmentagreementMember 2017-09-30 0001173313 abvcd:CodevelopmentagreementMember 2017-05-26 0001173313 abvcd:BioFirstCorporationMember 2020-03-31 0001173313 2020-01-01 2020-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2018-09-01 2018-09-30 0001173313 abvcd:ShareExchangeAgreementThreeMember 2016-02-04 2016-02-08 0001173313 abvcd:CodevelopmentagreementMember 2017-05-01 2017-05-26 0001173313 abvcd:BioFirstCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:RgeneCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-05-01 2018-05-09 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-05-09 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2020-03-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2020-01-01 2020-03-31 0001173313 abvcd:BioFirstAustraliaMember 2020-01-01 2020-03-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-06-22 2018-06-27 0001173313 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001173313 us-gaap:CommonStockMember 2020-03-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001173313 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001173313 us-gaap:RetainedEarningsMember 2020-03-31 0001173313 abvcd:CodevelopmentagreementMember 2017-09-01 2017-09-30 0001173313 abvcd:CodevelopmentagreementMember 2018-12-01 2018-12-24 0001173313 abvcd:RgeneCorporationMember 2020-03-31 0001173313 abvcd:CodevelopmentagreementMember 2017-12-31 0001173313 abvcd:BuildingsAndLeaseholdImprovementsMember srt:MinimumMember 2020-01-01 2020-03-31 0001173313 abvcd:BuildingsAndLeaseholdImprovementsMember srt:MaximumMember 2020-01-01 2020-03-31 0001173313 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2020-01-01 2020-03-31 0001173313 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2020-01-01 2020-03-31 0001173313 us-gaap:OfficeEquipmentMember srt:MinimumMember 2020-01-01 2020-03-31 0001173313 us-gaap:OfficeEquipmentMember srt:MaximumMember 2020-01-01 2020-03-31 0001173313 2019-03-05 2019-03-12 0001173313 2019-04-25 2019-05-03 0001173313 2018-12-31 0001173313 us-gaap:LandMember 2020-03-31 0001173313 abvcd:BuildingsAndLeaseholdImprovementsMember 2020-03-31 0001173313 us-gaap:MachineryAndEquipmentMember 2020-03-31 0001173313 us-gaap:OfficeEquipmentMember 2020-03-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001173313 us-gaap:RetainedEarningsMember 2018-12-31 0001173313 us-gaap:CommonStockMember 2018-12-31 0001173313 us-gaap:ComprehensiveIncomeMember 2020-01-01 2020-03-31 0001173313 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001173313 us-gaap:ComprehensiveIncomeMember 2018-12-31 0001173313 us-gaap:TreasuryStockMember 2018-12-31 0001173313 us-gaap:NoncontrollingInterestMember 2018-12-31 0001173313 us-gaap:ComprehensiveIncomeMember 2020-03-31 0001173313 us-gaap:TreasuryStockMember 2020-03-31 0001173313 us-gaap:NoncontrollingInterestMember 2020-03-31 0001173313 abvcd:BioLiteTaiwanMember 2020-01-01 2020-03-31 0001173313 abvcd:BioLiteTaiwanMember 2018-01-01 2018-09-30 0001173313 abvcd:CathayUnitedBankMember 2020-03-31 0001173313 abvcd:CTBCBankMember 2020-03-31 0001173313 abvcd:CathayBnakMember 2020-03-31 0001173313 abvcd:CathayUnitedLoanAgreementMember 2016-06-01 2016-06-28 0001173313 abvcd:CathayUnitedLoanAgreementMember 2016-06-28 0001173313 abvcd:CathayUnitedLoanAgreementMember abvcd:NTMember 2016-06-28 0001173313 abvcd:CathayUnitedLoanAgreementMember 2017-09-01 2017-09-06 0001173313 abvcd:CathayUnitedLoanAgreementMember 2017-09-06 0001173313 abvcd:CathayUnitedLoanAgreementMember abvcd:NTMember 2017-09-06 0001173313 abvcd:CathayUnitedLoanAgreementMember 2018-09-25 2018-10-01 0001173313 abvcd:CathayUnitedLoanAgreementMember 2018-10-01 0001173313 abvcd:CathayUnitedLoanAgreementMember abvcd:NTMember 2018-10-01 0001173313 abvcd:CTBCLoanAgreementsMember 2017-07-19 0001173313 abvcd:CTBCLoanAgreementsMember 2017-07-01 2017-07-19 0001173313 abvcd:CTBCLoanAgreementsMember 2017-06-01 2017-06-12 0001173313 abvcd:CTBCLoanAgreementsMember 2017-06-12 0001173313 abvcd:CTBCLoanAgreementsMember abvcd:NTMember 2017-07-19 0001173313 abvcd:CTBCLoanAgreementsMember abvcd:NTMember 2017-06-12 0001173313 abvcd:CTBCLoanAgreementsMember 2019-01-01 2019-01-18 0001173313 abvcd:CathayUnitedLoanAgreementMember 2020-01-01 2020-03-31 0001173313 abvcd:CTBCLoanAgreementsMember 2020-01-01 2020-03-31 0001173313 abvcd:LoanAgreementMember 2019-01-01 2019-01-08 0001173313 abvcd:LoanAgreementMember 2019-01-01 2019-01-21 0001173313 abvcd:LoanAgreementMember 2019-01-21 0001173313 abvcd:LoanAgreementMember 2020-01-01 2020-03-31 0001173313 abvcd:CathayUnitedBankMember abvcd:AprilThirtyTwoThousandTenMember 2020-01-01 2020-03-31 0001173313 abvcd:CathayUnitedBankMember abvcd:AprilThirtyTwoThousandTenMember 2020-03-31 0001173313 abvcd:CathayUnitedBankMember abvcd:AprilThirtyTwoThousandTenMember abvcd:NTMember 2020-03-31 0001173313 abvcd:CathayUnitedBankMember 2017-04-01 2017-04-30 0001173313 abvcd:CathayUnitedBankMember srt:MinimumMember 2017-04-30 0001173313 abvcd:CathayUnitedBankMember srt:MaximumMember 2017-04-30 0001173313 abvcd:BraingenesisBiotechnologyCoLtdMember 2020-03-31 0001173313 abvcd:BraingenesisBiotechnologyCoLtdMember 2020-01-01 2020-03-31 0001173313 abvcd:GenepharmBiotechCorporationMember 2020-03-31 0001173313 abvcd:GenepharmBiotechCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:BioHopeKingCorporationMember 2020-03-31 0001173313 abvcd:BioHopeKingCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:RgeneMember 2020-03-31 0001173313 abvcd:RgeneMember 2020-01-01 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2018-01-01 2018-12-31 0001173313 abvcd:BioFirstCorporationMember 2018-10-10 2018-11-02 0001173313 2018-01-01 2018-12-31 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2016-07-27 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2016-07-01 2016-07-27 0001173313 us-gaap:CollaborativeArrangementMember 2017-09-01 2017-09-25 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2015-12-01 2015-12-31 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2015-12-31 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2016-08-01 2016-08-31 0001173313 abvcd:BHKCoDevelopmentAgreementMember 2020-01-01 2020-03-31 0001173313 abvcd:AccountingStandardsCodificationMember 2020-03-31 0001173313 abvcd:YuangeneCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:AsiangeneCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:EugeneJiangMember 2020-01-01 2020-03-31 0001173313 abvcd:KeypointTechnologyMember 2020-01-01 2020-03-31 0001173313 abvcd:YoshinobuOdairaMember 2020-01-01 2020-03-31 0001173313 abvcd:EuroAsiaInvestmentAndFinanceCorpLtdMember 2020-01-01 2020-03-31 0001173313 abvcd:KimhoConsultantsCoLtdMember 2020-01-01 2020-03-31 0001173313 abvcd:BioFirstAustraliaMember 2020-03-31 0001173313 abvcd:AsiangeneCorporationMember 2020-03-31 0001173313 abvcd:YuangeneCorporationMember 2020-03-31 0001173313 abvcd:TheJiangsMember 2020-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0001173313 abvcd:AsiangeneCorporationMember 2018-01-01 2018-12-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-06-27 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-08-25 0001173313 abvcd:BioKeyMember 2019-02-01 2019-02-08 0001173313 abvcd:BioLiteMember 2019-02-01 2019-02-08 0001173313 2016-03-20 2016-03-21 0001173313 abvcd:ShareExchangeAgreementMember 2016-02-04 2016-02-08 0001173313 abvcd:ShareExchangeAgreementOneMember 2016-02-04 2016-02-08 0001173313 abvcd:ShareExchangeAgreementTwoMember 2016-02-04 2016-02-08 0001173313 abvcd:ShareExchangeAgreementFourMember 2016-02-04 2016-02-08 0001173313 abvcd:EquityIncentivePlanMember 2016-02-01 2016-02-17 0001173313 us-gaap:CollaborativeArrangementMember 2016-09-15 2016-10-02 0001173313 abvcd:CollaborativeArrangementOneMember 2016-03-01 2016-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2020-03-31 0001173313 abvcd:EuroAsiaInvestmentAndFinanceCorpLtdMember 2018-03-28 0001173313 abvcd:ConsultingAgreementMember 2018-03-28 0001173313 abvcd:KimhoConsultantsCoLtdMember 2018-03-28 0001173313 abvcd:CollaborativeArrangementOneMember 2016-08-26 0001173313 abvcd:ShareExchangeAgreementTwoMember 2016-02-08 0001173313 abvcd:LionArtsPromotionIncMember 2020-01-01 2020-03-31 0001173313 abvcd:GenePharmIncMember 2020-03-31 0001173313 abvcd:BioFirstAustraliaMember 2018-12-31 0001173313 abvcd:LionGeneCorporationMember 2020-03-31 0001173313 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001173313 2017-08-31 0001173313 abvcd:BioKeyMember 2019-02-08 0001173313 2016-04-15 2016-05-06 0001173313 2016-08-01 2016-08-26 0001173313 2017-02-01 2017-02-28 0001173313 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001173313 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001173313 us-gaap:ComprehensiveIncomeMember 2019-01-01 2019-03-31 0001173313 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001173313 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001173313 2019-01-01 2019-03-31 0001173313 abvcd:AsiageneCorporationMember 2020-01-01 2020-03-31 0001173313 abvcd:AsiageneCorporationMember 2020-03-31 0001173313 abvcd:BioHopeKingCorporationMember 2020-03-31 0001173313 abvcd:LbgUsaIncMember 2020-03-31 0001173313 abvcd:LbgUsaIncMember 2018-12-31 0001173313 abvcd:BioFirstAustraliaMember 2018-01-01 2018-12-31 0001173313 abvcd:CathayBnakMember 2020-01-01 2020-03-31 0001173313 us-gaap:CommonStockMember 2019-03-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001173313 us-gaap:RetainedEarningsMember 2019-03-31 0001173313 us-gaap:ComprehensiveIncomeMember 2019-03-31 0001173313 us-gaap:TreasuryStockMember 2019-03-31 0001173313 us-gaap:NoncontrollingInterestMember 2019-03-31 0001173313 2019-03-31 0001173313 abvcd:BioFirstStockPurchaseAgreementMember 2019-06-30 0001173313 abvcd:BioFirstStockPurchaseAgreementMember 2019-08-05 0001173313 abvcd:BioFirstCorporationMember 2018-10-02 2018-10-15 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-07-10 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-08-01 2019-08-28 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-08-28 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-09-01 2019-09-04 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-09-04 0001173313 abvcd:CathayUnitedLoanAgreementMember 2020-03-31 0001173313 abvcd:ConsultingAgreementMember 2018-01-01 2018-12-31 0001173313 abvcd:ConsultingAgreementMember 2017-01-01 2017-12-31 0001173313 abvcd:EuroAsiaAgreementMember 2018-01-01 2018-12-31 0001173313 abvcd:EuroAsiaAgreementMember 2017-01-01 2017-12-31 0001173313 abvcd:KimhoAgreementMember 2017-01-01 2017-12-31 0001173313 abvcd:KimhoAgreementMember 2018-01-01 2018-12-31 0001173313 srt:OfficerMember 2018-03-28 0001173313 abvcd:OfficerOneMember 2018-03-28 0001173313 abvcd:OfficerTwoMember 2018-03-28 0001173313 abvcd:LionArtsPromotionInctheLIONMember 2019-08-01 2019-08-31 0001173313 abvcd:LionGeneCorporationMember 2019-08-01 2019-08-31 0001173313 abvcd:BioFirstCorporationMember 2019-08-01 2019-08-31 0001173313 abvcd:AsiageneCorporationMember 2019-08-01 2019-08-31 0001173313 abvcd:YuangeneCorporationMember 2019-08-01 2019-08-31 0001173313 abvcd:TheJiangsMember 2019-08-01 2019-08-31 0001173313 2019-08-01 2019-08-31 0001173313 2019-08-31 0001173313 abvcd:StockSubscriptionReceivableMember 2019-01-01 2019-03-31 0001173313 abvcd:StockSubscriptionReceivableMember 2018-12-31 0001173313 abvcd:StockSubscriptionReceivableMember 2019-03-31 0001173313 abvcd:StockSubscriptionReceivableMember 2020-03-31 0001173313 2016-03-21 0001173313 abvcd:BioLiteTaiwanAndChengChiMember 2018-12-01 2018-12-27 0001173313 abvcd:HsuAndChowMember 2018-03-01 2018-03-27 0001173313 abvcd:HsuAndChowMember 2020-01-01 2020-03-31 0001173313 abvcd:LBDUSAINCMember 2020-01-01 2020-03-31 0001173313 abvcd:LionGeneMember 2020-01-01 2020-03-31 0001173313 abvcd:TsungShannJiandMember 2020-01-01 2020-03-31 0001173313 abvcd:AsiangeneCorporationMember abvcd:NTMember 2019-05-01 2019-05-27 0001173313 abvcd:AsiangeneCorporationMember 2019-05-27 0001173313 abvcd:BioFirstAustraliaMember 2018-05-01 2018-05-11 0001173313 abvcd:BioFirstAustraliaMember 2018-05-11 0001173313 abvcd:BioFirstAustraliaMember 2019-07-01 2019-07-12 0001173313 abvcd:BioLiteTaiwanMember 2018-12-31 0001173313 abvcd:LbgUsaIncMember 2019-02-01 2019-02-27 0001173313 abvcd:KimhoMember 2020-03-31 0001173313 abvcd:DueToshareholdersMember 2020-03-31 0001173313 abvcd:BioFirstAustraliaMember 2019-07-12 0001173313 abvcd:BioLiteTaiwanMember 2018-09-30 0001173313 abvcd:BioLiteTaiwanMember 2018-11-01 2018-11-30 0001173313 abvcd:BioLiteTaiwanMember 2018-11-30 0001173313 abvcd:BioLiteTaiwanMember abvcd:NTMember 2018-11-01 2018-11-30 0001173313 abvcd:BioFirstMember 2019-02-01 2019-02-02 0001173313 abvcd:BioFirstMember 2019-02-02 0001173313 abvcd:BioFirstMember 2017-12-31 0001173313 abvcd:BioFirstMember 2017-12-01 2017-12-31 0001173313 abvcd:BioFirstMember abvcd:NTMember 2017-12-01 2017-12-31 0001173313 abvcd:BioFirstMember abvcd:ConversionAgreementsOneMember 2017-12-01 2017-12-31 0001173313 abvcd:BioFirstMember abvcd:ConversionAgreementsOneMember 2017-12-31 0001173313 abvcd:BioLiteBVIMember abvcd:NTMember 2017-04-01 2017-04-12 0001173313 abvcd:BioLiteBVIMember 2017-04-01 2017-04-12 0001173313 abvcd:BioLiteBVIMember 2019-05-01 2019-05-12 0001173313 abvcd:BioLiteBVIMember 2019-05-12 0001173313 abvcd:BioFirstMember 2019-06-01 2019-06-30 0001173313 abvcd:EverfrontBiotechIncMember 2017-09-01 2017-09-30 0001173313 abvcd:YuanGeneMember 2019-01-01 2019-01-20 0001173313 abvcd:YuanGeneMember 2019-01-20 0001173313 abvcd:YuanGeneMember 2018-01-01 2018-01-31 0001173313 abvcd:YuanGeneMember 2018-01-31 0001173313 abvcd:YuanGeneMember 2018-01-01 2018-01-18 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-06-01 2018-06-27 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-06-27 0001173313 abvcd:JIANGSMember 2018-12-01 2018-12-31 0001173313 abvcd:BioFirstMember 2020-03-31 0001173313 abvcd:KimhoMember 2019-07-01 2019-07-02 0001173313 abvcd:DueToshareholdersMember 2020-01-01 2020-03-31 0001173313 abvcd:YuanGeneMember 2020-03-31 0001173313 abvcd:JIANGSMember 2020-01-01 2020-03-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-10-25 2019-10-29 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-10-29 0001173313 abvcd:ExchangeAgreementsMember us-gaap:SubsequentEventMember 2020-04-05 0001173313 abvcd:ExchangeAgreementsMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-05 0001173313 abvcd:ExchangeAgreementsMember us-gaap:SubsequentEventMember 2020-04-20 0001173313 abvcd:ExchangeAgreementsMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-20 0001173313 abvcd:StockSubscriptionReceivableMember 2020-01-01 2020-03-31 0001173313 abvcd:BioLiteTaiwanMember abvcd:NTMember 2018-01-01 2018-09-30 0001173313 abvcd:BioFirstMember 2017-01-01 2017-01-26 0001173313 abvcd:LBGUSAMember 2020-03-31 0001173313 abvcd:BioFirstMember 2020-01-01 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2017-09-15 2017-09-25 0001173313 abvcd:JIANGSMember 2018-01-01 2018-12-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2018-08-01 2018-08-25 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-05-01 2019-05-30 0001173313 abvcd:CathayUnitedLoanAgreementMember 2019-09-01 2019-09-06 0001173313 abvcd:CathayUnitedLoanAgreementMember 2019-09-06 0001173313 abvcd:CathayUnitedLoanAgreementMember abvcd:NTMember 2019-09-06 0001173313 abvcd:CTBCLoanAgreementsMember 2019-07-01 2019-07-18 0001173313 abvcd:CTBCLoanAgreementsMember 2019-07-18 0001173313 abvcd:CTBCLoanAgreementsMember abvcd:NTMember 2019-07-18 0001173313 abvcd:CTBCLoanAgreementsMember 2020-01-19 0001173313 abvcd:CTBCLoanAgreementsMember 2020-01-01 2020-01-19 0001173313 abvcd:CTBCLoanAgreementsMember abvcd:NTMember 2020-01-19 0001173313 abvcd:BioLiteTaiwanMember 2019-01-01 2019-01-31 0001173313 abvcd:GenePharmMember 2020-01-01 2020-03-31 0001173313 abvcd:EuroAsiaMember 2018-12-31 0001173313 abvcd:EuroAsiaMember 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2019-07-12 0001173313 abvcd:LionGeneMember abvcd:NTMember 2019-10-01 2019-10-15 0001173313 abvcd:LionGeneMember abvcd:NTMember 2019-10-15 0001173313 abvcd:LionGeneMember 2020-03-31 0001173313 abvcd:BioFirstCorporationMember 2019-07-01 2020-07-12 0001173313 abvcd:YuanGeneMember 2020-01-01 2020-03-31 0001173313 us-gaap:ParentMember 2020-01-01 2020-03-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-07-05 2019-07-10 0001173313 2019-02-08 0001173313 2019-02-04 2019-02-08 0001173313 2019-01-01 2019-12-31 0001173313 2019-12-31 0001173313 abvcd:BuildingsAndLeaseholdImprovementsMember 2019-12-31 0001173313 us-gaap:LandMember 2019-12-31 0001173313 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001173313 us-gaap:OfficeEquipmentMember 2019-12-31 0001173313 abvcd:BraingenesisBiotechnologyCoLtdMember 2019-12-31 0001173313 abvcd:GenepharmBiotechCorporationMember 2019-12-31 0001173313 abvcd:BioHopeKingCorporationMember 2019-12-31 0001173313 abvcd:RgeneMember 2019-12-31 0001173313 abvcd:BioFirstCorporationMember 2019-12-31 0001173313 abvcd:BioFirstCorporationMember 2019-12-31 0001173313 abvcd:RgeneCorporationMember 2019-12-31 0001173313 abvcd:BioFirstCorporationMember 2019-01-01 2019-03-31 0001173313 abvcd:RgeneCorporationMember 2019-01-01 2019-03-31 0001173313 abvcd:RgeneCorporationMember 2019-01-01 2019-12-31 0001173313 abvcd:BioFirstCorporationMember 2019-01-01 2019-12-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-12-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-01-01 2019-12-31 0001173313 abvcd:UnsecuredConvertiblePromissoryNoteMember 2019-01-01 2019-03-31 0001173313 abvcd:CathayUnitedBankMember 2019-12-31 0001173313 abvcd:CTBCBankMember 2019-12-31 0001173313 abvcd:CathayBnakMember 2019-12-31 0001173313 abvcd:CathayUnitedLoanAgreementMember 2019-12-31 0001173313 abvcd:CathayUnitedLoanAgreementMember 2019-03-31 0001173313 abvcd:CathayUnitedLoanAgreementMember 2019-01-01 2019-03-31 0001173313 abvcd:CTBCLoanAgreementsMember 2019-01-01 2019-03-31 0001173313 abvcd:CathayBnakMember 2019-01-01 2019-03-31 0001173313 abvcd:CathayUnitedBankMember 2019-03-31 0001173313 abvcd:HsuAndChowMember 2019-01-01 2019-03-31 0001173313 abvcd:BioLiteTaiwanMember 2019-01-01 2019-03-31 0001173313 us-gaap:CommonStockMember 2019-12-31 0001173313 abvcd:StockSubscriptionReceivableMember 2019-12-31 0001173313 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001173313 us-gaap:RetainedEarningsMember 2019-12-31 0001173313 us-gaap:ComprehensiveIncomeMember 2019-12-31 0001173313 us-gaap:TreasuryStockMember 2019-12-31 0001173313 us-gaap:NoncontrollingInterestMember 2019-12-31 0001173313 us-gaap:ParentMember 2019-01-01 2019-03-31 0001173313 abvcd:GenePharmIncMember 2019-12-31 0001173313 abvcd:AsiageneCorporationMember 2019-12-31 0001173313 abvcd:BioFirstMember 2019-12-31 0001173313 abvcd:BioFirstAustraliaMember 2019-12-31 0001173313 abvcd:BioHopeKingCorporationMember 2019-12-31 0001173313 abvcd:LBGUSAMember 2019-12-31 0001173313 abvcd:LionArtsPromotionIncMember 2019-12-31 0001173313 abvcd:LionGeneCorporationMember 2019-12-31 0001173313 abvcd:AsiangeneCorporationMember 2019-12-31 0001173313 abvcd:YuangeneCorporationMember 2019-12-31 0001173313 abvcd:TheJiangsMember 2019-12-31 0001173313 abvcd:KimhoMember 2019-12-31 0001173313 abvcd:EuroAsiaMember 2019-12-31 0001173313 abvcd:DueToshareholdersMember 2019-12-31 0001173313 abvcd:AsiangeneCorporationMember 2019-01-01 2019-12-31 0001173313 abvcd:LbgUsaIncMember 2019-12-31 0001173313 abvcd:KimhoMember 2020-01-01 2020-03-31 0001173313 abvcd:DueToshareholdersMember 2019-01-01 2019-03-31 0001173313 abvcd:DueToshareholdersMember 2019-03-31 0001173313 2019-02-01 2019-02-08 0001173313 us-gaap:CollaborativeArrangementMember 2017-09-01 2017-09-30 0001173313 abvcd:LoanAgreementMember 2020-03-31 0001173313 2019-05-01 2019-05-03 0001173313 2016-03-01 2016-03-21 0001173313 2015-10-01 2015-10-15 0001173313 abvcd:AmkeyVenturesLLCMember 2020-01-01 2020-03-31 0001173313 abvcd:AmkeyVenturesLLCMember 2020-03-31 0001173313 abvcd:AmkeyVenturesLLCMember 2019-12-31 0001173313 abvcd:KimhoMember 2019-01-01 2019-12-31 0001173313 abvcd:DueToEmployeesMember 2020-03-31 0001173313 abvcd:DueToEmployeesMember 2019-12-31 0001173313 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0001173313 2020-02-18 0001173313 2020-02-01 2020-02-18 0001173313 srt:MinimumMember abvcd:ArticlesOfIncorporationMember 2020-03-12 0001173313 srt:MaximumMember abvcd:ArticlesOfIncorporationMember 2020-03-12 0001173313 abvcd:ArticlesOfIncorporationMember 2020-03-12 0001173313 2020-06-26 0001173313 us-gaap:SubsequentEventMember 2020-05-01 2020-05-31 0001173313 us-gaap:SubsequentEventMember 2020-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 715303 3000000 100000000 100000000 425689 10000 428571 29561231 74997546 1642291 0.0017 0.0072 0.0713 0.1589 0.3161 0.7970 0.73 0.0017 0.0072 0.0713 0.3161 0.1589 0 0 0.2536-for-1 (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note as of December 31, 2019 and 2018. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses are $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note as of December 31, 2019 and 2018. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses are $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses are $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 126,530 shares of Common Stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses are $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 162,908 shares of Common Stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note as of March 31, 2020. (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaria Note as of December 31, 2019. On January 21, 2020, Odiara entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses are $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the company has received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 month. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note as of March 31, 2020. Loaned from the investee and provides research and development support service Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene No specific business relationship No specific business relationship Collaborating with the Company to develop and commercialize drugs Collaborating with the Company to develop and commercialize drugs Controlling beneficiary shareholder of the Company Former President and Chairman The Chairman of Keypoint is Eugene Jiang's mother. Director of the Company Shareholder of the Company Shareholder of the Company Shareholder of the Company Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling. Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm. An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc 300000 36903 248250 7500000 248250 7500000 248250 7500000 331000 331000 10000000 10000000 288360 8900000 250000 250000 250000 200000 257500 40000 150000 250000 250000 248250 7500000 662000 20000000 662000 20000000 150000 36332 1000000 802491 1235043 136936 878238 1350701 82254 7654601 2105938 462667 6814193 2060460 312950 -1136689 6301673 -227277 -150964 6661385 -167928 78786 12110 212242 10334 74827 1578 210743 1882 -70411 -66205 2020-04-14 2017-06-28 2018-01-19 2018-01-19 2019-07-18 2020-01-01 2017-04-30 2020-04-30 2019-12-31 2020-02-01 2020-05-27 2019-05-11 2020-05-11 2020-01-19 2019-01-19 2020-01-17 2020-07-19 100000000 360000000 100000000 20000000 100000000 0.001 1.60 1.60 1.60 1.60 1.60 1.60 0.001 0.001 0.001 i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split. 1 to 3.141 1 to 3.141 19488168 50000 4828 75000 50000 50000 50000 19478168 The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. The Company sold 552,000 shares of common stock of BioHopeKing Corporation (the "BHK") at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period. The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019. The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price The Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to the KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020,. At any time from the date hereof until this KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price 5 years 50 years 5 years 10 years 3 years 6 years 525 8550 52936583 52336000 52936583 51945225 65431144 50000 166273921 1642291 164387376 166273921 163159952 205519223 157050 0.2536-for-1 0.065 The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000. 80000 7725 120000 80000 80000 80000 131517 129886 The Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. The Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. The Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). 428571 414702 506297 289438 Cost Method Cost Method Cost Method Equity Method Equity Method 2009953 7301 22291 1980361 2028170 7367 22493 1998310 3264200 1254247 3364619 1336449 0.1589 0.3161 0.3161 0.1589 80000 3000000 97864 97864 428099 2902911 160000 92690 1190776 4872340 428099 693000 625646 597128 987134 50000 42690 13981 13981 61157 414702 22858 13242 170111 696051 61157 99000 89378 85304 141020 7143 6099 The Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split. 28800 5400 0 60000 90000 0 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 7.00 94508 94727 20491 20676 57384 57904 172383 173307 7238415 161255 7450032 62768 65847 62801 78888 0.08 0.08 0.20 0.20 0.20 0.08 0.20 0.20 300000 250000 200000 257500 250000 250000 250000 250000 2007500 2007500 277066 931584 515196 181852 P1Y P1Y P1Y P1Y P1Y P7Y P1Y P6M P6M 0.0224 0.0115 0.0077 0.0117 0.0222 0.0163 0.0222 0.0224 2018-09-06 2019-09-06 2020-09-06 56 1378 2755 284 13740 1330 2604 9527 500000 500000 The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate. The Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. 449683 577830 524445 282715 301105 304248 179994 297832 235555 -1172266 19488 28222862 -17098761 -5340386 14983714 -12209446 11885 655851 -9100000 317610 657302 -9100000 -35577 17694 15680674 -13001117 640439 -9100000 235964 -5526346 -3837580 -124817 19478 -4063320 28180348 -15851223 663755 -9100000 26146 0.001 0.001 20000000 20000000 19488168 19478168 American BriVision (Holding) Corp 0001173313 false --12-31 10-Q 2020-03-31 Q1 2020 Non-accelerated Filer true false Yes false 333-91436 Yes NV 19488168 11885468 -275347 -275347 17694289 -275347 19478168 -275347 267739 10 41989 1642 692577 694219 225740 525 525 8550 8550 -1309262 -1247538 -61724 -791671 -81646 -873317 -6451 -6451 -15412 -15412 1.00 ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment. 3000000 3000000 450000 3000000 2902911 1000000 1000000 0.50 0.50 0.10 0.10 10000000 31649000 3000000 10000000 1000000 3000000 3000000 3000000 3000000 The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. 0.12 0.12 The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements. 3755229 367861 2224270 986237 176861 3762224 2225386 371195 987234 178409 3249821 3241294 637390 218261 24017 9205 58503 10481 55000 233832 0 12000 425689 10275 24017 9205 40031 21500 284479 94004 94990 24017 100000 430817 13295000 625646 19430000 30000000 987134 42690 50000 58503 2950000 950000 300000 21317 9205 Bears interest at 1% per month (or equivalent to 12% per annum The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019 The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan. The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. The advances bear 0% interest rate and are due on demand. 12967 7950 335 233832 551 8468 7138 238 284479 0.12 0.00 0.00 0.12 0.00 0.12 0.12 0.00 0.12 0.00 0.12 0.08 0.00 0.00 0.12 0.00 128683 28953 40000 3310 40000 259480 29194 128683 3340 259480 675 0 0 12000 12000 675 115946 0 0 Pursuant to which the Company agreed to issue 428,571 shares of the Company’s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share. Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share. Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share. The Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of March 31, 2020 and December 31, 2019, the outstanding services charge was $55,000 and $21,500, respectively. Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share. The advances bear interest 1% per month The Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum. The Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of March 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $22,316 as of March 31, 2020. This loan bears zero interest rate and is due on demand. 2988 4641 5085 2916 Entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $99,300, for working capital purpose. Taiwan issued a promissory note of NT$450,000, equivalent to $14,715, to Taipei Veterans General Hospital to repay the clinical experiment costs. The note has been paid in full on January 2, 2019. Borrowing an aggregate amount of NT$4,660,000, equivalent to $155,800, for the period from March 27, 2018 to June 26, 2018. On September 26, 2018, BioLite Taiwan extended the original loan agreement through December 26, 2018. On September 26, 2019, BioLite Taiwan renewed and amended the contract with the "Hsu" only and extend the maturity date to December 26, 2019. The principal of the Hsu new Promissory Note bears interest at 13.6224% per annum. -70411 -66205 19488168 143677 1053 142225 143278 1053 142225 400 16148 16148 123645 144295 3598 4424 95214 16000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>4. INVENTORY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 22.9pt; text-align: justify; text-indent: -22.9pt"><font style="font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 22.9pt; text-align: justify; text-indent: -22.9pt"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 22.9pt; text-align: justify; text-indent: -22.9pt"><font style="font: 7pt Times New Roman, Times, Serif"><b></b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> &#160;2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> &#160;2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Finished goods</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">94,508</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">94,727</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Work-in-process</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">20,491</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">20,676</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Raw materials</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">57,384</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">57,904</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(172,383</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(173,307</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-indent: -23.75pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>5. PROPERTY AND EQUIPMENT</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-indent: -23.75pt"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-align: justify; text-indent: -23.75pt"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment as of March 31, 2020 and December 31, 2019 are summarized as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-align: justify; text-indent: -23.75pt"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: right">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">367,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">371,195</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,224,270</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,225,386</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">986,237</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">987,234</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">176,861</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,755,229</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,762,224</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,249,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,241,294</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">505,408</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">520,930</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation expenses were $11,174 and $13,940 for three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>8. BANK LOANS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Short-term bank loan consists of the following:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,500</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">CTBC Bank</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">662,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,910,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,918,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cathay United Bank</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the "Cathay United Loan Agreement") in an amount of NT$7,500,000, equivalent to $248,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $248,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which is due on September 6, 2020. As of March 31, 2020 and 2019, the effective interest rates per annum were 2.22%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $1,378 and $1,330 for the three months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>CTBC Bank</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the "CTBC Loan Agreements") in an amount of NT$10,000,000, equivalent to $331,000, and NT$10,000,000, equivalent to $331,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on July 19, 2020. The loan balances bear interest at a fixed rate of 1.63% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan is also personal guaranteed by the Company's chairman and BioFirst.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Interest expenses were $2,755 and $2,604 for the three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Cathay Bank</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the "Bank") pursuant to a business loan agreement (the "Loan Agreement") entered by and between the Company and Bank on January 8, 2019 and a promissory note (the "Note") executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the "Maturity Date") of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate. After the completion of Merger, the Company had updated relevant documents with the state of California and is working with the Bank to revise its internal records and reviewing the Company's request for loan extension.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the "Guaranty") to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned subsidiary of the Company effective by operation of law on or about February 5, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition, on January 8, 2019, each of the Company and BriVision, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the "Security Agreement") to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BriVision (each, a "Grantor", and collectively, the "Grantors") granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $13,740 and $9,527 for the three months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Long-term bank loan consists of the following:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,332</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,403</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion of long-term bank loan</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,403</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 30, 2010, BioLite Taiwan entered a seven-year bank loan of NT$8,900,000, equivalent to $288,360, with Cathay United Bank. The term started April 30, 2010 with maturity date at April 30, 2017. On April 30, 2017, BioLite Taiwan extended the original loan agreement for additional three years with the new maturity date at April 30, 2020. The loan balance bears interest at a floating rate of prime rate plus variable rates from 0.77% to 1.17%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. As of March 31, 2020 and 2019, the actual interest rates per annum were 2.24%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $56 and $284 for the three months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fiscal Year</u>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Inventory</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Forward Stock Split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair Value Measurements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 &#8211; Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</font></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 &#8211; Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 &#8211; Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Concentration of Credit Risk</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue Recognition</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Merchandise Sales &#8212; </b>The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company's products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or "transaction price," which includes applicable reserves for variable consideration, including discounts, allowances, and returns.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Trade discount and allowances: </i>The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Product returns:</i> The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company's customers have the right to return unopened packages, subject to contractual limitations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Collaborative Revenues &#8212;</b> The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&#38;D personnel costs, discount rates and probabilities of technical and regulatory success.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nonrefundable upfront payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Milestone payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Multiple Element Arrangements</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Royalties and Profit Sharing Payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Property and Equipment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life <br /> in Years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 93%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 0%">&#160;</td> <td style="width: 7%; text-align: center">5 ~ 50</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td> <td style="text-align: center">5 ~ 10</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Office equipment</td><td>&#160;</td> <td style="text-align: center">3 ~ 6</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment of Long-Lived Assets</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Long-term Equity Investment</u>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Non-marketable cost method investments when the equity method does not apply.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Other-Than-Temporary Impairment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three month ended March 31, 2020 and 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Goodwill</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research and Development Expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For CDMO business unit, the Company accounts for R&#38;D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Post-retirement and post-employment benefits</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Stock-based Compensation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation". Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation" and FASB ASC Topic 505-50 "Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Beneficial Conversion Feature</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 40.2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;"more likely than not"&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">On December 22, 2017, the SEC issued Staff Accounting Bulletin ("SAB 118"), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Valuation of Deferred Tax Assets</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A valuation allowance is recorded to reduce the Company's deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company's projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Loss Per Share of Common Stock</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company calculates net loss per share in accordance with ASC Topic 260, "Earnings per Share". Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Commitments and Contingencies</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has adopted ASC Topic 450 "Contingencies" subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Foreign-currency Transactions</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the Company's subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars ("NTD") at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders' Equity (Deficit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Translation Adjustment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accounts of the Company's subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar ("NT$"). Such financial statements were translated into U.S. Dollars ("$" or "USD") in accordance ASC 830, "Foreign Currency Matters", with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder's deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders' equity (deficit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recent Accounting Pronouncements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life <br /> in Years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 93%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 0%">&#160;</td> <td style="width: 7%; text-align: center">5 ~ 50</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td> <td style="text-align: center">5 ~ 10</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Office equipment</td><td>&#160;</td> <td style="text-align: center">3 ~ 6</td></tr></table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> &#160;2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> &#160;2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Finished goods</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">94,508</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">94,727</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Work-in-process</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">20,491</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">20,676</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Raw materials</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">57,384</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">57,904</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(172,383</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(173,307</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: right">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">367,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">371,195</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,224,270</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,225,386</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">986,237</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">987,234</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">176,861</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,755,229</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,762,224</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,249,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,241,294</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">505,408</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">520,930</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; width: 30%; text-align: left"><b>Name of related party</b></td><td style="width: 1%; padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; width: 69%; text-align: left"><b>The extent the investee relies on the Company for its business &#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td>&#160;</td> <td style="text-align: left">No specific business relationship </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td> <td style="text-align: left">No specific business relationship </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">Loaned from the investee and provides research and development support service </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td>&#160;</td> <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs </td></tr></table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif">Non-marketable Cost Method Investments, net</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7,301</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7,367</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">22,291</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">22,493</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,980,361</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,998,310</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Sub total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,009,953</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,028,170</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Equity Method Investments, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">BioFirst Corporation</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,254,247</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,336,449</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,264,200</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,364,619</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Current Assets</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">136.936</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">82,254</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent Assets</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">161,255</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">62,768</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Current Liabilities</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">462,667</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">312,950</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent Liabilities</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">62,801</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Shareholders' Deficit</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(227,277</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(167,928</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> &#160;2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December&#160;31,<br /> 2019</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,235,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,350,701</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,238,415</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,450,032</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,105,938</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,060,460</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font-style: normal; font-weight: 400; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">65,847</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78,888</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shareholders' Equity</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,301,673</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,661,385</td><td style="text-align: left">&#160;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Net sales</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Gross Profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(21,889</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(22,662</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Share&#160; of loss from investments accounted for using the equity method</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,334</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,578</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,882</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(325,652</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(307,034</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(70,411</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(66,205</td><td style="text-align: left">)</td></tr></table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Share of equity method investee losses</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(70,411</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(66,205</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,500</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">CTBC Bank</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">662,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,910,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,918,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,332</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,403</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion of long-term bank loan</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,403</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; font-weight: bold; text-align: left">Name of entity or Individual</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; font-weight: bold; text-align: center">Relationship with the Company and its subsidiaries</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">BioFirst Corporation (the "BioFirst")</td><td>&#160;</td> <td style="text-align: justify">Entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)")</td><td>&#160;</td> <td style="text-align: justify">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Rgene Corporation (the "Rgene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Yuangene Corporation (the "Yuangene")</td><td>&#160;</td> <td style="text-align: justify">Controlling beneficiary shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">AsiaGene Corporation (the "AsiaGene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Eugene Jiang</td><td>&#160;</td> <td style="text-align: justify">Former President and Chairman</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Keypoint Technology Ltd. (the "Keypoint')</td><td>&#160;</td> <td style="text-align: justify">The Chairman of Keypoint is Eugene Jiang's mother.</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Lion Arts Promotion Inc. (the "Lion Arts")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Yoshinobu Odaira (the "Odaira")</td><td>&#160;</td> <td style="text-align: justify">Director of the Company</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">GenePharm Inc. (the "GenePharm")</td><td>&#160;</td> <td style="text-align: justify">Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Euro-Asia Investment &#38; Finance Corp Ltd. (the "Euro-Asia")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">LBG USA, Inc. (the "LBG USA")</td><td>&#160;</td> <td style="text-align: justify">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">LionGene Corporation (the "LionGene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Kimho Consultants Co., Ltd. (the "Kimho")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs")</td><td>&#160;</td> <td style="text-align: justify">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst <br />&#160; <br />Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc. <br />&#160; <br />Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. <br />&#160; <br />Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang's sibling and the director of the Company. <br />&#160; <br />Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang's sibling.</td></tr> <tr style="background-color: White"> <td style="vertical-align: top; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Amkey Ventures, LLC ("Amkey")</font></td> <td style="vertical-align: bottom; font-size: 10pt">&#160;</td> <td style="vertical-align: bottom; text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Rgene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,052</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,053</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,677</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,278</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Rgene</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,332</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>AsiaGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,645</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,578</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>BioFirst</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">141,650</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">137,151</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,905</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">115,946</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">LBG USA</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">337,778</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">333,682</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160; 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">LionGene Corporation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,481</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,275</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">218,261</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,182</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>AsiaGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>YuanGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,503</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,031</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Kimho</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Euro Asia</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Due to shareholders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">233,832</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">284,479</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Due to employees</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,004</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">715,303</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">425,689</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount of Debt<br /> Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares<br /> Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Lion Arts Promotion Inc</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">LionGene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">AsiaGene Corporationoo</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">YuanGene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr></table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Month Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss attributable to ABVC's common stockholders</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,247,538</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(791,671</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted-average shares outstanding:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,965,665</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,965,665</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <p style="margin: 0pt"></p> 3310 9930 19484542 14965665 19484542 14965665 -0.06 -0.05 -0.06 -0.05 77527 73802 P2Y9M14D P3Y0M29D 0.0121 0.0055 232438 92101 49805 49805 473954 11245 462709 598937 -21107 44341847 531147 188550 56075 485684 10440 1271896 56204 251335 -267256 2880 577675 694221 43647626 1.50 0.001 0.001 0 0 248250 662000 1000000 250500 668000 1000000 3332 13403 3332 13403 6665209 6927811 43890 44103 112173 135443 3264200 3364619 505408 520930 71026 77269 337778 333682 110217 163566 7837475 7052628 2880 2880 1187500 1187500 820000 820000 13089 13085 2502749 2007573 3332 13403 1910250 1918500 20363 23995 6665209 6927811 -35577 26147 9100000 9100000 657302 663753 -17098761 -15851223 3837580 4063320 28222862 28180348 19488 19478 3959 1499 -1171377 -730566 1246204 941309 525 8550 92790 421956 1152889 510803 -40568 -57545 -1349830 -930862 -178453 -200296 6322 -500 -70411 -66205 2 -3 1200 400 5231 -4291 10720 189 -1253989 -878457 -6451 -86786 -1247538 -791671 -61724 -81646 -0.06 -0.05 19484542 14965665 -1247538 -791671 337778 36903 40000 3645 114905 141650 675 333682 36332 3578 137151 40000 115946 675 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company's lease expenses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Three Months Ended<br /> March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,802</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Three Months Ended <br /> March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,802</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>March 31, <br />2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>December 31, <br />2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td>Weighted Average Remaining Lease Term:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;2.79 years </font></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.08 years</font></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Discount Rate:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.21</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.55</td><td style="text-align: left">%</td></tr></table> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating leases</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 90%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2020 ((excluding the three months ended March 31, 2020)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">232,438</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">92,101</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">473,954</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Less: Imputed interest</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,245</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Present value of future minimum lease payments</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">462,709</font></td> <td style="padding-bottom: 4pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td>Purchase consideration:</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Allocation of the purchase price:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total assets acquired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">*</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</font></td></tr></table> 506297 289438 55000 21500 143677 143278 43647626 1.00 3000000 350000 1487364 1460033 100000 99300 100200 2016-04-08 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted $123,645 and $144,295, respectively. Some&#160;of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Restricted Cash Equivalents</u></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $16,148 and $16,148, respectively.</p> -325652 -21889 -307034 -22662 4166530 4167 -4167 77527 73802 49805 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>3. COLLABORATIVE AGREEMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Collaborative agreements with BHK</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement"), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK's net sales related to BLI-1401-2 Products. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Co-Development Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the "BHK Collaborative Agreements"), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for "Targeting Major Depressive Disorder" (BLI-1005 Products) and BLI-1006 for "Targeting Inflammatory Bowel Disease" (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Co-Development agreement with Rgene Corporation, a related party</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the "Co-Dev Agreement") with Rgene Corporation (the "Rgene"), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 11). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision's past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company has determined to fully write off this investment based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene's ability to remain in business. However, all projects that have been initiated and scheduled will be continuously managed and supported by the Company and Rgene.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Collaborative agreement with BioFirst Corporation, a related party</u></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst Corporation ("BioFirst"), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the "Product"): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 11).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst's past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the "Purchase Agreement") with BioFirst Corporation ("BioFirst"). Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the "Total Payment") in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the "Collaborative Agreement"). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 5, 2019, BriVision entered into a Stock Purchase Agreement (the "Purchase Agreement") with BioFirst Corporation ("BioFirst"). Pursuant to the Purchase Agreement, the Company issued 414,702 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst (the "Total Payment") in connection with a sunk payments that were due to related party prior to the conversion.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-indent: -23.75pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>6. LONG-TERM INVESTMENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 23.75pt; text-indent: -23.75pt"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The ownership percentages of each investee are listed as follows:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 331.3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15.89</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15.89</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31.61</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31.61</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Equity Method</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The extent the investee relies on the company for its business are summarized as follows:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; width: 30%; text-align: left"><b>Name of related party</b></td><td style="width: 1%; padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; width: 69%; text-align: left"><b>The extent the investee relies on the Company for its business &#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td>&#160;</td> <td style="text-align: left">No specific business relationship </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td> <td style="text-align: left">No specific business relationship </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">Loaned from the investee and provides research and development support service </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td>&#160;</td> <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(3)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Long-term investment mainly consists of the following:</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b></b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif">Non-marketable Cost Method Investments, net</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7,301</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">7,367</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">22,291</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">22,493</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,980,361</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,998,310</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Sub total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,009,953</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">2,028,170</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Equity Method Investments, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">BioFirst Corporation</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,254,247</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,336,449</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,264,200</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,364,619</td><td style="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">BioFirst Corporation (the "BioFirst):</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin-top: 0; margin-bottom: 0; margin-left: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company holds an equity interest in BioFirst Corporation, (the "BioFirst"), accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 15.89% and 15.89% common stock shares of BioFirst, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font>Summarized financial information for the Company's equity method investee, BioFirst, is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5.4pt"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>Balance Sheet</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br /> &#160;2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December&#160;31,<br /> 2019</b></font></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,235,043</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,350,701</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent Assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,238,415</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,450,032</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,105,938</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,060,460</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noncurrent Liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">65,847</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78,888</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shareholders' Equity</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,301,673</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,661,385</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><i>Statement of operation</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,334</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,578</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,882</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(325,652</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(307,034</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(70,411</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(66,205</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(b)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Rgene Corporation (the "Rgene")</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin-top: 0; margin-bottom: 0; margin-left: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the Company. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 31.61% and 31.61% Common Stock shares of Rgene, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Summarized financial information for the Company's equity method investee, Rgene, is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Balance Sheets</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">March 31,<br /> 2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December&#160;31,<br /> 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Current Assets</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">136.936</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">82,254</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent Assets</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">161,255</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">62,768</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Current Liabilities</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">462,667</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">312,950</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent Liabilities</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">62,801</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Shareholders' Deficit</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(227,277</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(167,928</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Statement of operations</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Net sales</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Gross Profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(21,889</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(22,662</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Share&#160; of loss from investments accounted for using the equity method</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(4)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Disposition of long-term investment</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2018, the Company sold 552,000 shares of common stock of BioHopeKing Corporation (the "BHK") at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24px; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 15, 2018 and November 2, 2018, the Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(5)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Losses&#160; on Equity Investments</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The components of losses on equity investments for each period were as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Unaudited)</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left">Share of equity method investee losses</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(70,411</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font-family: Times New Roman, Times, Serif">&#160;</td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">(66,205</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15.89</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15.89</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31.61</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31.61</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">Equity Method</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>7. CONVERTIBLE NOTES PAYABLE</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Yu and Wei Note") in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the "Yu and Wei"), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note as of December 31, 2019 and 2018. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses are $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Keypoint Note") in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. ("Keypoint"), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note as of December 31, 2019 and 2018. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses are $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the "Odaira Note") in the aggregate principal amount of $250,000 to Yoshinobu Odaira. ("Odaira"), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaria Note as of December 31, 2019. On January 21, 2020, Odiara entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses are $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the "KSL Note") in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the "KSL"), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to the KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020,. At any time from the date hereof until this KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company has received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 month.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "NEA Note") in an aggregate principal amount of $250,000 to New Eastern Asia (the "NEA"), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note as of March 31, 2020.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "KLS Note") in an aggregate principal amount of $200,000 to Kuo Li Shen (the "KLS"), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses are $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 126,530 shares of Common Stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the "C.L.L. Note") in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the "C.L.L."), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses are $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 162,908 shares of Common Stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "Lee Note") in an aggregate principal amount of $250,000 to Hawlin Lee (the "Lee"), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020 , and the company has not received any indication from NEA that it wants to claim the repayment of loan for 12 month. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note as of March 31, 2020.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2020 and December 31, 2019, the aggregate carrying values of the convertible debentures were $2,007,500 and $2,007,500, respectively; and accrued convertible interest was $277,066 and $181,852, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Total interest expenses in connection with the above convertible note payable were $95,214 and $16,000 for the three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><b>9. NOTES PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 27, 2018, BioLite Taiwan issued a promissory note of NT$450,000, equivalent to $14,715, to Taipei Veterans General Hospital to repay the clinical experiment costs. The note has been paid in full on January 2, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 27, 2018, BioLite Taiwan and two individuals entered into a promissory note, (the "Hsu and Chow Promissory Note"), for borrowing an aggregate amount of NT$4,660,000, equivalent to $155,800, for the period from March 27, 2018 to June 26, 2018. On September 26, 2018, BioLite Taiwan extended the original loan agreement through December 26, 2018. On September 26, 2019, BioLite Taiwan renewed and amended the contract with the "Hsu" only and extend the maturity date to December 26, 2019. The principal of the Hsu new Promissory Note bears interest at 13.6224% per annum. This Note was secured by common stock shares of ABVC and was also personal guaranteed by the Chairman of BioLite Taiwan. Interest expense was $5,269 and $5,085 for the three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $99,300, for working capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of the unsecured loans. Interest expense was $2,988 and $2,916 for the three months ended March 31, 2020 and 2019, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. SHORT-TERM LOAN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020.</p> 0.015 100000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>11. RELATED PARTIES TRANSACTIONS</b>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The related parties of the company with whom transactions are reported in these financial statements are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%; font-weight: bold; text-align: left">Name of entity or Individual</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; font-weight: bold; text-align: center">Relationship with the Company and its subsidiaries</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">BioFirst Corporation (the "BioFirst")</td><td>&#160;</td> <td style="text-align: justify">Entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)")</td><td>&#160;</td> <td style="text-align: justify">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Rgene Corporation (the "Rgene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Yuangene Corporation (the "Yuangene")</td><td>&#160;</td> <td style="text-align: justify">Controlling beneficiary shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">AsiaGene Corporation (the "AsiaGene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Eugene Jiang</td><td>&#160;</td> <td style="text-align: justify">Former President and Chairman</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Keypoint Technology Ltd. (the "Keypoint')</td><td>&#160;</td> <td style="text-align: justify">The Chairman of Keypoint is Eugene Jiang's mother.</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Lion Arts Promotion Inc. (the "Lion Arts")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Yoshinobu Odaira (the "Odaira")</td><td>&#160;</td> <td style="text-align: justify">Director of the Company</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">GenePharm Inc. (the "GenePharm")</td><td>&#160;</td> <td style="text-align: justify">Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Euro-Asia Investment &#38; Finance Corp Ltd. (the "Euro-Asia")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">LBG USA, Inc. (the "LBG USA")</td><td>&#160;</td> <td style="text-align: justify">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">LionGene Corporation (the "LionGene")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">Kimho Consultants Co., Ltd. (the "Kimho")</td><td>&#160;</td> <td style="text-align: justify">Shareholder of the Company</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs")</td><td>&#160;</td> <td style="text-align: justify">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst <br />&#160; <br />Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc. <br />&#160; <br />Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. <br />&#160; <br />Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang's sibling and the director of the Company. <br />&#160; <br />Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang's sibling.</td></tr> <tr style="background-color: White"> <td style="vertical-align: top; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Amkey Ventures, LLC ("Amkey")</font></td> <td style="vertical-align: bottom; font-size: 10pt">&#160;</td> <td style="vertical-align: bottom; text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Accounts receivable &#8211; related parties</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable due from related parties consisted of the following as of the periods indicated:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Rgene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,052</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,053</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,677</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,278</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Due from related parties</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Amount due from related parties consisted of the following as of the periods indicated:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Rgene</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,903</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,332</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>AsiaGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,645</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,578</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>BioFirst</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">141,650</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">137,151</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,905</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">115,946</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">LBG USA</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">337,778</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">333,682</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">As of March 31, 2020, and December 31, 2019, the Company has advanced an aggregate amount of $36,903 and $36,332 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the contract has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $28,953 and $29,194, and accrued interest was $7,950 and $7,138, respectively. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,310, to meet its working capital needs.&#160;&#160;Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the agreement has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $3,310 and $3,340, and accrued interest was $335 and $238, respectively. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(3)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">On July 12, 2019, the Company had an aggregate amount of loan with BioFirst of $150,000 to meet its working capital needs, pursuant to which the interest bears at 12% per annum. The Company paid back $21,317 in 2019. The remaining loan balance was $128,683 as of December 31, 2019. This loan is matured on July 11, 2020 and bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $128,683, and accrued interest was $12,967 and $8,468, respectively. </font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(4)</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and December 31, 2019, the outstanding loan balances were $40,000.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(5)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement", see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2020 and 2019, due from related parties was $114,905 and $115,946, respectively.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(6)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and 2019, the outstanding advance balances were $675.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Due to related parties</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Amount due to related parties consisted of the following as of the periods indicated:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#160; 31,</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">LionGene Corporation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,481</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,275</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">218,261</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,182</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>AsiaGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>YuanGene</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,503</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40,031</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Kimho</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,500</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Euro Asia</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Due to shareholders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">233,832</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">284,479</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Due to employees</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,004</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">715,303</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">425,689</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">In September, 2018, BioLite Taiwan has borrowed an aggregate amount of NT$2,950,000, equivalent to $94,990, from LION ARTS for working capital purpose. These loans bear interest at fixed rates at 12% per annum with various maturity dates through April 14, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert all of the remaining balance of $97,864 to 13,981 shares of the Company's common stock at a conversion price of $7.00 per share (see Note 11). As such, no balance is due as of March 31, 2020 and December 31, 2019.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In November 2018, BioLite Taiwan has borrowed an aggregate amount of NT$13,295,000, equivalent to $430,817 from LionGene for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the all of remaining balance of $428,099, to 61,157 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 15, 2019, LionGene has advanced funds to the Company for working capital purpose in an aggregate amount of NTD $300,000, equivalent to $9,930, The advances bear 1% interest rate and as of March 31, 2020, the accrued interest rate is $551.</font></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(3)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 26, 2017, BriVision and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. On February 2, 2019, BriVision and BioFirst agreed to extend the remaining loan balance of $693,000 for one year matured on February 1, 2020. Under the terms of the loan agreement, the loan bears interest at 12% per annum. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2017, BioLite Taiwan and BioFirst entered into several loan agreements for an aggregate amount of NT$19,430,000, equivalent to $625,646, to meet its working capital needs. Under the terms of the loan agreements, the loans bear interest at 12% per annum. The term of the loans has various maturity dates through May 27, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $625,646 to 89,378 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2017, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 12, 2017, BioLite BVI and BioFirst entered into a loan agreement for NT$30,000,000, equivalent to $987,134 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). BioLite BVI and BioFirst extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2019. On May 12, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On July 24, 2017, BriVision entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company's common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2019, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2020, the aggregate amount of outstanding balance and accrued interest is $218,261.</font></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: -24.1pt"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(4)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In September 2017, AsiaGene entered an investment and equity transfer agreement (the "Investment and Equity Transfer Agreement") with Everfront Biotech Inc. (the "Everfront"), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 7pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2018, AsiaGene has advanced the Company an aggregate amount of $24,017 for working capital purpose. This advance bears 0% interest rate and is due on demand.</font></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(5)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 19, 2019. On January 20, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on January 19, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $50,000 to 7,143 shares of the Company's common stock at a conversion price of $7.00 per share.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In January 2018, YuanGene Corporation has advanced an aggregate amount of $42,690 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2018, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.</font></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(6)</font></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of March 31, 2020, the Jiangs has advanced an aggregate amount of $58,503, to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.</font></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: -24.1pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(7)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">On July 2, 2019, the Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of March 31, 2020 and December 31, 2019, the outstanding services charge was $55,000 and $21,500, respectively.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(8)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">As of March 31, 2020 and December 31, 2019, Euro Asia has advanced of $12,000 and $12,000, respectively, to the Company for working capital purpose. The advances bear 0% interest rate.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(9)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2020, for working capital purpose, the Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum. As of March 31, 2020 and 2019, the aggregate amount of outstanding advance balance and accrued interest was $233,832 and $284,479, respectively.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">(10)</font></td> <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2020, the Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of March 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $22,316 as of March 31, 2020. This loan bears zero interest rate and is due on demand.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>12. EQUITY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2016, a Share Exchange Agreement ("Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation (the&#160;"Company"), American BriVision Corporation&#160;("BriVision"), Euro-Asia Investment &#38; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#160;"BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;"Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision's Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company's Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company's Common Stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;"Share Exchange"), BriVision became a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the "2016 Plan"), 157,050 (50,000 pre-stock split) shares were granted to the employees.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the "Forward&#160;Stock&#160;Split") and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama ("Kameyama") for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000. The Company's stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $28,800 and $5,400 for the years ended December 31, 2018 and 2017, respectively. On March 28, 2018, the Company issued 4,828 shares of the Company's common stock at $1.60 per share in a total of $7,725 to Kameyama in connection with this consulting agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 1, 2017, Euro-Asia Investment &#38; Finance Corp Ltd. And the Company entered into a service agreement (the "Euro-Asia Agreement") for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $60,000 in connection with the terms in the Euro-Asia Agreement, respectively. On March 28, 2018, the Company issued 50,000 shares of the Company's common stock at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 1, 2017, Kimho Consultants Co., Ltd. And the Company entered into a service agreement (the "Kimho Agreement") for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $90,000 in connection with the terms in the Kimho Agreement, respectively. On March 28, 2018, the Company issued 75,000 shares of the Company's common stock at $1.60 per share in a total of $120,000 to Kimho in connection with the Kimho Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 28, 2018, the Company also issued an aggregate of 50,000 shares of the Company's common stock at $1.60 per share for salaries in a total of $80,000 to three officers.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As stated in Note 10, in August 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of "due to related parties" in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company's common stock at a price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount of Debt<br /> Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares<br /> Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Lion Arts Promotion Inc</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">LionGene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">AsiaGene Corporationoo</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">YuanGene Corporation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company's Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>13. LOSS PER SHARE</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31, 2020 and 2019.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Month Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss attributable to ABVC's common stockholders</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,247,538</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(791,671</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted-average shares outstanding:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,965,665</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,965,665</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>14. LEASE</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted FASB Accounting Standards Codification, Topic 842, Leases ("ASC 842") using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 840.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use ("ROU") assets and lease liabilities. ROU assets represent the Company's right to use underlying assets for the lease terms and lease liabilities represent the Company's obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company's future minimum based payments used to determine the Company's lease liabilities mainly include minimum based rent payments. As most of Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months as of January 1, 2019. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of ASC 842 had a substantial impact on the Company's consolidated balance sheets. The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $577,830 and operating lease liabilities of $598,937 comprised of $301,105 of current operating lease liabilities and $297,832 of non-current operating lease liabilities on the consolidated balance sheet as of January 1, 2019. The adoption of ASC 842 also resulted in a cumulative-effect adjustment of $(21,107) to the opening balance of accumulated deficit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition, the adoption of the standard did not have a material impact on the Company's results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no finance leases. The Company's leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company's operating leases have remaining lease terms of up to approximately four years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">449,683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524,445</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities (current)</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">282,715</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">304,248</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">179,994</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">235,555</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Supplemental Information</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company's lease expenses:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Three Months Ended<br /> March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,802</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Three Months Ended <br /> March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,802</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>March 31, <br />2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>December 31, <br />2019</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td>Weighted Average Remaining Lease Term:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;2.79 years </font></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.08 years</font></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Discount Rate:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.21</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.55</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating leases</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 90%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2020 ((excluding the three months ended March 31, 2020)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">232,438</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">92,101</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;49,805</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Total future minimum lease payments, undiscounted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">473,954</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Less: Imputed interest</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11,245</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Present value of future minimum lease payments</font></td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: Black 4pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">462,709</font></td> <td style="padding-bottom: 4pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>15. BUSINESS COMBINATION</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey's results of operations were included in the Company's results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Purchase consideration:</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Allocation of the purchase price:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total assets acquired</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">*</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company's anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br /> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, <br /> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">449,683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">524,445</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liabilities (current)</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">282,715</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">304,248</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">179,994</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left"></td><td style="text-align: right">235,555</td><td style="text-align: left">&#160;</td></tr> </table> 1250 10446 26592 139793 242781 997434 160443 -20650 754653 -93 -1809 610387 1373791 9981 10016 460000 71688 312660 280940 1000000 267740 531147 -17801 17801 -630944 -599528 68750 11857 500743 305214 -3632 -37353 -797 7536 -1252 -39005 -27834 -29237 -52950 116334 -40568 -48028 2333 553 -70411 -66205 525 8550 11174 13940 -1309262 -873317 1602040 The exercise price of the warrant will be at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants. 6.00 2.25 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">American BriVision (Holding) Corporation (the "Company" or "Holding entity"), a Nevada corporation, through the Company's operating entity, American BriVision Corporation (the "BriVision"), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. &#160;The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center ("MSKCC") and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Reverse Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2016, a Share Exchange Agreement (the "Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation ("BriVision"), and Euro-Asia Investment &#38; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock (the "Common Stock") of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock").</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the "Merger").</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company's Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision had become a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon the consummation of the Share Exchange, BriVision became our wholly owned subsidiary of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision's historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and explore global markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 40.2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Accounting Treatment of the Reverse Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For financial reporting purposes, the Share Exchange represents a "reverse merger"&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 8, 2019, the Company, BioLite Holding, Inc. ("BioLite"), BioKey, Inc. ("BioKey"), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 1"), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 2") (collectively referred to as the "Parties") completed the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">BioLite Holding, Inc. (the "BioLite Holding") was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the "BioLite BVI"), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">BioLite, Inc., (the "BioLite Taiwan") was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the "BioLite Share Purchase / Exchange Agreement"). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">BioKey, Inc. was incorporated on August 9, 2000 in the State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Accounting Treatment of the Merger</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang's common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding's common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Basis of Presentation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fiscal Year</u>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Use of Estimates</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Inventory</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Forward Stock Split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Stock Reverse Split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Fair Value Measurements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 &#8211; Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</font></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 &#8211; Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 &#8211; Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Cash and Cash Equivalents</u></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted $123,645 and $144,295, respectively. Some&#160;of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><u>Restricted Cash Equivalents</u></font>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $16,148 and $16,148, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Concentration of Credit Risk</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Revenue Recognition</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Merchandise Sales &#8212; </b>The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company's products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or "transaction price," which includes applicable reserves for variable consideration, including discounts, allowances, and returns.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Trade discount and allowances: </i>The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i>Product returns:</i> The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company's customers have the right to return unopened packages, subject to contractual limitations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Collaborative Revenues &#8212;</b> The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&#38;D personnel costs, discount rates and probabilities of technical and regulatory success.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nonrefundable upfront payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Milestone payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Multiple Element Arrangements</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Royalties and Profit Sharing Payments</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Property and Equipment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life <br /> in Years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 93%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 0%">&#160;</td> <td style="width: 7%; text-align: center">5 ~ 50</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td> <td style="text-align: center">5 ~ 10</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Office equipment</td><td>&#160;</td> <td style="text-align: center">3 ~ 6</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Impairment of Long-Lived Assets</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Long-term Equity Investment</u>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Non-marketable cost method investments when the equity method does not apply.</font></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Other-Than-Temporary Impairment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three month ended March 31, 2020 and 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Goodwill</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Research and Development Expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For CDMO business unit, the Company accounts for R&#38;D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Post-retirement and post-employment benefits</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Stock-based Compensation</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation". Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation" and FASB ASC Topic 505-50 "Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Beneficial Conversion Feature</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 40.2pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as a benefit only if it is&#160;"more likely than not"&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: white">On December 22, 2017, the SEC issued Staff Accounting Bulletin ("SAB 118"), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Valuation of Deferred Tax Assets</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A valuation allowance is recorded to reduce the Company's deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company's projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Loss Per Share of Common Stock</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company calculates net loss per share in accordance with ASC Topic 260, "Earnings per Share". Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Commitments and Contingencies</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has adopted ASC Topic 450 "Contingencies" subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Foreign-currency Transactions</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the Company's subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars ("NTD") at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders' Equity (Deficit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Translation Adjustment</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accounts of the Company's subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar ("NT$"). Such financial statements were translated into U.S. Dollars ("$" or "USD") in accordance ASC 830, "Foreign Currency Matters", with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder's deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders' equity (deficit).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recent Accounting Pronouncements</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Stock Reverse Split</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>16. SUBSEQUENT EVENTS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 5, 2020, the Company entered into certain exchange agreements separately with certain U.S. and non-U.S. holders of certain convertible promissory notes issued by the Company on January 21, 2020. The non-U.S. holders are qualified as "non-U.S. Persons" as defined in Regulation S of the Securities Act of 1933, as amended (the "Securities Act"). The U.S. holder is an "accredited investor" as that term is defined in Rule 501(a) of Regulation D. Pursuant to the Exchange Agreements, the holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $931,584.07, and the Company agreed to issue to the holders an aggregate of 506,297 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 506,297 shares of Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 20, 2020, the Company entered into certain exchange agreements separately with additional non-U.S. holders of certain convertible promissory notes issued by the Company on August 28 and September 4, 2019. The non-U.S. holders are qualified as "non-U.S. Persons" as defined in Regulation S of the Securities Act. Pursuant to the Exchange Agreements, the holders agreed to deliver such notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $515,195.84, and the Company agreed to issue to the holders an aggregate of 289,438 shares of the Company's common stock, par value $0.001 per, and warrants to purchase 289,438 shares of Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2020, the Company received capital contributions of approximately $1,602,040 in cash from 40 investors through private placements of the sale of certain number of Common Stocks for the purchase price of $2.25 per share of Common Stock and a free warrant attaches with each Common stock that was purchased. The exercise price of the warrant will be at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2020 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, "Subsequent Events."</font>&#160;&#160;</p> 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019. EX-101.SCH 7 abvcd-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Long-Term Investments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Bank Loans link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Short-term Loan link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Parties Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Long-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Bank Loans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Parties Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Collaborative Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Long-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Long-Term Investments (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Long-Term Investments (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Long-Term Investments (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Long-Term Investments (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Long-Term Investments (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Long-Term Investments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Bank Loans (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Bank Loans (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Bank Loans (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Short-term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Related Parties Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Related Parties Transactions (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Related Parties Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Related Parties Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Related Parties Transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Lease (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Lease (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Lease (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Business Combination (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 abvcd-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 abvcd-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 abvcd-20200331_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] Co-Dev Agreement [Member] Related Party Transaction [Axis] BioFirst Corporation [Member] Collaborative Arrangement [Member] Share Exchange Agreement Three [Member] Rgene Corporation [Member] Short-term Debt, Type [Axis] Unsecured convertible promissory note [Member] BioFirst (Australia) [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings / Accumulated Deficit Property, Plant and Equipment, Type [Axis] Buildings and leasehold improvements [Member] Range [Axis] Minimum [Member] Maximum [Member] Machinery and Equipment [Member] Office Equipment [Member] Land [Member] Comprehensive Income / Loss Noncontrolling Interest Treasury Stock BioLite Taiwan [Member] Cathay United Bank [Member] CTBC Bank [Member] Cathay Bnak [Member] Cathay United Loan Agreement [Member] Type Of Currency [Axis] NT [Member] CTBC Loan Agreements [Member] Loan Agreement [Member] Date [Axis] April 30, 2010 [Member] Related Party [Axis] Braingenesis Biotechnology Co., Ltd. [Member] Genepharm Biotech Corporation [Member] BioHopeKing Corporation [Member] Rgene [Member] BHK Co-Development Agreement [Member] Accounting Standards Codification [Axis] Accounting Standards Codification [Member] YuanGene Corporation [Member] Asiangene Corporation [Member] Eugene Jiang [Member] Keypoint Technology Ltd [Member] Yoshinobu Odaira [Member] Euro-Asia Investment & Finance Corp Ltd [Member] Kimho Consultants Co., Ltd [Member] The Jiangs [Member] Title of Individual [Axis] BioKey [Member] BioLite [Member] Share Exchange Agreement [Member] Share Exchange Agreement One [Member] Share Exchange Agreement Two [Member] Share Exchange Agreement Four [Member] Plan Name [Axis] Equity Incentive Plan [Member] Collaborative Arrangement One [Member] Consulting Agreement [Member] Lion Arts Promotion Inc. (the "LION") [Member] GenePharm Inc. (the "GenePharm") [Member] LionGene Corporation (the "LionGene") [Member] AsianGene Corporation [Member] LBG USA, Inc.[Member] BioFirst Stock Purchase Agreement [Member] Euro-Asia Agreement [Member] Kimho Agreement [Member] Officer [Member] Officer One [Member] Officer Two [Member] Lion Arts Promotion Inc. (the "LION") [Member] Stock Subscription Receivable [Member] BioLite Taiwan And Cheng Chi [Member] Hsu and Chow [Member] LBD USA INC [Member] Lion Gene [Member] Tsung Shann Jiand [Member] Kimho [Member] Due to shareholders [Member] BioFirst [Member] Debt Conversion Description [Axis] Conversion Agreements One [Member] BioLite BVI [Member] Everfront Biotech Inc. [Member] YuanGene [Member] Debt Instrument [Axis] Jiangs [Member] JIANGS [Member] Agreemnet [Axis] Exchange Agreements [Member] Subsequent Event Type [Axis] Subsequent Event [Member] LBG USA [Member] GenePharm Inc. (the "GenePharm") [Member] Euro Asia [Member] Parent [Member] Amkey Ventures, LLC (“Amkey”) [Member] Due to employees [Member] Sale of Stock [Axis] Employee Stock [Member] Articles of Incorporation [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Filer Category Entity Small Business Entity Shell Company Entity Current Reporting Status Entity Emerging Growth Company Entity Filer Number Entity Interactive Data Current Entity Incorporation State Country Code Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Restricted cash and cash equivalents Accounts receivable, net Accounts receivable - related parties, net Due from related parties Inventory, net Prepaid expense and other current assets Total Current Assets Property and equipment, net Operating lease right-of-use assets Goodwill, net Long-term investments Deferred tax assets Prepaid expenses - noncurrent Security deposits Total Assets LIABILITIES AND EQUITY Current Liabilities Accounts payable Short-term bank loans Short-term loan Long-term bank loans - current portion Notes payable Accrued expenses and other current liabilities Advance from customers Operating lease liabilities – current portion Due to related parties Convertible notes payable - current portion Convertible notes payable - related parties, current portion Total Current Liabilities Tenant security deposit Operating lease liability – noncurrent portion Total Liabilities Equity Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding Common stock, $0.001 par value, 100,000,000 authorized, 19,488,168 and 19,478,168 shares issued and outstanding Additional paid-in capital Stock subscription receivable Accumulated deficit Other comprehensive income Treasury stock Total Stockholders' deficit Noncontrolling interest Total Equity (Deficit) Total Liabilities and Equity (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative expenses Research and development expenses Stock-based compensation Total operating expenses Loss from operations Other income (expense) Interest income Interest expense Rental income Rental income - related parties Gain/Loss on foreign exchange changes Gain/Loss on investment in equity securities Other income (expense) Total other expenses Loss before provision income tax Provision for income tax Net loss Net loss attributable to noncontrolling interests Net loss attributed to ABVC and subsidiaries Foreign currency translation adjustment Comprehensive loss Net loss per share: Basic and diluted Weighted average number of common shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock based compensation for nonemployees Gain/Loss on investment in equity securities Other non-cash income and expenses Deferred tax Changes in operating assets and liabilities: Decrease (increase) in accounts receivable Decrease (increase) in prepaid expenses and deposits Decrease (increase) in other receivable Decrease (increase) in due from related parties Decrease (increase) in inventory Increase (decrease) in accounts payable Increase (decrease) in accrued expenses and other current liabilities Increase (decrease) in due to related parties Net cash used in operating activities Cash flows from investing activities Long-term equity investment Net cash used in investing activities Cash flows from financing activities Issuance of common stock for acquisition Proceeds from short-term bank loan Proceeds from short-term borrowing from third parties Borrowings from related parties Repayment of borrowings from related parties Repayment of long-term bank loans Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents Beginning Ending Supplemental disclosure of cash flows Cash paid during the year for: Interest expense paid Income taxes paid Statement [Table] Statement [Line Items] Stock Subscription Receivable Additional Paid-in Capital Accumulated Deficit Comprehensive Income Balance Balance, Shares Issuance of common shares Issuance of common shares, Shares Effects of restructuring Effects of restructuring, shares Stock based compensation Net loss for the period Cumulative transaction adjustments Balance Balance, Shares Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Collaborative Agreements [Abstract] COLLABORATIVE AGREEMENTS Inventory Disclosure [Abstract] INVENTORY Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Long-Term Investment [Abstract] LONG-TERM INVESTMENTS Convertible Notes Payable [Abstract] CONVERTIBLE NOTES PAYABLE Bank Loans [Abstract] BANK LOANS Notes Payable [Abstract] NOTES PAYABLE Debt Disclosure [Abstract] SHORT-TERM LOAN Related Party Transactions [Abstract] RELATED PARTIES TRANSACTIONS Equity [Abstract] EQUITY Earnings Per Share [Abstract] LOSS PER SHARE Leases [Abstract] LEASE Business Combinations [Abstract] BUSINESS COMBINATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Fiscal Year Use of Estimates Inventory Reclassifications Forward Stock split Stock Reverse Split Fair Value Measurements Cash and Cash Equivalents Restricted Cash Equivalents Concentration of Credit Risk Revenue Recognition Property and Equipment Impairment of Long-Lived Assets Long-term Equity Investment Other-Than-Temporary Impairment Goodwill Research and Development Expenses Post-retirement and post-employment benefits Stock-based Compensation Beneficial Conversion Feature Income Taxes Valuation of Deferred Tax Assets Loss Per Share of Common Stock Commitments and Contingencies Foreign-currency Transactions Translation Adjustment Recent Accounting Pronouncements Schedule of property and equipment Schedule of inventory Schedule of property and equipment BioFirst [Member] Rgene [Member] Schedule of ownership percentages of investee Schedule of extent the investee relies Schedule of long-term investment Schedule of balance sheets Schedule of statements of operation Schedule of equity investments Schedule of short-term bank loan Schedule of long-term bank loan Schedule of related party transactions Schedule of accounts receivable due from related parties Schedule of amount due from related parties Schedule of amount due to related party Schedule of converted amount of debt and shares Schedule of loss per share Schedule of operating lease arrangements Schedule of supplemental information related to operating leases Schedule of minimum future annual payments under non-cancellable leases Schedule of assets acquired and liabilities assumed based on fair value Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Organization and Description of Business (Textual) Common stock issued post-stock split Common stock issued pre-stock split Percentage of common shares issued and outstanding Percentage of issued share capital Common stock converted to exchange ratio Machinery and equipment [Member] Office equipment [Member] Statistical Measurement [Axis] Estimated Life Summary of Significant Accounting Policies (Textual) Forward split ratio Common stock, authorized Restricted cash equivalents Impairments of equity investments Employee stock-based compensation expenses Post-retirement and post-employment benefits, Description Non-employee stock-based compensation expenses Effectiveness date Employee benefits amount Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Agreements (Textual) Description of payment settlement Amount received from BriVision Upfront payments Percentage of payments under co-development agreement Milestone payments to BioLite in cash Common stock newly issued, value Share price Licensing rights Company cash payments Research and development expense Outstanding balance Agreement, terms Co-Dev agreement, description Milestone payments royalty percentage Collaborative Agreements, description Shares issued Shares value Finished goods Work-in-process Raw materials Allowance for inventory valuation and obsolescence loss Subtotal Less: accumulated depreciation Property and Equipment (Textual) Depreciation expenses Braingenesis Biotechnology Co., Ltd [Member] Rgene Corporation [Member] Ownership percentage Accounting treatments Relationship with the Company and its subsidiaries, description Non-marketable Cost Method Investments, net Sub total Total BioFirst [Member] Current Assets Noncurrent Assets Current Liabilities Noncurrent Liabilities Shareholders' Deficit Net sales Gross profit Net loss Share of losses from investments accounted for using the equity method Share of equity method investee losses Long-Term Investments (Textual) Percentage of common stock shares Sale of common stock, description Convertible Notes Payable (Textual) Aggregate principal amount Bears interest rate Convertible promissory note received Equity offering, description Conversion price, description Convertible debenture Accrued convertible interest Interest expenses in connection with convertible notes payable Unsecured convertible promissory note, description Total interest expenses Cathay Bank [Member] Total Cathay United Bank Less: current portion of long-term bank loan Total TypeOfCurrencyAxis [Axis] DateAxis [Axis] Bank Loans (Textual) Principal amount Maturity date Debt instrument term Bears interest floating rate Debt instrument due date Interest expenses Received loan amount Exceeding amount Regular interest rate, description BioLite Taiwan [Member] Notes Payable (Textual) Interest expenses Unsecured loan agreements, description Notes payable, description Unsecured loan amount Interest rate BioFirst Corporation (the "BioFirst") [Member] BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") [Member] Rgene Corporation (the "Rgene") [Member] Yuangene Corporation (the "Yuangene") [Member] AsiaGene Corporation (the "AsiaGene") [Member] Keypoint Technology Ltd. (the "Keypoint') [Member] Lion Arts Promotion Inc. (the "Lion Arts") Yoshinobu Odaira (the "Odaira") [Member] Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") [Member] Kimho Consultants Co., Ltd. (the "Kimho") [Member] LBG USA, Inc. (the "LBG USA") [Member] LionGene Corporation (the "LionGene") [Member] Jiangs [Member] GenePharm Inc. [Member] Amkey [Member] Accounts receivable due from related parties AsiaGene [Member] Total LionGene Corporation [Member] AsiaGene [Member] YuanGene [Member] Lion Arts Promotion Inc. [Member] Total Keypoint Note [Member] Odaira Note [Member] Related Parties Transactions (Textual) Outstanding loan balance Accrued interest Interest expenses Loan agreement, description Aggregate working capital Amount of equivalent Interest rate percentage Loan maturity date Outstanding advance Other receivable from related parties Conversion price Convertion of debt Conversion of debt, shares Stock purchase agreement, description Investment and equity transfer agreement, description Related party transactions, description Outstanding advance balance Advances bear interest, description Outstanding services charge Lion Arts Promotion Inc [Member] Amount of Debt Converted Number of Shares Issued Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Officer One [Member] Officer Two [Member] Officer Three [Member] Euro-Asia Investment & Finance Corp Ltd. [Member] 2016 Equity Incentive Plan [Member] Equity (Textual) Issuance of common shares Issuance of common shares, shares Exchange ratio Percentage of payments under collaborative agreement Consulting agreement, description Professional fees Non-employee stock-based compensation Common stock, shares issued total Financial amendment, description Agreement, description Due to related parties consideration Common stock price per share Subscription receivable Numerator: Net loss Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding - Basic Stock options Weighted-average shares outstanding - Diluted Loss per share -Basic -Diluted LIABILITIES Operating lease liabilities (current) Operating lease liabilities (noncurrent) Operating lease expenses Cash paid for amounts included in the measurement of operating lease liabilities Weighted average remaining lease term Weighted average discount rate 2020 ((excluding the three months ended March 31, 2020) 2021 2022 2023 2024 Total future minimum lease payments, undiscounted Less: Imputed interest Present value of future minimum lease payments BioFirst Corporation [Member] ASC 842 [Member] Lease (Textual) Operating lease liabilities Current operating lease liabilities Non-current operating lease liabilities Cumulative-effect adjustment of opening balance of accumulated deficit Description of reverse stock split Purchase consideration: Common Stock Allocation of the purchase price: Cash and cash equivalents Accounts receivable, net Property and equipment, net Operating lease right-of-use assets Security deposits Total assets acquired Accounts payable Accrued expenses and other current liabilities Operating lease liability Tenant security deposit Total liabilities assumed Total net assets acquired Goodwill as a result of the Merger Business Combination (Textual) Goodwill write-down value Percentage of goodwill Common stock issued Reverse stock split Common stock per share AgreemnetAxis [Axis] Subsequent Events (Textual) Accrued interest expenses Per share Common stock par value Warrants to purchase Shares authorized, description Description of subsequent event Capital contributions received Warrant exercise price Aggregate working capital. Agreement related description. Allowance for inventory valuation and obsolescence loss. Disclosure of accounting policy for beneficial conversion feature. Co-Dev agreement description. Collaborative Agreements, description Contractual arrangement one that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Common stock issued after stock split. Common stock issued before stock split. Common stock shares issued total. Consulting agreement description. The exchange ratio per stock split. Disclosure of convertible notes payable. Cumulative-effect adjustment of opening balance of accumulated deficit. Cumulative transaction adjustments. Debt instrument due date. Disclosure of bank loans text block. Equity incentive plan member. Exceeding amount. Disclosure of accounting policy for forward stock splits. Disclosure of accounting policy for long-term equity investment. This element represents the amount of loss recognized for other than temporary impairments (OTTI) of investments in debt and equity securities. Milestone payments. Milestone payments royalty percentage. Net loss attributable to ABVC and subsidiaries. Organization and description of business textual. Accumulated other comprehensive income. Disclosure of accounting policy for other than temporary impairment. Percentage of issued share capital. Percentage of payments under co-development agreement. Percentage of payments under collaborative agreement. Received loan amount. Regular interest rate description. It represents related party descriptions. Schedule of extent the investee relies. Schedule of operating lease arrangements. Schedule of property and equipment. Tabular disclosure of related party transactions. Amount due to related party. Schedule of supplemental information related to operating leases. Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements. Stock based compensation for nonemployees. Disclosure of accounting policy for Stock Reverse Split. Summary of significant accounting policies textual. Disclosure of accounting policy for translation adjustment. Description of unsecured loan agreements. The amount of upfront payments which are paid during the term of agreement. Disclosure of accounting policy for valuation of deferred tax assets. Notes payable, description Accrued interest Stock purchase agreement description. Investment and equity transfer agreement description. Advances bear interest description. The number of warrants to purchase. Total interest expenses. The value of outstanding services charge. Amount of subscription receivable was fully collected from the shareholders. Number of shares issued during the period effects of restructuring. Number of value issued during the period effects of restructuring. GenePharmMember Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Note, Subscriptions Receivable Treasury Stock, Value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Other Nonoperating Income (Expense) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Parent NetLossAttributableToAbvcAndSubsidiaries Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted Average Number of Shares Outstanding, Basic and Diluted Unrealized Gain (Loss) on Investments Other Noncash Income (Expense) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable and Other Operating Assets Increase (Decrease) in Other Receivables Increase (Decrease) Due from Other Related Parties Increase (Decrease) in Inventories Net Cash Provided by (Used in) Operating Activities Payments to Acquire Investments Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Repayments of Bank Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Shares, Outstanding ScheduleOfPropertyAndEquipment AllowanceForInventoryValuationAndObsolescenceLoss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Short-term Debt Long-term Debt, Current Maturities Long-term Debt, Excluding Current Maturities Interest Expense, Other StockIssuedValue NetLoss Operating Leases, Future Minimum Payments Due Business Combination, Consideration Transferred, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities EX-101.PRE 11 abvcd-20200331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2020
Jun. 26, 2020
Document and Entity Information [Abstract]    
Entity Registrant Name American BriVision (Holding) Corp  
Entity Central Index Key 0001173313  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Mar. 31, 2020  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2020  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Current Reporting Status Yes  
Entity Emerging Growth Company false  
Entity Filer Number 333-91436  
Entity Interactive Data Current Yes  
Entity Incorporation State Country Code NV  
Entity Common Stock, Shares Outstanding   19,488,168
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 123,645 $ 144,295
Restricted cash and cash equivalents 16,148 16,148
Accounts receivable, net 110,217 163,566
Accounts receivable - related parties, net 143,677 143,278
Due from related parties 337,778 333,682
Inventory, net
Prepaid expense and other current assets 71,026 77,269
Total Current Assets 802,491 878,238
Property and equipment, net 505,408 520,930
Operating lease right-of-use assets 449,683 524,445
Goodwill, net
Long-term investments 3,264,200 3,364,619
Deferred tax assets 1,487,364 1,460,033
Prepaid expenses - noncurrent 112,173 135,443
Security deposits 43,890 44,103
Total Assets 6,665,209 6,927,811
Current Liabilities    
Accounts payable 20,363 23,995
Short-term bank loans 1,910,250 1,918,500
Short-term loan 100,000
Long-term bank loans - current portion 3,332 13,403
Notes payable 99,300 100,200
Accrued expenses and other current liabilities 2,502,749 2,007,573
Advance from customers 13,089 13,085
Operating lease liabilities – current portion 282,715 304,248
Due to related parties 715,303 425,689
Convertible notes payable - current portion 820,000 820,000
Convertible notes payable - related parties, current portion 1,187,500 1,187,500
Total Current Liabilities 7,654,601 6,814,193
Tenant security deposit 2,880 2,880
Operating lease liability – noncurrent portion 179,994 235,555
Total Liabilities 7,837,475 7,052,628
Equity    
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 19,488,168 and 19,478,168 shares issued and outstanding 19,488 19,478
Additional paid-in capital 28,222,862 28,180,348
Stock subscription receivable (3,837,580) (4,063,320)
Accumulated deficit (17,098,761) (15,851,223)
Other comprehensive income 657,302 663,753
Treasury stock (9,100,000) (9,100,000)
Total Stockholders' deficit (1,136,689) (150,964)
Noncontrolling interest (35,577) 26,147
Total Equity (Deficit) (1,172,266) (124,817)
Total Liabilities and Equity (Deficit) $ 6,665,209 $ 6,927,811
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 19,488,168 19,478,168
Common stock, shares outstanding 19,488,168 19,478,168
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Operations (unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Revenues $ 78,786 $ 212,242
Cost of revenues 3,959 1,499
Gross profit 74,827 210,743
Operating expenses    
Selling, general and administrative expenses 1,152,889 510,803
Research and development expenses 92,790 421,956
Stock-based compensation 525 8,550
Total operating expenses 1,246,204 941,309
Loss from operations (1,171,377) (730,566)
Other income (expense)    
Interest income 10,720 189
Interest expense (131,517) (129,886)
Rental income 5,231 (4,291)
Rental income - related parties 1,200 400
Gain/Loss on foreign exchange changes 2 (3)
Gain/Loss on investment in equity securities (70,411) (66,205)
Other income (expense) 6,322 (500)
Total other expenses (178,453) (200,296)
Loss before provision income tax (1,349,830) (930,862)
Provision for income tax (40,568) (57,545)
Net loss (1,309,262) (873,317)
Net loss attributable to noncontrolling interests (61,724) (81,646)
Net loss attributed to ABVC and subsidiaries (1,247,538) (791,671)
Foreign currency translation adjustment (6,451) (86,786)
Comprehensive loss $ (1,253,989) $ (878,457)
Net loss per share:    
Basic and diluted $ (0.06) $ (0.05)
Weighted average number of common shares outstanding:    
Basic and diluted 19,484,542 14,965,665
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities    
Net loss $ (1,309,262) $ (873,317)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 11,174 13,940
Stock based compensation for nonemployees 525 8,550
Gain/Loss on investment in equity securities 70,411 66,205
Other non-cash income and expenses (2,333) (553)
Deferred tax (40,568) (48,028)
Changes in operating assets and liabilities:    
Decrease (increase) in accounts receivable 52,950 (116,334)
Decrease (increase) in prepaid expenses and deposits 27,834 29,237
Decrease (increase) in other receivable 39,005
Decrease (increase) in due from related parties (7,536) 1,252
Decrease (increase) in inventory 797
Increase (decrease) in accounts payable (3,632) (37,353)
Increase (decrease) in accrued expenses and other current liabilities 500,743 305,214
Increase (decrease) in due to related parties 68,750 11,857
Net cash used in operating activities (630,944) (599,528)
Cash flows from investing activities    
Long-term equity investment (17,801)
Net cash used in investing activities (17,801)
Cash flows from financing activities    
Issuance of common stock for acquisition 267,740 531,147
Proceeds from short-term bank loan 1,000,000
Proceeds from short-term borrowing from third parties 280,940  
Borrowings from related parties 71,688 312,660
Repayment of borrowings from related parties (460,000)
Repayment of long-term bank loans (9,981) (10,016)
Net cash provided by financing activities 610,387 1,373,791
Effect of exchange rate changes on cash and cash equivalents (93) (1,809)
Net increase (decrease) in cash and cash equivalents (20,650) 754,653
Cash and cash equivalents    
Beginning 160,443 242,781
Ending 139,793 997,434
Cash paid during the year for:    
Interest expense paid 10,446 26,592
Income taxes paid $ 1,250
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($)
Common Stock
Stock Subscription Receivable
Additional Paid-in Capital
Accumulated Deficit
Comprehensive Income
Treasury Stock
Noncontrolling Interest
Total
Balance at Dec. 31, 2018 $ 11,885 $ 14,983,714 $ (12,209,446) $ 655,851 $ (9,100,000) $ 317,610 $ (5,340,386)
Balance, Shares at Dec. 31, 2018 11,885,468         (275,347)    
Issuance of common shares $ 1,642 692,577 694,219
Issuance of common shares, Shares 1,642,291              
Effects of restructuring $ 4,167 (4,167)
Effects of restructuring, shares 4,166,530              
Stock based compensation 8,550 8,550
Net loss for the period (791,671)     (81,646) (873,317)
Cumulative transaction adjustments (15,412) (15,412)
Balance at Mar. 31, 2019 $ 17,694 15,680,674 (13,001,117) 640,439 $ (9,100,000) 235,964 (5,526,346)
Balance, Shares at Mar. 31, 2019 17,694,289         (275,347)    
Balance at Dec. 31, 2019 $ 19,478 (4,063,320) 28,180,348 (15,851,223) 663,755 $ (9,100,000) 26,146 (124,817)
Balance, Shares at Dec. 31, 2019 19,478,168         (275,347)    
Issuance of common shares $ 10 225,740 41,989 267,739
Issuance of common shares, Shares 10,000              
Stock based compensation 525 525
Net loss for the period (1,247,538) (61,724) (1,309,262)
Cumulative transaction adjustments (6,451) (6,451)
Balance at Mar. 31, 2020 $ 19,488 $ (3,837,580) $ 28,222,862 $ (17,098,761) $ 657,302 $ (9,100,000) $ (35,577) $ (1,172,266)
Balance, Shares at Mar. 31, 2020 19,488,168         (275,347)    
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Description of Business
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

American BriVision (Holding) Corporation (the "Company" or "Holding entity"), a Nevada corporation, through the Company's operating entity, American BriVision Corporation (the "BriVision"), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center ("MSKCC") and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and exploit global markets. BriVision had to predecessor operations prior to its formation on July 21, 2015.

 

Reverse Merger

 

On February 8, 2016, a Share Exchange Agreement (the "Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation ("BriVision"), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock (the "Common Stock") of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock").

 

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the "Merger").

 

Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company's Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision had become a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

Upon the consummation of the Share Exchange, BriVision became our wholly owned subsidiary of the Company.

 

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision's historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and explore global markets.

 

Accounting Treatment of the Reverse Merger

 

For financial reporting purposes, the Share Exchange represents a "reverse merger" rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

 

Merger

 

On February 8, 2019, the Company, BioLite Holding, Inc. ("BioLite"), BioKey, Inc. ("BioKey"), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 1"), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent ("Merger Sub 2") (collectively referred to as the "Parties") completed the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.

 

Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.

 

BioLite Holding, Inc. (the "BioLite Holding") was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the "BioLite BVI"), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.

 

BioLite, Inc., (the "BioLite Taiwan") was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.

 

In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the "BioLite Share Purchase / Exchange Agreement"). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.

 

BioKey, Inc. was incorporated on August 9, 2000 in the State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.

 

Accounting Treatment of the Merger

 

The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang's common control, the transaction is accounted for as a restructuring transaction. All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding's common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars.

 

Fiscal Year 

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year. 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Inventory

 

Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.

 

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

Forward Stock Split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

Stock Reverse Split

 

On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

 

Fair Value Measurements

 

FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:

 

  ● Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.
     
  ● Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  ● Level 3 – Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.

 

The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.

 

Cash and Cash Equivalents 

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted $123,645 and $144,295, respectively. Some of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.

 

Restricted Cash Equivalents 

 

Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $16,148 and $16,148, respectively.

 

Concentration of Credit Risk

 

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.

 

Revenue Recognition

 

During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented.

 

Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

 

The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.

 

Merchandise Sales — The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company's products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or "transaction price," which includes applicable reserves for variable consideration, including discounts, allowances, and returns.

 

Trade discount and allowances: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.

 

Product returns: The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company's customers have the right to return unopened packages, subject to contractual limitations.

 

To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.

 

Collaborative Revenues — The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.

 

As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success.

 

The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.

 

(i)       Nonrefundable upfront payments

 

If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.

 

(ii)       Milestone payments

 

The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners.

 

The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.

 

(iii)       Multiple Element Arrangements

 

The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).

 

The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.

 

At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.

 

(iv)       Royalties and Profit Sharing Payments

 

Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.

 

Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.

 

If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.

 

The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.

 

The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.

 

Property and Equipment

 

Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:

 

   Estimated Life
in Years
Buildings and leasehold improvements  5 ~ 50
Machinery and equipment  5 ~ 10
Office equipment  3 ~ 6

 

Impairment of Long-Lived Assets

 

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

 

Long-term Equity Investment 

 

The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:

 

●Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.

 

●Non-marketable cost method investments when the equity method does not apply.

 

Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.

 

Other-Than-Temporary Impairment

 

The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:

 

●       Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.

 

●       Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three month ended March 31, 2020 and 2019.

 

Goodwill

 

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

 

The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.

 

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

 

For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.

 

Post-retirement and post-employment benefits

 

The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.

 

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation". Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.

 

The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation" and FASB ASC Topic 505-50 "Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.

 

Beneficial Conversion Feature

 

From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin ("SAB 118"), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.

 

Valuation of Deferred Tax Assets

 

A valuation allowance is recorded to reduce the Company's deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company's projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.

 

Loss Per Share of Common Stock

 

The Company calculates net loss per share in accordance with ASC Topic 260, "Earnings per Share". Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.

 

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 "Contingencies" subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 

Foreign-currency Transactions

 

For the Company's subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars ("NTD") at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders' Equity (Deficit).

 

Translation Adjustment

 

The accounts of the Company's subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar ("NT$"). Such financial statements were translated into U.S. Dollars ("$" or "USD") in accordance ASC 830, "Foreign Currency Matters", with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder's deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders' equity (deficit).

 

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Agreements
 3 Months Ended
Mar. 31, 2020
Collaborative Agreements [Abstract]  
COLLABORATIVE AGREEMENTS

3. COLLABORATIVE AGREEMENTS

 

Collaborative agreements with BHK

 

(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement"), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:

 

  ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

 

  ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment

 

  ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment

 

  ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment

 

  ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment

 

In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.

 

In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK's net sales related to BLI-1401-2 Products. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Co-Development Agreement.

 

(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the "BHK Collaborative Agreements"), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for "Targeting Major Depressive Disorder" (BLI-1005 Products) and BLI-1006 for "Targeting Inflammatory Bowel Disease" (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.

 

In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.

 

In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.

 

Co-Development agreement with Rgene Corporation, a related party

 

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the "Co-Dev Agreement") with Rgene Corporation (the "Rgene"), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 11). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision's past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides of $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

 

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of Yuangene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company has determined to fully write off this investment based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene's ability to remain in business. However, all projects that have been initiated and scheduled will be continuously managed and supported by the Company and Rgene.

 

Collaborative agreement with BioFirst Corporation, a related party

 

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst Corporation ("BioFirst"), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the "Product"): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of Yuangene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 11).

 

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst's past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

 

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.

 

On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the "Purchase Agreement") with BioFirst Corporation ("BioFirst"). Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the "Total Payment") in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the "Collaborative Agreement"). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.

 

On August 5, 2019, BriVision entered into a Stock Purchase Agreement (the "Purchase Agreement") with BioFirst Corporation ("BioFirst"). Pursuant to the Purchase Agreement, the Company issued 414,702 shares of the Company's common stock (the "Shares") to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst (the "Total Payment") in connection with a sunk payments that were due to related party prior to the conversion.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORY

4. INVENTORY

 

Inventory consists of the following:

 

   March 31,
 2020		   December 31,
 2019		 
   (Unaudited)     
Finished goods  $94,508   $94,727 
Work-in-process   20,491    20,676 
Raw materials   57,384    57,904 
Allowance for inventory valuation and obsolescence loss   (172,383)   (173,307)
Inventory, net  $-   $-
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
 3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

5. PROPERTY AND EQUIPMENT

 

Property and equipment as of March 31, 2020 and December 31, 2019 are summarized as follows:

 

   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Land  $367,861   $371,195 
Buildings and leasehold improvements   2,224,270    2,225,386 
Machinery and equipment   986,237    987,234 
Office equipment   176,861    178,409 
    3,755,229    3,762,224 
Less: accumulated depreciation   (3,249,821)   (3,241,294)
Property and equipment, net  $505,408   $520,930 

  

Depreciation expenses were $11,174 and $13,940 for three months ended March 31, 2020 and 2019, respectively.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments
 3 Months Ended
Mar. 31, 2020
Long-Term Investment [Abstract]  
LONG-TERM INVESTMENTS

6. LONG-TERM INVESTMENTS

  

(1) The ownership percentages of each investee are listed as follows:

 

   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2020   2019   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   7.13%   7.13%  Cost Method
BioFirst Corporation   15.89%   15.89%  Equity Method
Rgene Corporation   31.61%   31.61%  Equity Method

 

(2) The extent the investee relies on the company for its business are summarized as follows:

 

Name of related party  The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Loaned from the investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs

  

(3) Long-term investment mainly consists of the following:

 

   March 31,
2020		   December 31,
2019		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,301   $7,367 
Genepharm Biotech Corporation   22,291    22,493 
BioHopeKing Corporation   1,980,361    1,998,310 
Sub total   2,009,953    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   1,254,247    1,336,449 
Rgene Corporation   -    - 
Total  $3,264,200   $3,364,619 

  

(a) BioFirst Corporation (the "BioFirst):

 

The Company holds an equity interest in BioFirst Corporation, (the "BioFirst"), accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 15.89% and 15.89% common stock shares of BioFirst, respectively.

 

Summarized financial information for the Company's equity method investee, BioFirst, is as follows:

 

Balance Sheet

 

   March 31,
 2020		  

December 31,
2019

 
   (Unaudited)     
Current Assets  $1,235,043   $1,350,701 
Noncurrent Assets   7,238,415    7,450,032 
Current Liabilities   2,105,938    2,060,460 
Noncurrent Liabilities   65,847    78,888 
Shareholders' Equity   6,301,673    6,661,385 

 

Statement of operation

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $12,110   $10,334 
Gross profit   1,578    1,882 
Net loss   (325,652)   (307,034)
Share of losses from investments accounted for using the equity method   (70,411)   (66,205)

 

(b) Rgene Corporation (the "Rgene")

 

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the Company. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures ("ASC 323"). Equity method adjustments include the Company's proportionate share of investee's income or loss and other adjustments required by the equity method. As of March 31, 2020 and December 31, 2019, the Company owns 31.61% and 31.61% Common Stock shares of Rgene, respectively.

  

Summarized financial information for the Company's equity method investee, Rgene, is as follows:

 

Balance Sheets

 

   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $136.936   $82,254 
Noncurrent Assets   161,255    62,768 
Current Liabilities   462,667    312,950 
Noncurrent Liabilities   62,801    - 
Shareholders' Deficit   (227,277)   (167,928)

 

Statement of operations

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $      $   
Gross Profit          
Net loss   (21,889)   (22,662)
Share  of loss from investments accounted for using the equity method   -    - 

 

(4) Disposition of long-term investment

 

During the year ended December 31, 2018, the Company sold 552,000 shares of common stock of BioHopeKing Corporation (the "BHK") at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period.

 

On October 15, 2018 and November 2, 2018, the Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.

 

(5) Losses  on Equity Investments

 

The components of losses on equity investments for each period were as follows:

 

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(70,411)  $(66,205)
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes Payable
 3 Months Ended
Mar. 31, 2020
Convertible Notes Payable [Abstract]  
CONVERTIBLE NOTES PAYABLE

7. CONVERTIBLE NOTES PAYABLE

 

On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Yu and Wei Note") in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the "Yu and Wei"), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note as of December 31, 2019 and 2018. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses are $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock.

 

On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the "Keypoint Note") in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. ("Keypoint"), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note as of December 31, 2019 and 2018. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses are $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock.

 

On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the "Odaira Note") in the aggregate principal amount of $250,000 to Yoshinobu Odaira. ("Odaira"), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaria Note as of December 31, 2019. On January 21, 2020, Odiara entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses are $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock.

 

On May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the "KSL Note") in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the "KSL"), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to the KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020,. At any time from the date hereof until this KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company has received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 month.

 

On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "NEA Note") in an aggregate principal amount of $250,000 to New Eastern Asia (the "NEA"), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note as of March 31, 2020.

 

On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "KLS Note") in an aggregate principal amount of $200,000 to Kuo Li Shen (the "KLS"), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses are $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 126,530 shares of Common Stock.

 

On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the "C.L.L. Note") in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the "C.L.L."), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses are $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 162,908 shares of Common Stock.

 

On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the "Lee Note") in an aggregate principal amount of $250,000 to Hawlin Lee (the "Lee"), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020 , and the company has not received any indication from NEA that it wants to claim the repayment of loan for 12 month. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price (the "Conversion Price") equal to the lower of (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note as of March 31, 2020.

 

As of March 31, 2020 and December 31, 2019, the aggregate carrying values of the convertible debentures were $2,007,500 and $2,007,500, respectively; and accrued convertible interest was $277,066 and $181,852, respectively.

 

Total interest expenses in connection with the above convertible note payable were $95,214 and $16,000 for the three months ended March 31, 2020 and 2019, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Bank Loans
 3 Months Ended
Mar. 31, 2020
Bank Loans [Abstract]  
BANK LOANS

8. BANK LOANS

 

(1) Short-term bank loan consists of the following:

 

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $248,250   $250,500 
CTBC Bank   662,000    668,000 
Cathay Bank   1,000,000    1,000,000 
Total  $1,910,250   $1,918,500 

 

Cathay United Bank

 

On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the "Cathay United Loan Agreement") in an amount of NT$7,500,000, equivalent to $248,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $248,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $248,250 for one year, which is due on September 6, 2020. As of March 31, 2020 and 2019, the effective interest rates per annum were 2.22%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman.

 

Interest expenses were $1,378 and $1,330 for the three months ended March 31, 2020 and 2019, respectively.

 

CTBC Bank

 

On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the "CTBC Loan Agreements") in an amount of NT$10,000,000, equivalent to $331,000, and NT$10,000,000, equivalent to $331,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $662,000 for 6 months, which is due on July 19, 2020. The loan balances bear interest at a fixed rate of 1.63% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan is also personal guaranteed by the Company's chairman and BioFirst.

 

Interest expenses were $2,755 and $2,604 for the three months ended March 31, 2020 and 2019, respectively.

 

Cathay Bank

 

On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the "Bank") pursuant to a business loan agreement (the "Loan Agreement") entered by and between the Company and Bank on January 8, 2019 and a promissory note (the "Note") executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the "Maturity Date") of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate. After the completion of Merger, the Company had updated relevant documents with the state of California and is working with the Bank to revise its internal records and reviewing the Company's request for loan extension.

 

In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the "Guaranty") to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned subsidiary of the Company effective by operation of law on or about February 5, 2019.

 

In addition, on January 8, 2019, each of the Company and BriVision, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the "Security Agreement") to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BriVision (each, a "Grantor", and collectively, the "Grantors") granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020.

 

Interest expenses were $13,740 and $9,527 for the three months ended March 31, 2020 and 2019, respectively.

 

(2) Long-term bank loan consists of the following:

 

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $3,332   $13,403 
Less: current portion of long-term bank loan   (3,332)   (13,403)
Total  $-   $- 

 

On April 30, 2010, BioLite Taiwan entered a seven-year bank loan of NT$8,900,000, equivalent to $288,360, with Cathay United Bank. The term started April 30, 2010 with maturity date at April 30, 2017. On April 30, 2017, BioLite Taiwan extended the original loan agreement for additional three years with the new maturity date at April 30, 2020. The loan balance bears interest at a floating rate of prime rate plus variable rates from 0.77% to 1.17%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. As of March 31, 2020 and 2019, the actual interest rates per annum were 2.24%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company's chairman.

 

Interest expenses were $56 and $284 for the three months ended March 31, 2020 and 2019, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Notes Payable
 3 Months Ended
Mar. 31, 2020
Notes Payable [Abstract]  
NOTES PAYABLE

9. NOTES PAYABLE

 

On December 27, 2018, BioLite Taiwan issued a promissory note of NT$450,000, equivalent to $14,715, to Taipei Veterans General Hospital to repay the clinical experiment costs. The note has been paid in full on January 2, 2019.

 

On March 27, 2018, BioLite Taiwan and two individuals entered into a promissory note, (the "Hsu and Chow Promissory Note"), for borrowing an aggregate amount of NT$4,660,000, equivalent to $155,800, for the period from March 27, 2018 to June 26, 2018. On September 26, 2018, BioLite Taiwan extended the original loan agreement through December 26, 2018. On September 26, 2019, BioLite Taiwan renewed and amended the contract with the "Hsu" only and extend the maturity date to December 26, 2019. The principal of the Hsu new Promissory Note bears interest at 13.6224% per annum. This Note was secured by common stock shares of ABVC and was also personal guaranteed by the Chairman of BioLite Taiwan. Interest expense was $5,269 and $5,085 for the three months ended March 31, 2020 and 2019, respectively.

 

In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $99,300, for working capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of the unsecured loans. Interest expense was $2,988 and $2,916 for the three months ended March 31, 2020 and 2019, respectively.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Short-term Loan
 3 Months Ended
Mar. 31, 2020
Debt Disclosure [Abstract]  
SHORT-TERM LOAN

10. SHORT-TERM LOAN

 

On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions
 3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
RELATED PARTIES TRANSACTIONS

11. RELATED PARTIES TRANSACTIONS 

 

The related parties of the company with whom transactions are reported in these financial statements are as follows:

  

Name of entity or Individual  Relationship with the Company and its subsidiaries
BioFirst Corporation (the "BioFirst")  Entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)")  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene")  Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the "Yuangene")  Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the "AsiaGene")  Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang  Former President and Chairman
Keypoint Technology Ltd. (the "Keypoint')  The Chairman of Keypoint is Eugene Jiang's mother.
Lion Arts Promotion Inc. (the "Lion Arts")  Shareholder of the Company
Yoshinobu Odaira (the "Odaira")  Director of the Company
GenePharm Inc. (the "GenePharm")  Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia")  Shareholder of the Company
LBG USA, Inc. (the "LBG USA")  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the "LionGene")  Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the "Kimho")  Shareholder of the Company
Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs")  Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst
 
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc.
 
Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
 
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang's sibling and the director of the Company.
 
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang's sibling.
Amkey Ventures, LLC ("Amkey")   An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc

 

Accounts receivable – related parties

 

Accounts receivable due from related parties consisted of the following as of the periods indicated:

 

 

   March 31,   December 31, 
   2020   2019 
GenePharm Inc.  $142,225   $142,225 
Rgene   1,052    1,053 
Amkey   400    - 
Total  $143,677   $143,278 

 

Due from related parties

 

Amount due from related parties consisted of the following as of the periods indicated:

 

   March 31,   December 31, 
   2020   2019 
Rgene  $36,903   $36,332 
AsiaGene   3,645    3,578 
BioFirst   141,650    137,151 
BioFirst (Australia)   40,000    40,000 
BioHopeKing Corporation   114,905    115,946 
LBG USA   675    675 
Total  $337,778   $333,682 

 

(1) As of March 31, 2020, and December 31, 2019, the Company has advanced an aggregate amount of $36,903 and $36,332 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the contract has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $28,953 and $29,194, and accrued interest was $7,950 and $7,138, respectively.

 

(2) On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,310, to meet its working capital needs.  Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019. On January 1, 2020, the agreement has been renewed for another year, when the new maturity date now is on December 31, 2020. As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $3,310 and $3,340, and accrued interest was $335 and $238, respectively.

 

(3) On July 12, 2019, the Company had an aggregate amount of loan with BioFirst of $150,000 to meet its working capital needs, pursuant to which the interest bears at 12% per annum. The Company paid back $21,317 in 2019. The remaining loan balance was $128,683 as of December 31, 2019. This loan is matured on July 11, 2020 and bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2020, and December 31, 2019, the outstanding loan balance was $128,683, and accrued interest was $12,967 and $8,468, respectively.

 

(4) On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and December 31, 2019, the outstanding loan balances were $40,000.

 

(5) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the "BHK") entered into a co-development agreement, (the "BHK Co-Development Agreement", see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2020 and 2019, due from related parties was $114,905 and $115,946, respectively.

 

(6) On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of March 31, 2020 and 2019, the outstanding advance balances were $675.

  

Due to related parties

 

Amount due to related parties consisted of the following as of the periods indicated:

 

   March 31,   December  31, 
   2020   2019 
LionGene Corporation  $10,481   $10,275 
BioFirst Corporation   218,261    24,182 
AsiaGene   24,017    24,017 
YuanGene   9,205    9,205 
The Jiangs   58,503    40,031 
Kimho   55,000    21,500 
Euro Asia   12,000    12,000 
Due to shareholders   233,832    284,479 
Due to employees   94,004    - 
Total  $715,303   $425,689 

 

(1) In September, 2018, BioLite Taiwan has borrowed an aggregate amount of NT$2,950,000, equivalent to $94,990, from LION ARTS for working capital purpose. These loans bear interest at fixed rates at 12% per annum with various maturity dates through April 14, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert all of the remaining balance of $97,864 to 13,981 shares of the Company's common stock at a conversion price of $7.00 per share (see Note 11). As such, no balance is due as of March 31, 2020 and December 31, 2019.

 

(2)

In November 2018, BioLite Taiwan has borrowed an aggregate amount of NT$13,295,000, equivalent to $430,817 from LionGene for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the all of remaining balance of $428,099, to 61,157 shares of the Company's common stock at a conversion price of $7.00 per share.

 

On October 15, 2019, LionGene has advanced funds to the Company for working capital purpose in an aggregate amount of NTD $300,000, equivalent to $9,930, The advances bear 1% interest rate and as of March 31, 2020, the accrued interest rate is $551.

 

(3)

On January 26, 2017, BriVision and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. On February 2, 2019, BriVision and BioFirst agreed to extend the remaining loan balance of $693,000 for one year matured on February 1, 2020. Under the terms of the loan agreement, the loan bears interest at 12% per annum. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $693,000 to 99,000 shares of the Company's common stock at a conversion price of $7.00 per share.

 

Since 2017, BioLite Taiwan and BioFirst entered into several loan agreements for an aggregate amount of NT$19,430,000, equivalent to $625,646, to meet its working capital needs. Under the terms of the loan agreements, the loans bear interest at 12% per annum. The term of the loans has various maturity dates through May 27, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $625,646 to 89,378 shares of the Company's common stock at a conversion price of $7.00 per share.

 

Since 2017, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $597,128 to 85,304 shares of the Company's common stock at a conversion price of $7.00 per share.

 

On April 12, 2017, BioLite BVI and BioFirst entered into a loan agreement for NT$30,000,000, equivalent to $987,134 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). BioLite BVI and BioFirst extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2019. On May 12, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on May 11, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $987,134 to 141,020 shares of the Company's common stock at a conversion price of $7.00 per share.

 

On July 24, 2017, BriVision entered into a collaborative agreement (the "BioFirst Collaborative Agreement") with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company's common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.

 

Since 2019, BioFirst has also advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2020, the aggregate amount of outstanding balance and accrued interest is $218,261.

 

(4)

In September 2017, AsiaGene entered an investment and equity transfer agreement (the "Investment and Equity Transfer Agreement") with Everfront Biotech Inc. (the "Everfront"), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company's common stock at a conversion price of $7.00 per share.

 

Since 2018, AsiaGene has advanced the Company an aggregate amount of $24,017 for working capital purpose. This advance bears 0% interest rate and is due on demand.

 

(5)

On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The maturity date of this loan is January 19, 2019. On January 20, 2019, the two parties extended the loan with the same interest rate and amount for one year. The loan will be matured on January 19, 2020. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $50,000 to 7,143 shares of the Company's common stock at a conversion price of $7.00 per share. 

 

In January 2018, YuanGene Corporation has advanced an aggregate amount of $42,690 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share. 

 

Since 2018, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.

 

(6)

Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share.

 

Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.

 

As of March 31, 2020, the Jiangs has advanced an aggregate amount of $58,503, to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

 

(7) On July 2, 2019, the Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of March 31, 2020 and December 31, 2019, the outstanding services charge was $55,000 and $21,500, respectively.

 

(8) As of March 31, 2020 and December 31, 2019, Euro Asia has advanced of $12,000 and $12,000, respectively, to the Company for working capital purpose. The advances bear 0% interest rate.

 

(9) During the three months ended March 31, 2020, for working capital purpose, the Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum. As of March 31, 2020 and 2019, the aggregate amount of outstanding advance balance and accrued interest was $233,832 and $284,479, respectively.

 

(10) During the three months ended March 31, 2020, the Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of March 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $22,316 as of March 31, 2020. This loan bears zero interest rate and is due on demand.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Equity
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
EQUITY

12. EQUITY

 

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

 

On February 8, 2016, a Share Exchange Agreement ("Share Exchange Agreement") was entered into by and among American BriVision (Holding) Corporation (the "Company"), American BriVision Corporation ("BriVision"), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China ("Euro-Asia"), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the "BriVision Stock"). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the "Acquisition Stock") (subject to adjustment for fractionalized shares as set forth below) of the Company's Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company's Common Stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision's Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company's Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company's Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company's Common Stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the "Share Exchange"), BriVision became a wholly owned subsidiary (the "Subsidiary") of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

 

On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the "2016 Plan"), 157,050 (50,000 pre-stock split) shares were granted to the employees.

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the "Forward Stock Split") and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.

 

On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).

 

On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.

 

On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama ("Kameyama") for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000. The Company's stocks shall be calculated and issued in December every year. On October 1, 2017, the Company and Kameyama agreed to extend the service period for one more year expiring on September 30, 2018. As a result, the non-employee stock-based compensation related to this consulting agreement was $28,800 and $5,400 for the years ended December 31, 2018 and 2017, respectively. On March 28, 2018, the Company issued 4,828 shares of the Company's common stock at $1.60 per share in a total of $7,725 to Kameyama in connection with this consulting agreement.

 

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. And the Company entered into a service agreement (the "Euro-Asia Agreement") for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $60,000 in connection with the terms in the Euro-Asia Agreement, respectively. On March 28, 2018, the Company issued 50,000 shares of the Company's common stock at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.

 

On January 1, 2017, Kimho Consultants Co., Ltd. And the Company entered into a service agreement (the "Kimho Agreement") for the maintenance of the listing in the U.S. stock exchange market. During the years ended December 31, 2018 and 2017, the Company recognized non-employee stock based compensation expenses of $0 and $90,000 in connection with the terms in the Kimho Agreement, respectively. On March 28, 2018, the Company issued 75,000 shares of the Company's common stock at $1.60 per share in a total of $120,000 to Kimho in connection with the Kimho Agreement.

 

Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

 

On March 28, 2018, the Company also issued an aggregate of 50,000 shares of the Company's common stock at $1.60 per share for salaries in a total of $80,000 to three officers.

 

On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.

 

As stated in Note 10, in August 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of "due to related parties" in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company's common stock at a price of $7.00 per share.

 

   Amount of Debt
Converted		   Number of Shares
Issued		 
         
Lion Arts Promotion Inc   97,864    13,981 
LionGene Corporation   428,099    61,157 
BioFirst Corporation   2,902,911    414,702 
AsiaGene Corporationoo   160,000    22,858 
YuanGene Corporation   92,690    13,242 
The Jiangs   1,190,776    170,111 
Total  $4,872,340   $696,051 

 

On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company's Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Loss per Share
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
LOSS PER SHARE

13. LOSS PER SHARE

 

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31, 2020 and 2019. 

 

   For the Three Month Ended 
   March 31,
2020		   March 31,
2019		 
Numerator:        
Net loss attributable to ABVC's common stockholders  $(1,247,538)  $(791,671)
           
Denominator:          
Weighted-average shares outstanding:          
Weighted-average shares outstanding - Basic   19,484,542    14,965,665 
Stock options        - 
Weighted-average shares outstanding - Diluted   19,484,542    14,965,665 
           
Loss per share          
-Basic  $(0.06)  $(0.05)
-Diluted  $(0.06)  $(0.05)

 

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Lease
 3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
LEASE

14. LEASE

 

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases ("ASC 842") using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. As such, the disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under ASC 840.

 

The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:

 

  ● Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.

 

  ● Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.

 

  ● Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.

 

  ● Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.

 

  ● Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.

 

The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use ("ROU") assets and lease liabilities. ROU assets represent the Company's right to use underlying assets for the lease terms and lease liabilities represent the Company's obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company's future minimum based payments used to determine the Company's lease liabilities mainly include minimum based rent payments. As most of Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

 

The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months as of January 1, 2019. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities.

 

The adoption of ASC 842 had a substantial impact on the Company's consolidated balance sheets. The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. Accordingly, adoption of this standard resulted in the recognition of operating lease right-of-use assets of $577,830 and operating lease liabilities of $598,937 comprised of $301,105 of current operating lease liabilities and $297,832 of non-current operating lease liabilities on the consolidated balance sheet as of January 1, 2019. The adoption of ASC 842 also resulted in a cumulative-effect adjustment of $(21,107) to the opening balance of accumulated deficit.

 

In addition, the adoption of the standard did not have a material impact on the Company's results of operations or cash flows. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

 

The Company has no finance leases. The Company's leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company's operating leases have remaining lease terms of up to approximately four years.

 

ASSETS  March 31,
2020		   December 31,
2019		 
Operating lease right-of-use assets  $449,683   $524,445 
LIABILITIES          
Operating lease liabilities (current)  282,715   304,248 
Operating lease liabilities (noncurrent)  179,994   235,555 

 

Supplemental Information

 

The following provides details of the Company's lease expenses:

 

   Three Months Ended
March 31,		 
   2020   2019 
Operating lease expenses  $77,527   $73,802 

 

Other information related to leases is presented below:

 

   Three Months Ended
March 31,		 
   2020   2019 
Cash paid for amounts included in the measurement of operating lease liabilities  $77,527   $73,802 

 

   March 31,
2020		   December 31,
2019		 
Weighted Average Remaining Lease Term:        
Operating leases    2.79 years     3.08 years 
           
Weighted Average Discount Rate:          
Operating leases   1.21%   0.55%

 

The minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as follows:

 

    Operating leases  
2020 ((excluding the three months ended March 31, 2020)   $ 232,438  
2021     92,101  
2022     49,805  
2023     49,805  
2024      49,805  
Total future minimum lease payments, undiscounted     473,954  
Less: Imputed interest     11,245  
Present value of future minimum lease payments   $ 462,709  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combination
 3 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
BUSINESS COMBINATION

15. BUSINESS COMBINATION

 

On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, "Business Combination" to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey's results of operations were included in the Company's results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:

 

Purchase consideration:    
Common Stock (*)  $44,341,847 
Allocation of the purchase price:     
Cash and cash equivalents  $531,147 
Accounts receivable, net   188,550 
Property and equipment, net   56,075 
Operating lease right-of-use assets   485,684 
Security deposits   10,440 
Total assets acquired   1,271,896 
Accounts payable   (56,204)
Accrued expenses and other current liabilities   (251,335)
Operating lease liability   (267,256)
Tenant security deposit   (2,880)
Total liabilities assumed   (577,675)
Total net assets acquired   694,221 
Goodwill as a result of the Merger  $43,647,626 

 

* 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.

 

On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company's anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
 3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

16. SUBSEQUENT EVENTS

 

On April 5, 2020, the Company entered into certain exchange agreements separately with certain U.S. and non-U.S. holders of certain convertible promissory notes issued by the Company on January 21, 2020. The non-U.S. holders are qualified as "non-U.S. Persons" as defined in Regulation S of the Securities Act of 1933, as amended (the "Securities Act"). The U.S. holder is an "accredited investor" as that term is defined in Rule 501(a) of Regulation D. Pursuant to the Exchange Agreements, the holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $931,584.07, and the Company agreed to issue to the holders an aggregate of 506,297 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 506,297 shares of Common Stock.

 

On April 20, 2020, the Company entered into certain exchange agreements separately with additional non-U.S. holders of certain convertible promissory notes issued by the Company on August 28 and September 4, 2019. The non-U.S. holders are qualified as "non-U.S. Persons" as defined in Regulation S of the Securities Act. Pursuant to the Exchange Agreements, the holders agreed to deliver such notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $515,195.84, and the Company agreed to issue to the holders an aggregate of 289,438 shares of the Company's common stock, par value $0.001 per, and warrants to purchase 289,438 shares of Common Stock.

 

In May 2020, the Company received capital contributions of approximately $1,602,040 in cash from 40 investors through private placements of the sale of certain number of Common Stocks for the purchase price of $2.25 per share of Common Stock and a free warrant attaches with each Common stock that was purchased. The exercise price of the warrant will be at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants.

 

The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2020 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, "Subsequent Events."  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the "U.S. GAAP"). All significant intercompany transactions and account balances have been eliminated.

 

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company's financial statements are expressed in U.S. dollars.
Fiscal Year

Fiscal Year 

 

The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Inventory

Inventory

 

Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.
Reclassifications

Reclassifications

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.
Forward Stock split

Forward Stock Split

 

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.
Stock Reverse Split

Stock Reverse Split

 

On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.
Fair Value Measurements

Fair Value Measurements

 

FASB ASC 820, "Fair Value Measurements" defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:

 

  ● Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.
     
  ● Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  ● Level 3 – Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.

 

The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company's short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company's long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.
Cash and Cash Equivalents

Cash and Cash Equivalents 

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company's cash and cash equivalents amounted $123,645 and $144,295, respectively. Some of the Company's cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.
Restricted Cash Equivalents

Restricted Cash Equivalents 

 

Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of March 31, 2020 and December 31, 2019, the Company's restricted cash equivalents amounted $16,148 and $16,148, respectively.
Concentration of Credit Risk

Concentration of Credit Risk

 

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation's insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.
Revenue Recognition

Revenue Recognition

 

During the fiscal year 2018, the Company adopted Accounting Standards Codification ("ASC"), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company's reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company's review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company's revenue during all periods presented.

 

Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

 

The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.

 

Merchandise Sales — The Company recognizes net revenues from dietary supplements product sales when customers obtain control of the Company's products, which typically occurs upon delivery to customer. Product revenues are recorded at the net sales price, or "transaction price," which includes applicable reserves for variable consideration, including discounts, allowances, and returns.

 

Trade discount and allowances: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that, based on its experience, its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.

 

Product returns: The Company estimates the amount of each product that will be returned and deducts these estimated amounts from its gross revenues at the time the revenues are recognized. The Company's customers have the right to return unopened packages, subject to contractual limitations.

 

To date, product allowance and returns have been minimal and, based on its experience, the Company believes that returns of its products will continue to be minimal.

 

Collaborative Revenues — The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: nonrefundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.

 

As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&D personnel costs, discount rates and probabilities of technical and regulatory success.

 

The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company's deliverables requires the use of management's judgment. Significant factors considered in management's evaluation of the estimated performance periods include, but are not limited to, the Company's experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.

 

(i)       Nonrefundable upfront payments

 

If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.

 

(ii)       Milestone payments

 

The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company's obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company's obligations under the collaborative agreement with collaboration partners.

 

The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.

 

(iii)       Multiple Element Arrangements

 

The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).

 

The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company's contractual or estimated performance period for the undelivered elements, which is typically the term of the Company's research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.

 

At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.

 

(iv)       Royalties and Profit Sharing Payments

 

Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.

 

Revenues Derived from Research and Development Activities Services — Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.

 

If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.

 

The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company's transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.

 

The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.
Property and Equipment

Property and Equipment

 

Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:

 

   Estimated Life
in Years
Buildings and leasehold improvements  5 ~ 50
Machinery and equipment  5 ~ 10
Office equipment  3 ~ 6
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment ("ASC 360-10"). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
Long-term Equity Investment

Long-term Equity Investment 

 

The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:

 

●Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.

 

●Non-marketable cost method investments when the equity method does not apply.

 

Significant judgment is required to identify whether an impairment exists in the valuation of the Company's non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee's industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees' revenue, costs, and discount rates. The Company's assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.
Other-Than-Temporary Impairment

Other-Than-Temporary Impairment

 

The Company's long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:

 

●       Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee's credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.

 

●       Non-marketable equity investments based on the Company's assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee's ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 for the three month ended March 31, 2020 and 2019.
Goodwill

Goodwill

 

The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.

 

The Company completed the required testing of goodwill for impairment as of March 31, 2020, and determined that goodwill was impaired because of the current financial condition of the Company and the Company's inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.
Research and Development Expenses

Research and Development Expenses

 

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

 

For CDMO business unit, the Company accounts for R&D costs in accordance with Accounting Standards Codification ("ASC") 730, Research and Development ("ASC 730"). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.
Post-retirement and post-employment benefits

Post-retirement and post-employment benefits

 

The Company's subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the "Act") in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker's monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees' salaries to the employees' pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $3,598 and $4,424 for three months ended March 31, 2020 and 2019, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.
Stock-based Compensation

Stock-based Compensation

 

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation". Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2020 and 2019.

 

The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 "Compensation-Stock Compensation" and FASB ASC Topic 505-50 "Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $525 and $8,550 for the three months ended March 31, 2020 and 2019, respectively.
Beneficial Conversion Feature

Beneficial Conversion Feature

 

From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.
Income Taxes

Income Taxes

 

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

 

Under ASC 740, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2020 and 2019. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

 

On December 22, 2017, the SEC issued Staff Accounting Bulletin ("SAB 118"), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.
Valuation of Deferred Tax Assets

Valuation of Deferred Tax Assets

 

A valuation allowance is recorded to reduce the Company's deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company's projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.
Loss Per Share of Common Stock

Loss Per Share of Common Stock

 

The Company calculates net loss per share in accordance with ASC Topic 260, "Earnings per Share". Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.
Commitments and Contingencies

Commitments and Contingencies

 

The Company has adopted ASC Topic 450 "Contingencies" subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.
Foreign-currency Transactions

Foreign-currency Transactions

 

For the Company's subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars ("NTD") at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders' Equity (Deficit).
Translation Adjustment

Translation Adjustment

 

The accounts of the Company's subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar ("NT$"). Such financial statements were translated into U.S. Dollars ("$" or "USD") in accordance ASC 830, "Foreign Currency Matters", with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder's deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders' equity (deficit).
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of property and equipment

   Estimated Life
in Years
Buildings and leasehold improvements  5 ~ 50
Machinery and equipment  5 ~ 10
Office equipment  3 ~ 6
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Tables)
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of inventory

   March 31,
 2020		   December 31,
 2019		 
   (Unaudited)     
Finished goods  $94,508   $94,727 
Work-in-process   20,491    20,676 
Raw materials   57,384    57,904 
Allowance for inventory valuation and obsolescence loss   (172,383)   (173,307)
Inventory, net  $-   $- 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
 3 Months Ended
Mar. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment

   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Land  $367,861   $371,195 
Buildings and leasehold improvements   2,224,270    2,225,386 
Machinery and equipment   986,237    987,234 
Office equipment   176,861    178,409 
    3,755,229    3,762,224 
Less: accumulated depreciation   (3,249,821)   (3,241,294)
Property and equipment, net  $505,408   $520,930 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2020
Schedule of ownership percentages of investee
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2020   2019   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   7.13%   7.13%  Cost Method
BioFirst Corporation   15.89%   15.89%  Equity Method
Rgene Corporation   31.61%   31.61%  Equity Method
Schedule of extent the investee relies

Name of related party  The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Loaned from the investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment

   March 31,
2020		   December 31,
2019		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,301   $7,367 
Genepharm Biotech Corporation   22,291    22,493 
BioHopeKing Corporation   1,980,361    1,998,310 
Sub total   2,009,953    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   1,254,247    1,336,449 
Rgene Corporation   -    - 
Total  $3,264,200   $3,364,619 
Schedule of equity investments

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(70,411)  $(66,205)
BioFirst [Member]  
Schedule of balance sheets

   March 31,
 2020		  

December 31,
2019

 
   (Unaudited)     
Current Assets  $1,235,043   $1,350,701 
Noncurrent Assets   7,238,415    7,450,032 
Current Liabilities   2,105,938    2,060,460 
Noncurrent Liabilities   65,847    78,888 
Shareholders' Equity   6,301,673    6,661,385 
Schedule of statements of operation

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $12,110   $10,334 
Gross profit   1,578    1,882 
Net loss   (325,652)   (307,034)
Share of losses from investments accounted for using the equity method   (70,411)   (66,205)
Rgene [Member]  
Schedule of balance sheets
   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $136.936   $82,254 
Noncurrent Assets   161,255    62,768 
Current Liabilities   462,667    312,950 
Noncurrent Liabilities   62,801    - 
Shareholders' Deficit   (227,277)   (167,928)
Schedule of statements of operation
   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $      $   
Gross Profit          
Net loss   (21,889)   (22,662)
Share  of loss from investments accounted for using the equity method   -    - 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Bank Loans (Tables)
 3 Months Ended
Mar. 31, 2020
Bank Loans [Abstract]  
Schedule of short-term bank loan

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $248,250   $250,500 
CTBC Bank   662,000    668,000 
Cathay Bank   1,000,000    1,000,000 
Total  $1,910,250   $1,918,500 
Schedule of long-term bank loan

   March 31,   December 31, 
   2020   2019 
Cathay United Bank  $3,332   $13,403 
Less: current portion of long-term bank loan   (3,332)   (13,403)
Total  $-   $- 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Tables)
 3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
Schedule of related party transactions

Name of entity or Individual  Relationship with the Company and its subsidiaries
BioFirst Corporation (the "BioFirst")  Entity controlled by controlling beneficiary shareholder of Yuangene
BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)")  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene")  Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the "Yuangene")  Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the "AsiaGene")  Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang  Former President and Chairman
Keypoint Technology Ltd. (the "Keypoint')  The Chairman of Keypoint is Eugene Jiang's mother.
Lion Arts Promotion Inc. (the "Lion Arts")  Shareholder of the Company
Yoshinobu Odaira (the "Odaira")  Director of the Company
GenePharm Inc. (the "GenePharm")  Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia")  Shareholder of the Company
LBG USA, Inc. (the "LBG USA")  100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the "LionGene")  Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the "Kimho")  Shareholder of the Company
Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs")  Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst
 
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc.
 
Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
 
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang's sibling and the director of the Company.
 
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang's sibling.
Amkey Ventures, LLC ("Amkey")   An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc
Schedule of accounts receivable due from related parties

   March 31,   December 31, 
   2020   2019 
GenePharm Inc.  $142,225   $142,225 
Rgene   1,052    1,053 
Amkey   400    - 
Total  $143,677   $143,278 
Schedule of amount due from related parties

   March 31,   December 31, 
   2020   2019 
Rgene  $36,903   $36,332 
AsiaGene   3,645    3,578 
BioFirst   141,650    137,151 
BioFirst (Australia)   40,000    40,000 
BioHopeKing Corporation   114,905    115,946 
LBG USA   675    675 
Total  $337,778   $333,682 
Schedule of amount due to related party

   March 31,   December  31, 
   2020   2019 
LionGene Corporation  $10,481   $10,275 
BioFirst Corporation   218,261    24,182 
AsiaGene   24,017    24,017 
YuanGene   9,205    9,205 
The Jiangs   58,503    40,031 
Kimho   55,000    21,500 
Euro Asia   12,000    12,000 
Due to shareholders   233,832    284,479 
Due to employees   94,004    - 
Total  $715,303   $425,689 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Schedule of converted amount of debt and shares

   Amount of Debt
Converted		   Number of Shares
Issued		 
         
Lion Arts Promotion Inc   97,864    13,981 
LionGene Corporation   428,099    61,157 
BioFirst Corporation   2,902,911    414,702 
AsiaGene Corporationoo   160,000    22,858 
YuanGene Corporation   92,690    13,242 
The Jiangs   1,190,776    170,111 
Total  $4,872,340   $696,051 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Loss per Share (Tables)
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Schedule of loss per share

   For the Three Month Ended 
   March 31,
2020		   March 31,
2019		 
Numerator:        
Net loss attributable to ABVC's common stockholders  $(1,247,538)  $(791,671)
           
Denominator:          
Weighted-average shares outstanding:          
Weighted-average shares outstanding - Basic   19,484,542    14,965,665 
Stock options        - 
Weighted-average shares outstanding - Diluted   19,484,542    14,965,665 
           
Loss per share          
-Basic  $(0.06)  $(0.05)
-Diluted  $(0.06)  $(0.05)
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Lease (Tables)
 3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Schedule of operating lease arrangements
ASSETS  March 31,
2020		   December 31,
2019		 
Operating lease right-of-use assets  $449,683   $524,445 
LIABILITIES          
Operating lease liabilities (current)  282,715   304,248 
Operating lease liabilities (noncurrent)  179,994   235,555 
Schedule of supplemental information related to operating leases

The following provides details of the Company's lease expenses:

 

   Three Months Ended
March 31,		 
   2020   2019 
Operating lease expenses  $77,527   $73,802 

 

Other information related to leases is presented below:

 

   Three Months Ended
March 31,		 
   2020   2019 
Cash paid for amounts included in the measurement of operating lease liabilities  $77,527   $73,802 

 

   March 31,
2020		   December 31,
2019		 
Weighted Average Remaining Lease Term:        
Operating leases    2.79 years     3.08 years 
           
Weighted Average Discount Rate:          
Operating leases   1.21%   0.55%
Schedule of minimum future annual payments under non-cancellable leases

    Operating leases  
2020 ((excluding the three months ended March 31, 2020)   $ 232,438  
2021     92,101  
2022     49,805  
2023     49,805  
2024      49,805  
Total future minimum lease payments, undiscounted     473,954  
Less: Imputed interest     11,245  
Present value of future minimum lease payments   $ 462,709  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combination (Tables)
 3 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
Schedule of assets acquired and liabilities assumed based on fair value
Purchase consideration:    
Common Stock (*)  $44,341,847 
Allocation of the purchase price:     
Cash and cash equivalents  $531,147 
Accounts receivable, net   188,550 
Property and equipment, net   56,075 
Operating lease right-of-use assets   485,684 
Security deposits   10,440 
Total assets acquired   1,271,896 
Accounts payable   (56,204)
Accrued expenses and other current liabilities   (251,335)
Operating lease liability   (267,256)
Tenant security deposit   (2,880)
Total liabilities assumed   (577,675)
Total net assets acquired   694,221 
Goodwill as a result of the Merger  $43,647,626 

 

* 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Description of Business (Details) - shares
Feb. 08, 2016
Aug. 31, 2017
Organization and Description of Business (Textual)    
Percentage of common shares issued and outstanding   73.00%
Share Exchange Agreement [Member]    
Organization and Description of Business (Textual)    
Common stock issued post-stock split 164,387,376  
Common stock issued pre-stock split 52,336,000  
Share Exchange Agreement One [Member]    
Organization and Description of Business (Textual)    
Common stock issued post-stock split 166,273,921  
Common stock issued pre-stock split 52,936,583  
Share Exchange Agreement Two [Member]    
Organization and Description of Business (Textual)    
Common stock issued post-stock split 163,159,952  
Common stock issued pre-stock split 51,945,225  
Percentage of common shares issued and outstanding 79.70%  
Percentage of issued share capital 100.00%  
Share Exchange Agreement Three [Member]    
Organization and Description of Business (Textual)    
Common stock issued post-stock split 166,273,921  
Common stock issued pre-stock split 52,936,583  
Common stock converted to exchange ratio 0.2536-for-1  
Share Exchange Agreement Four [Member]    
Organization and Description of Business (Textual)    
Common stock issued post-stock split 205,519,223  
Common stock issued pre-stock split 65,431,144  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details)
 3 Months Ended
Mar. 31, 2020
Buildings and leasehold improvements [Member] | Minimum [Member]  
Estimated Life 5 years
Buildings and leasehold improvements [Member] | Maximum [Member]  
Estimated Life 50 years
Machinery and equipment [Member] | Minimum [Member]  
Estimated Life 5 years
Machinery and equipment [Member] | Maximum [Member]  
Estimated Life 10 years
Office equipment [Member] | Minimum [Member]  
Estimated Life 3 years
Office equipment [Member] | Maximum [Member]  
Estimated Life 6 years
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
May 03, 2019
Mar. 12, 2019
Mar. 21, 2016
Mar. 21, 2016
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Summary of Significant Accounting Policies (Textual)              
Forward split ratio The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split. i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. 1 to 3.141 1 to 3.141      
Common stock, par value     $ 0.001 $ 0.001 $ 0.001   $ 0.001
Common stock, authorized     360,000,000 360,000,000 100,000,000   100,000,000
Cash and cash equivalents         $ 123,645   $ 144,295
Restricted cash equivalents         16,148   $ 16,148
Impairments of equity investments         0 $ 0  
Employee stock-based compensation expenses         0 0  
Non-employee stock-based compensation expenses         525 8,550  
Effectiveness date     Apr. 08, 2016        
Employee benefits amount         $ 3,598 $ 4,424  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 24, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 25, 2017
May 26, 2017
Aug. 31, 2016
Jul. 27, 2016
Dec. 31, 2015
Mar. 31, 2020
Dec. 31, 2019
Aug. 05, 2019
Jun. 30, 2019
Dec. 31, 2017
Collaborative Agreements (Textual)                          
Outstanding balance                 $ 337,778 $ 333,682      
Milestone payments royalty percentage                 12.00% 12.00%      
BHK Co-Development Agreement [Member]                          
Collaborative Agreements (Textual)                          
Description of payment settlement             ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment.            
Upfront payments             $ 1,000,000 $ 1,000,000          
Percentage of payments under co-development agreement             10.00% 10.00%          
Milestone payments to BioLite in cash           $ 31,649,000 $ 10,000,000            
Common stock newly issued, value           $ 1,000,000   $ 10,000,000          
Collaborative Agreements, description               The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2020 and December 31, 2019, the Company has not earned the royalty under the BHK Collaborative Agreements.        
Co-Dev Agreement [Member]                          
Collaborative Agreements (Textual)                          
Amount received from BriVision     $ 3,000,000   $ 3,000,000               $ 450,000
Percentage of payments under co-development agreement         50.00%                
Company cash payments     3,000,000   $ 3,000,000                
Co-Dev agreement, description The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                        
BioFirst Stock Purchase Agreement [Member]                          
Collaborative Agreements (Textual)                          
Amount received from BriVision                     $ 2,902,911 $ 3,000,000  
Shares issued                     414,702 428,571  
Collaborative Arrangement [Member]                          
Collaborative Agreements (Textual)                          
Percentage of payments under co-development agreement   50.00%                      
Common stock newly issued, value   $ 3,000,000                      
Licensing rights       $ 3,000,000                  
Company cash payments   $ 3,000,000                      
Research and development expense     $ 3,000,000                    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Finished goods $ 94,508 $ 94,727
Work-in-process 20,491 20,676
Raw materials 57,384 57,904
Allowance for inventory valuation and obsolescence loss (172,383) (173,307)
Inventory, net
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Subtotal $ 3,755,229 $ 3,762,224
Less: accumulated depreciation (3,249,821) (3,241,294)
Property and equipment, net 505,408 520,930
Land [Member]    
Subtotal 367,861 371,195
Buildings and leasehold improvements [Member]    
Subtotal 2,224,270 2,225,386
Machinery and equipment [Member]    
Subtotal 986,237 987,234
Office equipment [Member]    
Subtotal $ 176,861 $ 178,409
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Details Textual) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Property and Equipment (Textual)    
Depreciation expenses $ 11,174 $ 13,940
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details)
 3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Aug. 31, 2017
Ownership percentage     73.00%
Braingenesis Biotechnology Co., Ltd [Member]      
Ownership percentage 0.17% 0.17%  
Accounting treatments Cost Method    
Genepharm Biotech Corporation [Member]      
Ownership percentage 0.72% 0.72%  
Accounting treatments Cost Method    
BioHopeKing Corporation [Member]      
Ownership percentage 7.13% 7.13%  
Accounting treatments Cost Method    
BioFirst Corporation [Member]      
Ownership percentage 15.89% 15.89%  
Accounting treatments Equity Method    
Rgene Corporation [Member]      
Ownership percentage 31.61% 31.61%  
Accounting treatments Equity Method    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details 1)
 3 Months Ended
Mar. 31, 2020
BioFirst Corporation [Member]  
Relationship with the Company and its subsidiaries, description Loaned from the investee and provides research and development support service
Braingenesis Biotechnology Co., Ltd. [Member]  
Relationship with the Company and its subsidiaries, description No specific business relationship
Genepharm Biotech Corporation [Member]  
Relationship with the Company and its subsidiaries, description No specific business relationship
BioHopeKing Corporation [Member]  
Relationship with the Company and its subsidiaries, description Collaborating with the Company to develop and commercialize drugs
Rgene Corporation [Member]  
Relationship with the Company and its subsidiaries, description Collaborating with the Company to develop and commercialize drugs
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details 2) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Sub total $ 2,009,953 $ 2,028,170
Total 3,264,200 3,364,619
BioFirst Corporation [Member]    
Total 1,254,247 1,336,449
Rgene Corporation [Member]    
Total
Braingenesis Biotechnology Co., Ltd. [Member]    
Sub total 7,301 7,367
Genepharm Biotech Corporation [Member]    
Sub total 22,291 22,493
BioHopeKing Corporation [Member]    
Sub total $ 1,980,361 $ 1,998,310
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details 3) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current Assets $ 802,491 $ 878,238
Current Liabilities 7,654,601 6,814,193
Shareholders' Deficit (1,136,689) (150,964)
BioFirst [Member]    
Current Assets 1,235,043 1,350,701
Noncurrent Assets 7,238,415 7,450,032
Current Liabilities 2,105,938 2,060,460
Noncurrent Liabilities 65,847 78,888
Shareholders' Deficit 6,301,673 6,661,385
Rgene [Member]    
Current Assets 136,936 82,254
Noncurrent Assets 161,255 62,768
Current Liabilities 462,667 312,950
Noncurrent Liabilities 62,801
Shareholders' Deficit $ (227,277) $ (167,928)
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details 4) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Net sales $ 78,786 $ 212,242
Gross profit 74,827 210,743
BioFirst [Member]    
Net sales 12,110 10,334
Gross profit 1,578 1,882
Net loss (325,652) (307,034)
Share of losses from investments accounted for using the equity method (70,411) (66,205)
Rgene [Member]    
Net sales
Gross profit
Net loss (21,889) (22,662)
Share of losses from investments accounted for using the equity method
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details 5) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Long-Term Investment [Abstract]    
Share of equity method investee losses $ (70,411) $ (66,205)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Details Textual)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 15, 2018
Nov. 02, 2018
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Rgene [Member]          
Long-Term Investments (Textual)          
Percentage of common stock shares     31.61% 31.61%  
BioFirst [Member]          
Long-Term Investments (Textual)          
Percentage of common stock shares     15.89% 15.89%  
Sale of common stock, description The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019. The Company subsequently purchased an aggregate of 200,000 and 366,200 shares of common stock of BHK at NT$10, equivalent to $0.33, and NT$50, equivalent $1.64, from one of directors of BHK and eleven shareholders of BHK, respectively. The percentage of ownership accordingly increased to 7.13% as of March 31, 2020 and December 31, 2019.     The Company sold 552,000 shares of common stock of BioHopeKing Corporation (the "BHK") at prices ranging from NT$25, equivalent $0.82, to NT$32, equivalent $1.05, to two directors of BHK and 25 individuals. As a result of the transactions, the Company recognized investment loss of $395,476 for the same period.
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Notes Payable (Details) - Unsecured convertible promissory note [Member] - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 29, 2019
Sep. 04, 2019
Jul. 10, 2019
Jun. 27, 2018
May 09, 2018
Aug. 28, 2019
May 30, 2019
Aug. 25, 2018
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Convertible Notes Payable (Textual)                      
Aggregate principal amount $ 250,000 $ 257,500 $ 250,000 $ 250,000 $ 300,000 $ 200,000   $ 250,000      
Bears interest rate 20.00% 20.00% 20.00% 8.00% 8.00% 20.00% 20.00% 8.00%      
Convertible promissory note received $ 250,000 $ 257,500 $ 250,000 $ 250,000 $ 300,000 $ 200,000 $ 250,000 $ 250,000      
Equity offering, description       The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. The Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an “Equity Offering”) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note.   The Company received $160,000 and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to the KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020,. At any time from the date hereof until this KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an "Equity Offering") then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company's common stock at a conversion price      
Conversion price, description (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note as of March 31, 2020. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses are $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 162,908 shares of Common Stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note as of March 31, 2020. (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note as of December 31, 2019 and 2018. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Keypoint" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Keypoint". The aggregate principal amount plus accrued interest expenses are $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company's common stock, and warrants to purchase 159,145 shares of the Company's common stock. (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note as of December 31, 2019 and 2018. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Yu and Wei" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Yu and Wei". The aggregate principal amount plus accrued interest expenses are $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company's common stock, and warrants to purchase 192,784 shares of the Company's common stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note as of December 31, 2019. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses are $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company's common stock, par value $0.001 per share, and warrants to purchase 126,530 shares of Common Stock. (i) $.50 per share (the "Fixed Conversion Price"), subject to adjustment, or (ii) 70% of the per share offering price (the "Alternative Conversion Price") of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the "Public Offering"), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the company has received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 month. (i) $2.00 per share (the "Fixed Conversion Price"), subject to adjustment or (ii) 80% of the per share offering price (the "Alternative Conversion Price") of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaria Note as of December 31, 2019. On January 21, 2020, Odiara entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new "Odaira" Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with "Odaira". The aggregate principal amount plus accrued interest expenses are $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company's common stock, and warrants to purchase 154,368 shares of the Company's common stock.      
Convertible debenture                 $ 2,007,500   $ 2,007,500
Accrued convertible interest                 277,066   $ 181,852
Total interest expenses                 $ 95,214 $ 16,000  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Bank Loans (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Cathay United Bank [Member]    
Total $ 248,250 $ 250,500
CTBC Bank [Member]    
Total 662,000 668,000
Cathay Bank [Member]    
Total $ 1,000,000 $ 1,000,000
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Bank Loans (Details 1) - Cathay United Loan Agreement [Member] - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Cathay United Bank $ 3,332 $ 13,403
Less: current portion of long-term bank loan (3,332) (13,403)
Total
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Bank Loans (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 06, 2019
Jan. 08, 2019
Oct. 01, 2018
Sep. 06, 2017
Jun. 12, 2017
Jan. 19, 2020
Jul. 18, 2019
Jan. 21, 2019
Jan. 18, 2019
Jul. 19, 2017
Apr. 30, 2017
Jun. 28, 2016
Mar. 31, 2020
Mar. 31, 2019
Bank Loans (Textual)                            
Interest expenses                         $ 56 $ 284
Cathay United Loan Agreement [Member]                            
Bank Loans (Textual)                            
Principal amount $ 248,250   $ 248,250 $ 248,250               $ 248,250    
Maturity date                       Jun. 28, 2017    
Debt instrument term 1 year   1 year 1 year               1 year    
Bears interest floating rate                       1.15% 2.22% 2.22%
Debt instrument due date Sep. 06, 2020   Sep. 06, 2019 Sep. 06, 2018                    
Interest expenses                         $ 1,378 $ 1,330
Cathay United Loan Agreement [Member] | NT [Member]                            
Bank Loans (Textual)                            
Principal amount $ 7,500,000   $ 7,500,000 $ 7,500,000               $ 7,500,000    
CTBC Loan Agreements [Member]                            
Bank Loans (Textual)                            
Principal amount         $ 331,000 $ 662,000 $ 662,000     $ 331,000        
Maturity date         Jan. 19, 2018 Jul. 19, 2020 Jan. 17, 2020   Jul. 18, 2019 Jan. 19, 2018        
Debt instrument term         1 year 6 months 6 months     1 year        
Bears interest floating rate           1.63%                
Interest expenses                         2,755 $ 2,604
CTBC Loan Agreements [Member] | NT [Member]                            
Bank Loans (Textual)                            
Principal amount         $ 10,000,000 $ 20,000,000 $ 20,000,000     $ 10,000,000        
Loan Agreement [Member]                            
Bank Loans (Textual)                            
Principal amount                         $ 1,000,000  
Maturity date               Jan. 01, 2020            
Received loan amount               $ 500,000            
Exceeding amount   $ 500,000                        
Regular interest rate, description               The Note executed in connection with the Loan Agreement bears an interest rate (the "Regular Interest Rate") equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the "Index") and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.         The Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020. On March 31, 2020, the Company extended the Loan Agreement with the same term for 7 months, which is due on October 31, 2020.  
Cathay United Bank [Member]                            
Bank Loans (Textual)                            
Maturity date                     Apr. 30, 2020      
Bears interest floating rate                         2.24% 2.24%
Cathay United Bank [Member] | Minimum [Member]                            
Bank Loans (Textual)                            
Bears interest floating rate                     0.77%      
Cathay United Bank [Member] | Maximum [Member]                            
Bank Loans (Textual)                            
Bears interest floating rate                     1.17%      
Cathay United Bank [Member] | April 30, 2010 [Member]                            
Bank Loans (Textual)                            
Principal amount                         $ 288,360  
Maturity date                         Apr. 30, 2017  
Debt instrument term                         7 years  
Cathay United Bank [Member] | NT [Member] | April 30, 2010 [Member]                            
Bank Loans (Textual)                            
Principal amount                         $ 8,900,000  
Cathay Bank [Member]                            
Bank Loans (Textual)                            
Interest expenses                         $ 13,740 $ 9,527
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Notes Payable (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 31, 2019
Dec. 27, 2018
Mar. 27, 2018
Mar. 31, 2020
Mar. 31, 2019
BioLite Taiwan [Member]          
Notes Payable (Textual)          
Notes payable, description   Taiwan issued a promissory note of NT$450,000, equivalent to $14,715, to Taipei Veterans General Hospital to repay the clinical experiment costs. The note has been paid in full on January 2, 2019.      
Hsu and Chow [Member]          
Notes Payable (Textual)          
Interest expenses       $ 4,641 $ 5,085
Notes payable, description     Borrowing an aggregate amount of NT$4,660,000, equivalent to $155,800, for the period from March 27, 2018 to June 26, 2018. On September 26, 2018, BioLite Taiwan extended the original loan agreement through December 26, 2018. On September 26, 2019, BioLite Taiwan renewed and amended the contract with the "Hsu" only and extend the maturity date to December 26, 2019. The principal of the Hsu new Promissory Note bears interest at 13.6224% per annum.    
BioLite Taiwan [Member]          
Notes Payable (Textual)          
Interest expenses       $ 2,988 $ 2,916
Unsecured loan agreements, description Entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $99,300, for working capital purpose.        
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Short-term Loan (Details)
 1 Months Ended
Feb. 18, 2020
USD ($)
Debt Disclosure [Abstract]  
Unsecured loan amount $ 100,000
Interest rate 1.50%
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Details)
 3 Months Ended
Mar. 31, 2020
BioFirst Corporation (the "BioFirst") [Member]  
Relationship with the Company and its subsidiaries, description Loaned from the investee and provides research and development support service
BioFirst (Australia) Pty Ltd. (the "BioFirst (Australia)") [Member]  
Relationship with the Company and its subsidiaries, description 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the "Rgene") [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company; entity controlled by controlling beneficiary shareholder of Yuangene
Yuangene Corporation (the "Yuangene") [Member]  
Relationship with the Company and its subsidiaries, description Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the "AsiaGene") [Member]  
Relationship with the Company and its subsidiaries, description Shareholder; entity controlled by controlling beneficiary shareholder of Yuangene
Eugene Jiang [Member]  
Relationship with the Company and its subsidiaries, description Former President and Chairman
Keypoint Technology Ltd. (the "Keypoint') [Member]  
Relationship with the Company and its subsidiaries, description The Chairman of Keypoint is Eugene Jiang's mother.
Lion Arts Promotion Inc. (the "Lion Arts")  
Relationship with the Company and its subsidiaries, description Shareholder of the Company
Yoshinobu Odaira (the "Odaira") [Member]  
Relationship with the Company and its subsidiaries, description Director of the Company
Euro-Asia Investment & Finance Corp Ltd. (the "Euro-Asia") [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company
Kimho Consultants Co., Ltd. (the "Kimho") [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company
LBG USA, Inc. (the "LBG USA") [Member]  
Relationship with the Company and its subsidiaries, description 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the "LionGene") [Member]  
Relationship with the Company and its subsidiaries, description Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Jiangs [Member]  
Relationship with the Company and its subsidiaries, description Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint, LION, and BioFirst; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
GenePharm Inc. (the "GenePharm") [Member]  
Relationship with the Company and its subsidiaries, description Mr. George Lee, the Director and Chairman of Biokey, is the Chairman of GenePharm.
Amkey Ventures, LLC (“Amkey”) [Member]  
Relationship with the Company and its subsidiaries, description An entity controlled by Dr. George Lee, who serves as the Chairman of the board of directors of BioKey, Inc
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Details 1) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Accounts receivable due from related parties $ 143,677 $ 143,278
GenePharm Inc. [Member]    
Accounts receivable due from related parties 142,225 142,225
Rgene [Member]    
Accounts receivable due from related parties 1,053 1,053
Amkey [Member]    
Accounts receivable due from related parties $ 400
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Details 2) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Total $ 337,778 $ 333,682
Rgene [Member]    
Total 36,903 36,332
AsiaGene [Member]    
Total 3,645 3,578
BioFirst [Member]    
Total 141,650 137,151
BioFirst (Australia) [Member]    
Total 40,000 40,000
BioHopeKing Corporation [Member]    
Total 114,905 115,946
LBG USA [Member]    
Total $ 675 $ 675
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Details 3) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Total $ 637,390 $ 425,689
LionGene Corporation [Member]    
Total 10,481 10,275
BioFirst Corporation [Member]    
Total 218,261  
AsiaGene [Member]    
Total 24,017 24,017
YuanGene [Member]    
Total 9,205 9,205
The Jiangs [Member]    
Total 58,503 40,031
Kimho [Member]    
Total 55,000 21,500
Due to shareholders [Member]    
Total 233,832 284,479
Euro Asia [Member]    
Total 12,000  
Lion Arts Promotion Inc. [Member]    
Total  
Due to employees [Member]    
Total $ 94,004
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Related Parties Transactions (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 15, 2019
Jul. 12, 2019
Jul. 02, 2019
May 12, 2019
Feb. 02, 2019
May 11, 2018
Sep. 25, 2017
Apr. 12, 2017
Aug. 31, 2019
Jun. 30, 2019
May 27, 2019
Feb. 27, 2019
Jan. 20, 2019
Dec. 31, 2018
Nov. 30, 2018
Jun. 27, 2018
Jan. 31, 2018
Jan. 18, 2018
Dec. 31, 2017
Sep. 30, 2017
Jan. 26, 2017
Mar. 31, 2020
Mar. 31, 2019
Sep. 30, 2018
Jul. 12, 2020
Dec. 31, 2019
Dec. 31, 2018
Related Parties Transactions (Textual)                                                      
Interest expenses                                           $ 131,517 $ 129,886        
Conversion price                 $ 7.00                                    
Convertion of debt                 $ 4,872,340                                    
Conversion of debt, shares                 696,051                                    
Related party transactions, description                                                     Since 2018, Mr. Tsung-Shann Jiang, Mr. Chang-Jen Jiang, Ms. Shu-Ling Jiang, and Ms. Mei-Ling Jiang have entered into various loans with the Company for working capital purpose in an aggregate amount of $795,340. These loans bear interest at 12% per annum and are due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $837,726 to 119,675 shares of the Company's common stock at a conversion price of $7.00 per share.
Outstanding advance balance                                           $ 637,390       $ 425,689  
Employee Stock [Member]                                                      
Related Parties Transactions (Textual)                                                      
Advances bear interest, description                                           The Company had advances from employees for working capital purpose. The outstanding balance due to one employee amounted to $71,688 as of March 31, 2020. This loan bears interest rate of 1.5% per annum, and is due on demand. The outstanding balance due to one other employee amounted to $22,316 as of March 31, 2020. This loan bears zero interest rate and is due on demand.          
Keypoint Note [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount                               $ 250,000                      
Interest rate percentage                               8.00%                      
Kimho [Member]                                                      
Related Parties Transactions (Textual)                                                      
Related party transactions, description     The Company entered into an agreement with Kimho, starting from September 2019 with a fixed monthly retainer of $7,500 before the IPO and the amount will be increased to $13,000 after IPO. As of March 31, 2020 and December 31, 2019, the outstanding services charge was $55,000 and $21,500, respectively.                                                
Outstanding advance balance                                           $ 55,000       21,500  
Outstanding services charge                                           55,000       21,500  
BioFirst [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount   $ 150,000                                                  
Outstanding loan balance                                           128,683       128,683  
Accrued interest                                           $ 12,967       8,468  
Loan agreement, description                                           Bears interest at 1% per month (or equivalent to 12% per annum          
Aggregate working capital                                                 $ 21,317    
Stock purchase agreement, description             On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.                                        
Outstanding advance balance                                           $ 218,261          
Rgene Corporation [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount                                           36,903       36,332  
Outstanding loan balance                                           28,953       29,194  
Accrued interest                                           $ 7,950       7,138  
Loan agreement, description                                           The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019          
Euro Asia [Member]                                                      
Related Parties Transactions (Textual)                                                      
Outstanding advance                           $ 0               $ 12,000       12,000 $ 0
Outstanding advance balance                                           12,000          
Asiangene Corporation [Member]                                                      
Related Parties Transactions (Textual)                                                      
Outstanding loan balance                                           3,310       3,340  
Accrued interest                                           335       238  
Aggregate working capital                                                     $ 24,017
Amount of equivalent                     $ 3,310                                
Interest rate percentage                                                     0.00%
Outstanding advance balance                                           24,017       24,017  
Asiangene Corporation [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Loan agreement, description                     The loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan will be matured on December 31, 2019.                                
Aggregate working capital                     $ 100,000                                
BioFirst (Australia) [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate principal amount   $ 150,000       $ 40,000                                          
Outstanding loan balance                                           40,000         $ 40,000
Interest rate percentage   12.00%       0.00%                                          
Loan maturity date   Dec. 31, 2019                                                  
Other receivable from related parties                           0               115,946         0
Advances bear interest, description   The advances bear interest 1% per month                                                  
LBG USA, Inc.[Member]                                                      
Related Parties Transactions (Textual)                                                      
Loan agreement, description                       The advances bear 0% interest rate and are due on demand.                              
Outstanding advance                           0               $ 675       675 0
BioLite Taiwan [Member]                                                      
Related Parties Transactions (Textual)                                                      
Loan agreement, description                                           The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.          
Aggregate working capital                             $ 430,817                 $ 94,990      
Interest rate percentage                             0.00%                 12.00%      
Loan maturity date                                               Apr. 14, 2020      
Other receivable from related parties                           $ 0                         $ 0
Conversion price                             $ 7.00                 $ 7.00      
Convertion of debt                             $ 428,099                 $ 97,864      
Conversion of debt, shares                             61,157                 13,981      
BioLite Taiwan [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                             $ 13,295,000                 $ 2,950,000      
BioFirst [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                     $ 625,646   $ 950,000            
Interest rate percentage         12.00%                           12.00%     12.00%          
Loan maturity date         Feb. 01, 2020                           May 27, 2020                
Conversion price         $ 7.00                           $ 7.00                
Convertion of debt         $ 693,000                           $ 625,646                
Conversion of debt, shares         99,000                           89,378                
Stock purchase agreement, description                   Pursuant to which the Company agreed to issue 428,571 shares of the Company’s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst.                                  
BioFirst [Member] | Conversion Agreements One [Member]                                                      
Related Parties Transactions (Textual)                                                      
Interest rate percentage                                     0.00%                
Conversion price                                     $ 7.00                
Convertion of debt                                     $ 597,128                
Conversion of debt, shares                                     85,304                
BioFirst [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                     $ 19,430,000                
BioLite BVI [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital               $ 987,134                                      
Interest rate percentage               12.00%                                      
Loan maturity date       May 11, 2020       May 11, 2019                                      
Conversion price       $ 7.00                                              
Convertion of debt       $ 987,134                                              
Conversion of debt, shares       141,020                                              
BioLite BVI [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital               $ 30,000,000                                      
Everfront Biotech Inc. [Member]                                                      
Related Parties Transactions (Textual)                                                      
Investment and equity transfer agreement, description                                       Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsiaGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. AsiaGene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand. On August 1, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $160,000 to 22,858 shares of the Company’s common stock at a conversion price of $7.00 per share.              
YuanGene [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                 $ 42,690 $ 50,000       $ 9,205          
Interest rate percentage                                 0.00% 12.00%       0.00%          
Loan maturity date                         Jan. 19, 2020         Jan. 19, 2019                  
Conversion price                         $ 7.00       $ 7.00                    
Convertion of debt                         $ 50,000       $ 42,690                    
Conversion of debt, shares                         7,143       6,099                    
Related party transactions, description                                 Company entered into a Conversion Agreements to convert the remaining balance of $42,690 to 6,099 shares of the Company's common stock at a conversion price of $7.00 per share.                    
Outstanding advance balance                                           $ 0          
Jiangs [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital                                           $ 58,503          
Interest rate percentage                           0.00%               0.00%          
Related party transactions, description                                                     Since 2018, the Jiangs have also advanced funds to the Company for working capital purpose in an aggregate amount of $353,050. The advances bear 0% interest rate and are due on demand. On August 4, 2019, the Company entered into a Conversion Agreements to convert the remaining balance of $353,050 to 50,436 shares of the Company's common stock at a conversion price of $7.00 per share.
Lion Gene [Member]                                                      
Related Parties Transactions (Textual)                                                      
Accrued interest                                           $ 551          
Lion Gene [Member] | NT [Member]                                                      
Related Parties Transactions (Textual)                                                      
Aggregate working capital $ 300,000                                                    
Amount of equivalent $ 9,930                                                    
Due to shareholders [Member]                                                      
Related Parties Transactions (Textual)                                                      
Outstanding loan balance                                           259,480 259,480        
Accrued interest                                           233,832 $ 284,479        
Outstanding advance balance                                           $ 233,832       $ 284,479  
Advances bear interest, description                                           The Company entered into several agreements with our shareholders. The advances bear interest from 12% to 13.6224% per annum.          
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Details)
 1 Months Ended
Aug. 31, 2019
USD ($)
shares
Amount of Debt Converted | $ $ 4,872,340
Number of Shares Issued | shares 696,051
Lion Arts Promotion Inc [Member]  
Amount of Debt Converted | $ $ 97,864
Number of Shares Issued | shares 13,981
LionGene Corporation [Member]  
Amount of Debt Converted | $ $ 428,099
Number of Shares Issued | shares 61,157
BioFirst Corporation [Member]  
Amount of Debt Converted | $ $ 2,902,911
Number of Shares Issued | shares 414,702
AsianGene Corporation [Member]  
Amount of Debt Converted | $ $ 160,000
Number of Shares Issued | shares 22,858
YuanGene Corporation [Member]  
Amount of Debt Converted | $ $ 92,690
Number of Shares Issued | shares 13,242
The Jiangs [Member]  
Amount of Debt Converted | $ $ 1,190,776
Number of Shares Issued | shares 170,111
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
May 03, 2019
May 03, 2019
Mar. 12, 2019
Feb. 08, 2019
Mar. 21, 2016
Feb. 08, 2016
Oct. 15, 2015
Aug. 31, 2019
Feb. 28, 2017
Oct. 02, 2016
Aug. 26, 2016
May 06, 2016
Mar. 31, 2016
Mar. 21, 2016
Feb. 17, 2016
Mar. 31, 2020
Dec. 31, 2018
Dec. 31, 2017
Mar. 12, 2020
Dec. 31, 2019
Mar. 28, 2018
Aug. 31, 2017
May 26, 2017
Equity (Textual)                                              
Common stock, authorized         360,000,000                 360,000,000   100,000,000       100,000,000      
Common stock, par value         $ 0.001                 $ 0.001   $ 0.001       $ 0.001      
Percentage of common shares issued and outstanding                                           73.00%  
Issuance of common shares                                 $ 80,000            
Due to related parties                               $ 715,303       $ 425,689      
Common stock, shares issued                               19,488,168       19,478,168      
Financial amendment, description   The Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority ("FINRA"). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company's common stock were exchanged for 17,693,625 shares of the Company's Common Stock. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.                                          
Agreement, description                 The Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company's Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company's Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).   The Company issued 1,468,750 shares ("Shares") of the Company's Common Stock, par value $0.001 (the "Offering") to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the "SPA"). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. The Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company's first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.                      
Due to related parties consideration               $ 4,872,340                              
Common stock price per share               $ 7.00                              
Forward split ratio The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.   i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes.   1 to 3.141                 1 to 3.141                  
Subscription receivable             $ 350,000                                
Kimho Consultants Co., Ltd [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Common stock, shares issued                                         75,000    
Common stock, shares issued total                                         120,000    
2016 Equity Incentive Plan [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split                             50,000                
Common stock issued post-stock split                             157,050                
Share Exchange Agreement [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split           52,336,000                                  
Common stock issued post-stock split           164,387,376                                  
Share Exchange Agreement One [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split           52,936,583                                  
Common stock issued post-stock split           166,273,921                                  
Share Exchange Agreement Two [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split           51,945,225                                  
Common stock issued post-stock split           163,159,952                                  
Percentage of common shares issued and outstanding           79.70%                                  
Percentage of issued share capital           100.00%                                  
Share Exchange Agreement Three [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split           52,936,583                                  
Common stock issued post-stock split           166,273,921                                  
Exchange ratio           0.2536-for-1                                  
Share Exchange Agreement Four [Member]                                              
Equity (Textual)                                              
Common stock issued pre-stock split           65,431,144                                  
Common stock issued post-stock split           205,519,223                                  
Collaborative Arrangement [Member]                                              
Equity (Textual)                                              
Issuance of common shares                               $ 3,000,000              
Issuance of common shares, shares                               428,571              
Due to related parties                               $ 100,000,000              
Consulting agreement, description                   The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's Common Stock at $1.00 per share for any amount exceeding $3,000.                          
Collaborative Arrangement One [Member]                                              
Equity (Textual)                                              
Due to related parties                     $ 100,000,000                        
Percentage of payments under collaborative agreement                         6.50%                    
Euro-Asia Investment & Finance Corp Ltd. [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Common stock, shares issued                                         50,000    
Common stock, shares issued total                                         80,000    
Consulting Agreement [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Non-employee stock-based compensation                                 28,800 $ 5,400          
Common stock, shares issued                                         4,828    
Common stock, shares issued total                                         7,725    
Co-Dev Agreement [Member]                                              
Equity (Textual)                                              
Due to related parties                                             $ 3,000,000
Euro-Asia Agreement [Member]                                              
Equity (Textual)                                              
Non-employee stock-based compensation                                 0 60,000          
Kimho Agreement [Member]                                              
Equity (Textual)                                              
Non-employee stock-based compensation                                 $ 0 $ 90,000          
BioKey [Member]                                              
Equity (Textual)                                              
Common stock issued post-stock split       1,642,291                                      
Issuance of common shares, shares       29,561,231                                      
BioLite [Member]                                              
Equity (Textual)                                              
Issuance of common shares, shares       74,997,546                                      
Officer One [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Common stock, shares issued                                         50,000    
Common stock, shares issued total                                         80,000    
Officer Two [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Common stock, shares issued                                         50,000    
Common stock, shares issued total                                         80,000    
Officer Three [Member]                                              
Equity (Textual)                                              
Common stock, par value                                         $ 1.60    
Common stock, shares issued                                         50,000    
Common stock, shares issued total                                         80,000    
Articles of Incorporation [Member]                                              
Equity (Textual)                                              
Common stock, par value                                     $ 0.001        
Maximum [Member] | Articles of Incorporation [Member]                                              
Equity (Textual)                                              
Common stock, authorized                                     100,000,000        
Minimum [Member] | Articles of Incorporation [Member]                                              
Equity (Textual)                                              
Common stock, authorized                                     20,000,000        
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Loss per Share (Details) - Parent [Member] - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Numerator:    
Net loss $ (1,247,538) $ (791,671)
Weighted-average shares outstanding:    
Weighted-average shares outstanding - Basic 19,484,542 14,965,665
Stock options  
Weighted-average shares outstanding - Diluted 19,484,542 14,965,665
Loss per share    
-Basic $ (0.06) $ (0.05)
-Diluted $ (0.06) $ (0.05)
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Lease (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
ASSETS    
Operating lease right-of-use assets $ 449,683 $ 524,445
LIABILITIES    
Operating lease liabilities (current) 282,715 304,248
Operating lease liabilities (noncurrent) $ 179,994 $ 235,555
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Lease (Details 1) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating lease expenses $ 77,527 $ 73,802
Cash paid for amounts included in the measurement of operating lease liabilities $ 77,527 $ 73,802
Weighted average remaining lease term 2 years 9 months 14 days 3 years 29 days
Weighted average discount rate 1.21% 0.55%
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Lease (Details 2)
Mar. 31, 2020
USD ($)
Leases [Abstract]  
2020 ((excluding the three months ended March 31, 2020) $ 232,438
2021 92,101
2022 49,805
2023 49,805
2024 49,805
Total future minimum lease payments, undiscounted 473,954
Less: Imputed interest 11,245
Present value of future minimum lease payments $ 462,709
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Lease (Details Textual) - USD ($)
 1 Months Ended
May 03, 2019
Mar. 12, 2019
Mar. 21, 2016
Mar. 21, 2016
Mar. 31, 2020
Dec. 31, 2019
Lease (Textual)            
Operating lease right-of-use assets         $ 449,683 $ 524,445
Current operating lease liabilities         282,715 304,248
Non-current operating lease liabilities         179,994 $ 235,555
Description of reverse stock split The Company filed a certificate of amendment to the Company's articles of incorporation (the "Amendment") to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority ("FINRA") informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split. i) effect a stock reverse split at the ratio of 1-for-18 (the "Reverse Split") of both the authorized Common Stock of the Company and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company's shareholders pursuant to Section 78.207 of Nevada Revised Statutes. 1 to 3.141 1 to 3.141    
ASC 842 [Member]            
Lease (Textual)            
Operating lease right-of-use assets         577,830  
Operating lease liabilities         598,937  
Current operating lease liabilities         301,105  
Non-current operating lease liabilities         297,832  
Cumulative-effect adjustment of opening balance of accumulated deficit         $ (21,107)  
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combination (Details)
Feb. 08, 2019
USD ($)
Purchase consideration:  
Common Stock $ 44,341,847 [1]
Allocation of the purchase price:  
Cash and cash equivalents 531,147
Accounts receivable, net 188,550
Property and equipment, net 56,075
Operating lease right-of-use assets 485,684
Security deposits 10,440
Total assets acquired 1,271,896
Accounts payable (56,204)
Accrued expenses and other current liabilities (251,335)
Operating lease liability (267,256)
Tenant security deposit (2,880)
Total liabilities assumed (577,675)
Total net assets acquired 694,221
Goodwill as a result of the Merger $ 43,647,626
[1] 29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combination (Details Textual)
Feb. 08, 2019
USD ($)
$ / shares
shares
Business Combination (Textual)  
Goodwill write-down value | $ $ 43,647,626
Percentage of goodwill 100.00%
BioKey [Member]  
Business Combination (Textual)  
Common stock issued 29,561,231
Reverse stock split 1,642,291
Common stock per share | $ / shares $ 1.50
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
 1 Months Ended
Apr. 05, 2020
May 31, 2020
Apr. 20, 2020
Subsequent Events (Textual)      
Per share   $ 2.25  
Description of subsequent event   The exercise price of the warrant will be at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants.  
Capital contributions received   $ 1,602,040  
Warrant exercise price   $ 6.00  
Exchange Agreements [Member]      
Subsequent Events (Textual)      
Accrued interest expenses $ 931,584   $ 515,196
Shares issued 506,297   289,438
Common stock par value $ 0.001   $ 0.001
Warrants to purchase 506,297   289,438
EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�L%E!,XC*)S=Z+\8) MQ1?'HU5\JX3-UT&XU&A[$]+0O96/GUIK$IS(5U,!6I$+DJ 14,M)L-2K8V/, MJ!C3L@ C"WXN@0IW7TG/7&PB4VPWS0(50ZF$F'*_>P!9:"RR)<9#7+^(N%K[ M]9!?1'R#MH+W,$W1_ SBCMT]OKNJ'/888MZE-EO1)_*GC50(X/6:&W-I'LU M/34FT KVNLEC@*Q 80'\M@*K'V":S2ZO-ZD;)"#2#J%X('@+AF]X^\,0?&-? M $J.KN4-;/7! 1S=V.)T(.0X/1O]R1X8H!^^=R'2JS^LJ/WYT'+ .A_AII0 MI33W!Y8/,!F=U;5U@\#W*=I RO !_&-WA5 1)D%\KOZP8R4KHZQ.N0/P?@!( MVQEXEMP&2!'C7[7I&G=4'8W2I>/$<'\+RD$J#TYA?B45&(BNB M:RU:$!Z122*7FXN \^NV@XBQ$;\!*<,A/":O.3N]..>C+]=7#YIPJG"5MF S MJ]V$W]&3@83UO*R@P%T )I*G56R$Q7DB\UN GHLDC* ^*W 1>.,HO\VQ9GL0 MRP;8UKD#'5!'<(5IX=6$7@")$,2TK:XR?Y$9,OT.6 N*@-;A>V6HM6V5U=-\,K, &Y94 M )1 %PQV3D4*\I_&[%S>J3?/,19@VQGZ=6O!>-'VW*XU +=2UE*X[=/C'=L6 M[YZJ>-:L>$H]2OG-BO< $76'0RIF>K9E^_VJZMDS58\<7!X%CX:4,P94_TJ*L0MF+:E!J!=(,]I8 NH0Y9 MZWRH6GYC6!Q:&/Z:PF(/DS9BR9=J@Z2K/DA#B@5MLEJM:^)K-0NCR0.9=M4@ MVCW/LEWS[!:C4-+"P8.AY?8'#V18]DRC4!9 T35*Y=-#["[8G;UP+GN,R\(5RF$9H3AG#M>,=?CU];!0'O](^U9BE!I3F7+659 MN#V:(K:)HHW-U!5%SX'LC\XOAH'@@0X"Y*>8.]MJ[M3+T_V:"F)9:\%$43"F MPO3.[!G7;L0<58:MFC#[I!7C(.K*[,E<&+4@=WS#]5;A;2HB6!(I0IP+4A ( MU$#V>"4#JO'(P@00D,V9'19\B"9>[]OE')L MBW$8Q".JIK8'!!?5;T"7,)BE4FI\7]F\PGR9BX8_/!>5;FQ&,O;4QK+JU*TC M(;/%5+AB4PN9L+_NSJA.,=2GA@F3^9;MFL(*L)&^NO""ZR+M@%SHWMT-4EWS MJ]7]&,J])VKX=3&\[E_\!#P$RE>8#^I SS OPI0O6_L6@PIC%B:J_W7?09LL M+0X'GU;IW+BQ96RI[!)];5%8N%/:4F&$30%L=2>G%!G$L+;=Z1G1BF$-N-XV MAW*^R*_P53E+V^ZI376O82S V(018G1]2MU_5@W 5:_WFM8I.Q3%,AV#;C+\ M4A"44:ASF,@)YO)'>X%9]>%J3.7VQK:J)O-IR(P]"_86$H?!CF,-_ +VLI=" M9F6H&1B.56DJ5(]FFF\,Z,;I U(/TU5_&:7-=I.V/@8I^P!(:O.I4=FQW;T3 M0/!WUQ*?_5W'T47>"S&APH1$Y:D% *AR<5HRNB\\(4+TI@%8]4"9B#9.($NY M#AN.M!TS_[)G <2-D'4C0*Q2!B"1_14E4Q 9 ][3CI9>7/-LM_Q54/^ZLO79":8:\4_:/#GCH8^E%1K[=? M(7/3Y=%-%T7K-TKIHJAQ@92IJZ*SX*X6+XL&D&H)K?V28'L_F6V257_HXXV2 M!PZ"JB<_AA&RO\,(!WCYSJ&FDPV[X-V\7>R0/6!_2V^_[?J MP7P(IT\_5U[IP'NJ#MA.@5C3BIQ#3/;E,E4RICARBL#H.M MQX3AITN?[?57]ZL:KU=5Y6^"'_)G.JRV\*=&D,N!-#J:J]190S4PT$>S!;A( M1 8Z4G>QVWT\Y"[0.U4WEQ91<[=(R!^.$^/P90!_,)CLY OTI+@,P(EM4M>LN66VRG./:HW_64>5*Y MO["UMT#FA:&=SL<[/:BK4+NXLN6"6G'10EF&NFVQ9AIVMQ O MVU&\U<;7="4*8GYUC>-!S1ME 0FKA?P:<;R!.'6EM9E$J%]=N[<;B>Q_ GQM!Y34],/1 ^.W MN7,! 0%_@8SI 6A1/],MGY8_*)^ M=:R^9')!O_0=RRR3<_HX$P$X! Z ]S=29L47W*#\Z?>[_P-02P,$% @ M"I?=4,"$JI /#P /"H !D !X;"]W;W)K&UL MO5I;<]LXEG[GKT"I/#M)%2V3E*A+;Y(JQ>E,NR]I=YS,UM36/D 4+'&:)#2\ M6%'_^OG. 4!2LJ1D9K?VP8E$ 0?G\ITK^&JGR]^KC5*U^))G1?5ZL*GK[7KU(""&5*:2FBA( M_/>D;E66$2&P\0]+<] >21O[GQWU]RP[9%G*2MWJ[+_25;UY/9@-Q$H]RB:K M/^K=#\K*$Q.]1&<5_RMV9FV(Q4E3U3JWF\%!GA;F?_G%ZJ&W81:J=*&DUJ-$'%I5W@[FT(*,\U"5^3;&O?O/]/YJTWK^ZJ4&+ MGMPD=M];LR\ZLV\D?M%%O:G$]\5*K0[WWX"'EI'(,?(VNDCP%UD.Q2CT111$ MP05ZHU:P$=,;711,_/=B6=4E;/\_%VB.6YICICD^1_.WSW>?_G9*69?WA='0 M,WO%NZ9,B[7W:U+KI2HA;!C[XFH4!WX0!$(_PCN655*FV]J@/E'IDUQF2NQD M)1Z;+-L+F)PPK5;BL=2YJ#=*5!M9JHW.5JJLAN+7PGNOEF4#)Q,S4F@X\844 M#[1(?/\EVR&(E9*Z+M5CD MJDP368BW9?K7E#S5>_$#^(",+\6M+K>ZE"S)"V)S<*OSK2SV@Y?^B9V'ZP?M M%)5S7S_A\RW_RG>IX4L$L6[A^+G-$^A&I(W,8>!Z\02 MA@@-X%JRSC*YJTCA/Y Z6WF?IS MY7U4VV:9I0D]O-V ?#;LDC\+A4TP,?H70&CT$(84Y%=10LJ \U+LC[0ZCGW.5+TDP2H22$YS1#-F-X?X,B)'(T6P%DN/9Z"QZ#:@6"0)RE=;MV8@M+Q#L_HY0 M!E1YJ4<$N,H\J")^V'XA-(/U.@2P2(45EKH5*!PXJT.)T/I\&? MCGR?3D!I5M7X0'GH0E@1:9ZK50J@@;I\K&W8O,UTA9T^04+G8"7W[%# M& V#8WZ\"[$(]"7V/\%."GY5KLE%[3F_\-?G8>D7N^QYT#L2W)K-ZY]X;+2= M(M8T\DUI,DH-*IW,[%AT2C",XM'D&CJX#GV3([%.KA$3U]">"?BG/,:[ *8S M0"(Q.A4M54*.*\4.@(:5#,RH@DAAN!*9X="D!D@6_-Z%4YB%OOVW94JJ[VM9 M;%2V>B9I%,1^',[A*R/Q8A+[8Y1TX7C\S&^\KXGJB[>0KJG:N-0J_DPHRYE49+^=D4Z$NV#P7'<<:FL-)4:J@\^AI0,"-6ESHXW/.(DO7.Q M.S%NQ18B&O1/H4&K+('O"I;DBK B#]!TCE"FP$T+Q/B&XF;EG J>@S,+V_?L M4L3*MDCLU"A=SCXL&,.IJQBW1\Y%3X4MJ^\0L@JNCNXSZ>H&7D#?2;EA//6# M.$#P#$[6-@X +.F:A+1!CTR=;S.]1S!FUM 9(&='H>.+C:^E*6_>(5BBEBZ/ M(["0VVVIGY1!*,1<<6K! 0LDT"0ST+MK2T/2%'Y4CX^4CR2A:4=',+,>N7[G M\"&M''T7CD,K^'N[V,#M@;8 ((0(U)X4Q)7)L@T5!T1!-Z603;W193^['95Y ML( LQ9/,D'*O@F$0A&*+[;S89Q8FK%K^ W)3:(FK=9:!; -*"WANYKH J\Z] MF/1UV4?PVU3_C/I9?)+ICET;&&&SL J-ZNT2],&97&I;)/O=RS,7I[=H1Z6RLZ?C;D1RT#IO0XB!H7"N*:OT-V4SE= MA<-)T-.>1\'B('1UMHDGD1\#L.8HGX(A[% _S_"/:5G5['_2E:Y8L[7"'7O/ M,_%-,+8"M64>&9 :ETS5IGC]L2E4:SRQ:-:HDD1TTH VU87^>#+SIW'0%F F M]E6#E][%,N4$X R^?P6BJ&T%J"'-$4;Z@DJN3U'WVBH6^1G1INHWFRMNPX[D M8 MRIUCX*=-BGIO9131YB=G8VJ=X-B386RJ2&;*NILOKB;DM<0891;4?ZBL<[E2 MIB&E@XR_WGUX1XD]A[-P=FS#)C^LK=?9G,-N=U>(-COBR?30Z8 ]LZO>I(0O MW9CFT>F:M7 UB0]U1K'V*O9GW6/F4)CF-DP1PW%9ZVWD%B!@B.I>9"%'D46E6G5H/%ZIU1Q ()^ M4M$]19J,-/54R<" MK!2Z9]0?;2X $6.%^3-QV[3816;2%1%M5(2*@92.1\/M#;1=^4$]R)4]G M93K4BN\Q.-.Z,I.^;9ME=B6!JD )6)-!V?'-H(L&5'?%"M$31]H0I?%Q8EL9FTOUJOBN$UH"\\S39;@&ICM M6AFPFN3BM=FFR_^C<.:/9VBUT7:?IG2(ESY=4TJZ^M8@ ]XZF8_\"3KWKL@Z M#[FA6"!RN&$#=^,9J^&QU7U:F)L0VZ*RU]/] +K;Z]_HFB+C@08]/M:1D5'XD_RC*6!Z?,C57N8TC'0?D;%=7T3EL)GJ MT919E4\ 5M4*: &29&D!>&1P*0AK=&#:#7DX%*6[%DJ7/ 5E(AQ-^:EKYTN9 MFE$!B&TA ,=]7NA[=]RCH)M2-I$3F\RBL7<#MW%,'I6I74F(9)L7Z>.^BU59 M36BGT4%A8[%)6[$)AALJO-/"XQC<;(G(UD]!J M6QLF1@$?-X/;5#RL(0.8LPM=7+LVSHAW39=G*X^*6X648:NW'OK2Z@S($3VO MHID_@X9MWASCH\,U\4=7%%36M>HQ%TEP/=I@- +NMFY:-O1^;7.\"<6SDZ7T MV)]%LV\+/@8$_2[#3+"ZVFGJ3Z/8ZV/J9*-^1@T<,'Z4A6G2G9F[>>+%>Q'Q MWP M(9?E[PHRO;-5Q-?LZ'5V/"R^$KTNN(=^#CB^K5V) \ !Q_ALC'EEX33I2K,3 M4Q.H**\\*TJG[E[1? L\6W LG7?MR#+^SJR9H8:K-@Q>$:<$Q*<1M9/:;[1 M8,D%58IY0_]_!21#L@@CLQ5LE,EC2X.1L\ZPUPC6=HD,Z\1X$NL;L) M3QS+MK[NOZC!UUVVM>7(-/?C2>A'H]#=3IW?])/:4]'E M<8O+:/V@028,^%[.3=>>M;4'@;JB&A)*N.4K+IZ&M)[-#%,QBN9VE?)\G=V( ME$F1V;U)X?$EK*@9WV!ML#)ELROL:'(*G0]L0#FJ]_MF0*DUC?S1.!!Z9^Y* M^XR#Y!.LIYO*ZSAJ8T6_4\RTFUNS'$/QN7WCXZ2@?BNBV<62VUL_WM6U$2NU MK+UVGGT>?;(W>)X>] 5#;]%2>P=JXD,[A3$#3^]GYJZ$ >[1\VM6U5V1"*!I M-AF+<.3/9R&O^HLJU,$K,V.X53"?"V HC*<>4/*>)U[]-9$_#_ 7AF(DM!:AK8JBR)_%,^]O"/+/#IQ':*X#XBD:1QZ%JA]3)&8TOGZ(?#B= M3M!_!WX8AMXGMO.5Z*Q\)2;SB1_$81<6PLB\_64PNW17/*MON.+!WTIOZQ/7 M/8>F.GOYXWO<4/9N:T[=S_"PXW"6<>F.ALVF]T8? MWWW3>XMT-,!C7NYKG[:O1B[,&X'=)72[1E(0F7K$UF XC0>B-.\JFB^U MWO+[@4M=USKGCQLEX32T +\_:H06^X4.:%\8??-/4$L#!!0 ( J7W5#8 M03!Y8@, / ' 9 >&PO=V]R:W-H965TL..WW0!EO) M6LI[V_F03?W0"L("4V,9&/T>\ J+PA*1C%\MI]^EM,##]I[]O:N=:EDSC5>R M^,XSDT_] V.EN$CF5U\RPV43)'2@;36RVX4IU:!+'A=V4E5$TRPEG9A^E MUE"A@E7.%$X"0YQV)DA;_*+!QT?P0_@DA>L5^9[03S36DLJQJ@QFLGR#C M#SRCND#0P76A-&ARA)WS(69]]H"*CA6(NEP3B]Q8?$D'P?%IH!.J#1..)*N5 M_5G\$]H-N.:%S?3715!^8J%<=#2AD@:%X:QH@[S32DVN$*%L[(?6?D#F2?/. M/8X]#J.+@4J.[,K06. M<'Y\80ROW^2G4L-!.&Z*IM:(*N[OB5Z9/.8SP^Y)#Q>TSBQ-92V,V[UG@S2> MH84W.3.T"761@4S36@'?@$9J<,-M2>0Y0BH*$>[(:[MW7.L:X:K9.K^=EO4$L#!!0 ( J7W5#;"HST;PH ,; 9 >&PO=V]R:W-H M965T(Q M2W/W=K MR^+Z\M+%6Y5)-S2%RO%F;6PF2]S:S:4KK)();\K2RV@T>GV929T/ M;M[PLV_VYHVIRE3GZIL5KLHR:9_>J=3LW@[&@^;!=[W9EO3@\N9-(3=JJ+N\M62J(SE3MM<%O6NU@WJLT)4$PX\]:YJ!521N[UXWT3^P[?%E)I]Z;]'>=E-NW@_E M)&HMJ[3\;G;_4+4_,Y(7F]3Q7['S:\=8'%>N-%F]&19D.O?_Y6,=A\Z&^>B9 M#5&](6*[O2*V\H,LY7-9P67WER6 M$$4/+N-ZVSN_+7IFVT1\,7FY=>)CGJCDBQ4HE5>XKDLA4Q1PX[7-!;G M!N\,Y+I2EDKHTHF87EE)&D2AK#8PN\ _2PMI+WL)^P.SYGM7>R=0I?^4>05R M$(R$\6(H;AT(@TRDE8EV<6IE+7RJ $$K:K>%M(J-XE#G%$PP5VO' M2N%.>5FPERQHK!F*3V0BWIQUH%D>'H1AKZUOYFZKXZW8*6@]MCB83T?#0P04 M1:IK,6M#\::LG,B($SKG58 W*)(IKHYO#BYL8XI_/F_]2%T'?_W+XO75XF_B M.Z #[#AP;4D1@0XV$PZK1^T8%S'*G8QPUV1NZS?C!DM;&'A)H9"E3S6YX]'* M 0\1#X475O#N8T5!JXA5HJO@?>*(]T]'!1&I8&R[BE*6J%)9$'E3 M;-X?>B8NN,BTXR#EY+_32!BM])AS)%$]EBI/ D(C"Z*RVPMB+XTH*AMO63#> M<-K3)Y)#Z2E?\BK8XI-%SS4,UY8 (."6)6-?E>856<];.JX?HZ6.$0?=QS\E M!60/+3H/&?4@TXI\^+D<3T)<2M@M*E<^M3DM"YVZ>I\'0!^%-*+PU+H MU<^),AN*OYL:*CN44TC%1;%O&;5GXDZG*5BF=6M?=#_$O\R02.WUJU&T#^=2 M>:[Q=+A/8F[R5PW8$3F3^TA^]@LV5G5C4I>*6)ERVY/1%\$$N5&YL@A%)W(! M1K,O@J(XELAXHP0-IHC M2."HE_Q/B>]??P0>A@0.+R#5DIL2Y0U.[L#TYJ4..I-OC?DSJ0ZX=2N)+(?DW>*; .\?.68-5?.Q0"& MHP][TP-R[LCV(3E7KX#FNH]T>\NOM=2&3?K5[-T_I!(G3BH+GE-@5JG>R*:' M9/*/1E@AG[(:-9K#M;8FVRN#^5_1(>6>([OND VF>1T4^JMZ&56CG/ MX@UIJU[4 /0 "( MHM%*->J"^VAW^JAH!XU>F,)T1M ,8(!EKT%F*V.MGR-HZV&<=>X/=EQ]#U*G M2N$Y<$!ME:-] M)7U,K+MSA3G$*0)M\@UC!K$M=RI]4#5'4!U#YM$D2L#IH)O[D$S^BS,:0:8S M@G8ZRJ8"52"*P?IH)'EE5=IE$58*.K:5\E,;O&2O"#4A7)09.+03/J08;S"D MN@8FD/7$K&=L/?#07&ZK&!CG$NSRSGUG$B?5C?5;"?68N5?$C#0:!30N=8 A> MNYB'B\D5MV40*R$;3R>C<3@>S>@ZKJSE^>J,(%+T(EJ0UHCV4+>O]YTWX&>= M[+ @H,".(48[O;=*$K8GU4IGZ!>J?4:(B(E^O7C9G%OK*1.8V MAOA:\%) 9XE:$_<-Q5T>R"31^Q/885X[A\E$^QES*U'94A M6AKTGT.S=X ] MKZ-' S> %4NW%6LZ^0Z#?K>CXP(F]BZWT9 IJ%>FJKN(^%70MPB&#WTC($[3 MSW0NFL^]5)OXF"Y5BDV;,*AG-W^P2XB,22H?5FEJS1GZOZ%?,Y.?H$1B=K(& MAS5N5SA.4,A#8A&XAW(JY6.-+\-GM3V:&@U!KW?#Z?I54T7^X.Q/,@PW\.Q& M\:EUS<<[$A]KBQQ3RF(/3']:IO4/SWA BKD9! ;XL ?]'+EVR+E8:_:H)8). M%]IW6!1>!AW[9LTJ<9X @ V/W2@'1JX;M '^!,.:#4VQ1/B%N-4ISS)/BA8 MG;;'C59,;_21UE((]IVQ.X#UNQ.C%AU<^F;;'>VHWQ7\*8(^WSQRPT^) RLK MGI2T@.GMR&FTT7X>C[!U2R:AM/I M+/A\=_ON[O/=_=W'Y9&,+L%=F>6^]YV$^Z"C006SC&M(H0UTG8H&QM?!_18G MJ8./F0%]@63&.S*WV8:8@.QGT15=3,+Y*!)?N5"ZTU33WI&H.J?:!?OO1"OZ M'OX3_>^)>7@&X&-M1BT,ZE1Y 7= JOPTW5,'P,#33_UI[+$$/:"VO)'U M* $J7*.X^+,5S(D\1),HG$[F)&$L%A&:XIBN(X'RFX]F=#WI7$^;ZWM#H_W90Q$-C4D= M:>B>(N6+V33XC 'Q6MQE1>7;-1S'E"C&8Y3H+/C6GZW/G[O $Z]1XZ.%./6! M_;+SPT2F[(9_?J'!$1;YWRC:I^TO/+?^AXW]&ULE5=; M4^,V&'WWK]!DME/8,8GMQ$E@@!F@NRW3#0(")'*16++ \>])7(D\)T. \;6S.>A=DN+N>FO] MHW+1_6>-DQ^,!2VIC M5=$I T$A2_>??^ORL*,P#]Y0B#J%J,7M'+4H?^*6GY]JU3!-TK!&BS;45AO@ M9$E%65B-4PD]>WY9&^P8PZY4L90EIU2=CBPLT_DHZ:Q<.BO1&U;&[$:5-C/L M4YF*]*7^"(AZ6-$6UF7TKL$;KH=L'/HL"J+@'7OC/LQQ:V_\/\(T[*^+I;$: MC?'W.RXFO8M)ZV+REHO?%]>WGQ8+=G5W_%P?7>[+Y/O6PGCH;?/$KLK MO<]BJ6M,#IM37L)CG]E,4$05+S(K#4])G2^E>Q80<+(=BMPF9X.&3WM38U+RVSJK5CA2Y(T]LQ>K'60F TK;_/ MWE(DO(!BHUB3J3S?'*FF!"I3+XU,)==2M%!VT6- 7X8PVV'+K M*7GVQ&JTNFZ=5+5.,C #O-E,I>2@,R++];!S]J,!+@.N: & 5'77A(W0@LDR MR6N,#A9DTNNBWE%:BK4L2QA\(T\]B$K+1# LH2) >WFN$M<4KI[<&&&-"UMC MFPI'^[GD2YDC#\)XD*D+G!'?I50;"$C-5AQ_GGA>PXIUQG:2EW)J ]/QN_RG MCX:MT 2J ?83[WX+D]I5IET63BC@ C865B6/[.#C(?O )A-_/ G]^63F7;@@ MR$O7-R_#A3XW61M*0@L!5,")!C4P%(-(0K+BBD(Y303.E[GP68F++YS/_3@. MO'M-=;&;UA#9J%R/DTP\]8-9[-VYPJ$,N2#WFEC_2*V.:M.G=C*/_>E\XBU$ M4FL)(^""3ND(UU# M6'S#M6PP1P15(2,:MX76@+M;2'80Q:$_'L?0?(U\*X;YCZ8S/XJG$'H0)8V^ M>84<(OY\'I! "WW7Q;97#N+9S)_.XEZ(LO8ZQNGQQ(^BT/M9J;21>>[FR_7X MMK0=QZ !QOYT IO1U/O(HF,_GB)%X] S&=<46XCCR(^.0\978"EFVN;1XDEH MQ&\@4V773GW;1^!V2GO0+UY%[*-^VYYBF* MZ>^A@^]>%40.CB0)-+HR^(&MMQ5I4'AQE(*RR%K+4IJ M922DMC5RJ/K.!HVJ0GA4,3Q VPO'HI_)F0$=&/:D'['.M:;(*185\"8BL)K)JB;6#051+I0ZHB2 MTHV^W$:!@/N$2\-*91D!4@@3$&BDD$%'[/L*T[0%7-'3EBI(,Y0*%Y*'YN6I MRRO"1BW2(^IG7DD:RHZ1D1;;7N"$A)@.F.JJZ[/^);%3FJ[W][V31CNOS_:^ MI3[T^B[O? 'CVX98S8*@55(/A+!XXAMU^6%6U;]FE MLG@9M\L,/T6$)@&,=T'.>A_W)S_"U!+ P04 " *E]U0V-8CKW8% M "W#0 &0 'AL+W=O+-]]=_?=B3K9*_W5%$26W52E-*=Q86W]>C0R64$5-T-5D\23C=(5MUCJ M[E3X[48TMA:0KS4Q355S?GE.I]J?Q.#[< M^"2VA74W1F.6-;< MT(4J_Q2Y+4[C>D*\K*:CP5 ML+-GJV9MZ%M#TK++'7[-R<@"UCT<92W$>8!(GX"8L ]*VL*P2YE3?M]^!#H= MI_3 Z3Q]%O #UT,V&0]8FJ3),WB3+L:)QYO\:(SLK^7:6 U%_/T,_+2#GWKX MZ5/PU^>KRS^N+S]^9I=?\+MZ+(7/0XR/A]$#&/:[9,M:BY+-0BH&S!;$+E15 MKH:, MRYQ))7_UBT*5.6G#U*;;E"FYPZ58E\1JK2IAC-*W,+%D&!8-&*QOHSXQ]-IO M7#9H<9:V11RRS]CPP _7Q+XUO!0; 1AN6-QMN<)S)4WL[J+)D"\7*?M$VZ;D MKI^CE:/I_*XH:[2P H26F75WQXO)9. L.3( 3;(7;E]\?V/\,K#J,4) 2 B+ M>98AL\)ZGSM"$^HX IPMN&7(>N4V]EDUR,XL&;_@+YW[.Y+L#2)IM&DXM&>5 MIWMY*-&R*U$H;)<5=S]WVW,J,;*T>QI]]!EO,0ZIQE!F&9<9AIKW-W#N]X7( M"K^-;P&U1>E1.B$S4?,2*5$-R-1E T^(LPD2@I2,A7PP[ V%RAPMT(.S^728 MO!I$3B=]SW,5, 61SJ%P+]HN!S*H*Z4*FLZ\# M!KVR'2\!>Y0,DV0ZYUMQ)&U[K1B.?AAYQ<1% 5PYT>-=-KI%^ M8COQ'$I![I';_]Y(OM2]1EHV6[P#6#KW<:^HME2MD8RI"V&\^%E]%?4D^T1? M_10AFP;*E(\H.?I_E3P;SP;CQ6PXGP8!/51R]*-*3N>+P70R_Y=*9E#R?0U' M?0T_!+^OX?>2?>"WCZA74T;(<(XLZ^_O0_:IXN!&=,@8X]9RG$U-:#_"]<'$)]U/ MZ6@/?1^\Y:%-Z(9T)OK.':4#ZEZ4)5M#:98=':-4GE._F&VWX_ EMHF!5?]J<+5<7[+.J1<;F,YR@X@?' MP&'\V.EOU#M,5Z2W_I/!]36&33A7=W>[KY)E.(S?;0^?-$C-5J"\)6U@F@Q? MS6*FPV="6%A5^Z/Y6ED<]/UE@2\KTFX#GF\49F6[< ZZ;[6S?P!02P,$% M @ "I?=4'>TWG&M. 0+X !D !X;"]W;W)K&ULK7W9^:F[__/S3KMSX M*]__L?O0PK^>Q%%68>OK+C1UT?KU7TXNSW]X]90^H#?^'OQM9_XN<"N+IOF, M_WBW^LO)&:[(5W[9XQ E_.?&O_95A2/!.OZ404_BG/BA_5M'_X4V#YM9E)U_ MW53_"*O^^B\G+T^*E5^7^ZK_V-S^=R\;>H[C+9NJH_\O;OG=Y\].BN6^ZYNM M? PKV(::_UM^$4"8#UZ>'?C@0CZXH'7S1+3*-V5?_OQ3V]P6+;X-H^$?M%7Z M&A87:CR5J[Z%7P-\U_]\Q:=1-.OB*FSJL [+LNZ+R^6RV==]J#?%AZ8*R^"[ MXI'^]?BG)SU,C0,\6-W5_W15OZY5?Y=\_@27'=5_HNE]= M'!WP?=G.BZ?GL^+B[.+LR'A/(QR>TGA/#XPWM>'_?;GH^A;PYO\!9G. 9 M3?#LP 2ORBYT".8/K>]\W9>(E%. ?, P;C!,\>G:NQ)VL-V5]1WN8=G4'6QC M5?9^5:Q#7=;+4%9%!^][H*F^*Z[+&U\LO*\+H.9=V<)[ 8EDV;0K>-L#'O;7 M17_MBXVO?5M6U1W^ZGWS_CSK@.U7%9P:(,WH6Z]ZWLHP#8UUU)U-L591VG!3*L<(F= M2YOP50#JP.W. 1H HH7"VZPUU#=-=0.+PH64NQV<,\./7VOW "+S.DZ)@/1_ M[@%DU=T,V-"-K_>>5[,!G@=_M1X>+QO8P[]@U[?7N)BRK?UJYO M_P48:">? M5$U'?TY\ U#O&03?=M.'AP/ P( "'9\; 7755%79=O,CV/H\8NOS MHVCV2^B6,.7_@IU,X>A#/G;X,6&F;*987I?U!M?;X[9H@CM\9]TV6SJ2'>!) MLX(#W82ZQA. H_E]V3<+WQ;G74\@]/5*?KE"7-SB;T_/$%6;R3$L2\XAK^0'QOBC+;"Y!#T^)C'=DQ MDSK_CK_69?:W'C"QV#)7],@5AQL"I.SVRVL:]]B9OHAG^N+HL?S1>1SS;=>' M+9+FU,'>.X*S(]#I,ON(=#2)KP I("34(4)_QYQEDH5,\9I[N(IK@3P#4 )( MQ1KT")P0@;PM/P.-Q)42^^A ]]@Q.^FO2\"%]1J4 QH>-M&TQ-JVN"SF'$!= MO1!N*!>A"GV0H59PY$#,^Y8 GO#C>#,A[[A69 ?X\CX]_TL&@(N>^1K "%05#J8=E_A^M>(C B;-A"\A0B;SNNK MQW#NNXASWQW%F'GTY:W $@#Z$7 IQN PXQ !BB#3 A.S\_CL$$X,D%^I4<%ZBH B X7N$:#L&H_ M^YYX^DU9[>%-5"J!@F\0W+>D_N'G-X# &\^?D1":%^_ITP+DTW-1,=D 80=\FDK'/R1-T2F>DQ/'L9\>SE463Y M" L%TB,U@E8QA6]?.43QVK<]R'@W?)ZTCFVY\E'P$.=G@39%S?":\$#]@@0^ M$+8(CJ3/\>FW@P6!MK,JZJ8(@!3 M1K2W&Y"L^^ ?"/_0FQ"-0./$'CH?KNO M"/9@J< Y],> _7T$]O?'Y7O3WI8M\N)F^;GH0(WJI\#]H$$<#W*%@Q2_UPY( M!43>!J@0"NEP+^(_8!MP2I*E*@4M@ALN* M!<:[&G1;@!*+*OC1,_LO$6-I0[05AX*AH+?PJW-\\^G\_-EY(:@/M I,$J>O M]R2MX:UF#]#> _ML2:/K@"YX4ECA%G45W.6L $')=%1\!X#$+5 AKQ.,5SSS2\"SJGC)\#EVFN=GR00\.WH4? 0?0;:T ML+&K0^?YD%%<-DHZT/,+6O#W#SW0Q5VQ!QH*(/FZXK8-?>]KUL7)2 #9ZOU;6%04 CN&QP,R50(&XN5:612>L+#Z=\2E@P.GY2[%0LCV(.( 5? M@6*)3@Z'C[.U,Q]A:!L26=E=C#XB]0P6"SP:N5^"+;"S?.YO.T>X>]U4*_B^ MV(%0V)=,>%?B=?GNY?SB[#O\\#=_4ZY*G"MTHLCM03.; Y* @+PKGEH,T=VM M0X5++I; BID1HO[D,AK/5G0$<'RXE_KIR6/# Z:A0$<*.VE]KSZ27C0XW@T# M^)?([M_5JWW7PZL?_0;Y+HJZ2X8UZ+V/3GYY]]O'2Y@XD!P0Z,>3O&:\'-#0 MB ,@L)C^OQ<#FKD-'FSKJX$^R5,Q!$B5!BT$_5G%^=GIWQ1UZ+&+9!"I)3'X MHYS&.)O.CS/],K3%WXD!O@('6:%[=F9W/W#K5),8EX M4378ESTBH+PH!GC"$$#9?5124"^UHP/>^"^ AR!WEK"-;?DE;(%S$.KNV:0$ M;W-?I59AWM^H*_> MB5]HBU8O'3]Q!AS)C<\CHTI[BB#A!)1JNXV J1 RT!R\.P%/M[B3\^=WRWYB MQ(5G2)#GJ;PI0X6_ BL>S]VF@\*Q$L/PF3W-UA$J.*SNP];=+9F:N-10TX'J MZH6$ /&MC1P-(AD++.-2A!!R-+1/.]"ST/L2ZI7?H=.$S6+#1>?%'P8F[@&[ M2**#3!:S)R:T!^RTF-JIBSNU&[T#9+_Q%9A+Q@+$-Q> YQFSCL>B'I!E:$&= M1QUBB6(3)4_"U@$=*#*$F@1DZV&"M@'[H<+9NWQJ0,]@,#E]#LL']E2!*=S] MX/[S/[Y_\=WW/Q:_X@CNO/C/_WAY<7[^(\B\".(_]PVB.=%NQ^YD$EH,,K8, M QX:FK('L$"E8!2+:(<2*'F%#M6D)9KXJL89S04#!-__TPW%?,Z0-]M"(=&V9#X-?I7XG4RZA^&U Z!.6,/9#P0CXK M'F0'_ BV,7V,/XZ7.5H?G@"O_4?\FK!M?,LM$\0S[7R S;MMF@7H=4E&V M%\L[:)7[!5),STXNW.-Z#RH3RAO=].0&AB?R-)Y(1"Y#19:WX*HSOLP:1#]: MM5DJ4_- %Q'0X^+BW1,Z MJB9VP*&:<_V$I[0_$M#X!](W#(E4C\$;8 %AJ5"8J0NZ1MF!0>T3= 28 -'5@;/7I&]RUC,N%6#N$I0PZ^.B6R6)3UYZ)JRGJ& M6L\-6EZ(QH#"WNZ"XW&T$XK:H?PR2^UD95:A96:*D\0#7"!1W**X1+J)6I;8 M7PI,P;$VNO+)F;Y/KAS9[AT2!FWE0;N&7=8;VK2+F\[W8%:_\,MR+XZ?N&%9 MD3FA;*DC8<;>=U9JB,A7?L%[=8GZ$#RD\Z4S/&9]723KZ^*HS?1::8/^>)MH M8]+^NG\L-S56YKBF\R3? I80,X*V$I@1W#7DS1V=-!IJWQ(*(^^;\V;/9Q??/B;?LV$*O@*5=D2]]B&PT*.BM31=ZUB.N?46N]=P6 M"_V>>6O5+,5M7GPJPRW@YBV&'7%8U&<[)0]R_Y*_(9#V7'-,"=4?,)PV[(: MD8%>,+"/[BS =J><*8\U+$ 9]!PC#T,K4596<&"==":PD59@KOVY+XF;'\/3 ME(IQ_O0>3WQDU _"U(>.YD:X^C$7"=F1@]P"6D:E3;@21?KP+3VV$H\=I+QG MEJG9"?&XOAH5#;(,A)4[@(PO9N?/7@HNTM\#5#QV'BESY?QXSLGK!M"F[I/_ M\34?^L?0?9X\D*\8SN7#V7R!;P\Z*:*&^P6(B0WZI1V4%0@>M<51Y03-F>I9 M3E'[W&7!MZHD#;8W_*'W6]2'@*SHD6%G>/I$&$(1N@Q+V+-BP78E*4CITVV) MY >/G/]"!@XL4@C_->VM KPA]@%F@5+S:^/A5,E(V2"_^)6_]Y-O.\,8,(5F MN/MH*WD4>079D].G@M+LVJ\V(&YGF+K#*1:@50(V[ED[0>Z-)W928?.1H.5$RI-(<2JAXVBC.C%&_(&4<6O$WNP$R0W#]=KAI*4C#I8U?HY"_; M50''VHGB$?DKX Q[J(DCS! *AM+..E:#7 ME 4(0G0FZCU9:C2V1VNR;QNE>%'J*90 5LXR#D0D<^O%ZD+G%89Y5V+Z2;*+ MDV074>YVN^I.IZO]K28?%)UL$#]&?6GUSSUCL#KC,644/Y0T+.C6T4<=H!K7)0S&?0URS0'V0]Y*A'M:HUH/,CN(6$L 5@THFJ@ MG$(.!_6.4&EX5[*+-$DDFK$$ PFN<#8(:^<+DUG"PY(9E+!%@4G9?%*^NRL7O&= "$L?\"+(Z3_ZJJ)$,305>B4T-\D?:T=?,SERNH];+:KR@T M(0=$.&XB3X@+&]#BZ&Q7@8U;BHF762X?IWM-KICPB--6'"*J'E<\@WGQ08)) MZ.^)1V%7&A/HTHB<2(>,6DA&-.V.*:&A !:HZEN*0%%>"'$HD.'HI9B14*\U MWX9L7_$4&B?PRJO9,53NT1I%]GK,@4S U9)24JK8U-&HT_AVSP< M8+) '7F3\+6;Q\C@2#\>OL0N)Y,.^+"ID7(?P; 1K7*L>M2TKH3=6LAU,%:W M)A/]P#RY:MW4U1VGG8J3%F%\BC!F3XWH,GT08KT$.N9B_(H()%%W4<#!AS_ )WS1(A6)&^5",=>A:Z30P,UYS)' 9T)>@?:?%&#)A:HSJY %5=96)??9;K-XG6C $PN&+_2A$]J?T']A'QN% \ M/O >NE $LSD;V26NP%IWN=U)A)W&O(>WK-)71AJX\COS+AX8:G(X-N .6LY"S4V,P67>$3)Q9-IT=$A*IE1#F2N M.0QE9+;[J'F>NNG+SJ$[,+JLDP(AM-OY3#H,M%3A.3&L,9D5>(Q=PKD[Q6>F M!PEC9J>9J9#-*3C'L1'%B6 C2YR[0@L5.NB M@C,0HT?G'RH3!* F#P!RB!G-LL!:$4IA#R9?3XHWG]%,0<&0#5N/%@;YF\-V M 5H,1Z;8(8B;_OB?0#\_OL'M=DU=^XIR18V;WO@YF?-KC@&>/OGFEY*8T*8T MDVY/0;%YEG&/&8.@0_>87 W+K (FIRZ0FI(R>DA;G,FF$6+9I^QKQO-MBDU; M2K(T+0RC"7>N O"B5WQFUT>:,4"&UFX@)HFYY#4E#H,\3!S7DFAN9(I%$54: M1[[LP6IC+D0,FZ=,\6\34T#=9;B.&D%/]F[:91Y-!BK6G$CGE)K25!A?5$&\KLX#DGE/(Y:L;% M;TT-5@+,P0DP.[#AZS[)MW=K5Q9"$N-T-8PDD/:&.?H("]]R%&.D'D4V&1)(/]UI2<0X-1M5VD\5HD\-\ H8O&[?(>UW.^]'.6[9AD=07 M!1#GU:3G?=-C&G7VM0K!M!]U#/#B0S>LKG)V"OA955DS42Y34-C6&+=0E]JA MGS%[ "$"HR!SP=<7OO;K8,Y))IX[E$ZDBC"40-?9D4B?!N[:PX%@]A^FRF.% MAKI% $0P7B3178F!*- R,WLU_">!$Q)Z0T+]CHZ2E9?W TT%Y1H1^4 >_XX MRM=PLFIO4R@JLL$:(FR ]%OW9*N=L=KX/ MP/-[1+B(FE8>H@T$2PMR8FJE;_6KA-#WRD<)4$XO-I(#Z#>H&5)"!=9S 3MC MMUTF 8=B$L %ZB\Z6!&C>ZH@B;5-(G8D>;0N&>(B@&Y8I6[#9N.U**CSID I MPF6F&#)P]W1QE#5Z9CB!Z!8,4YAR0\4R/Q2/RL?Z$JM(4E@Y5B&'HMEBQG\) MQ+S\1XO!0E8-8>6!];CA>HK_;^M10ZE%KY/ BJ(,$[AEJYC$!.4#X[P0JTX. ME+PDQY4>@#3;P$5,+F'7O<1B\&F J22Q[2I;,T4P/ II6:2GDB7Z6/*"A-I6CCPM M_77;[#?7JAFO]U6&FP-.B)F7-249;1LF*-07K"HY8Q9C2)J\KE-K=L2V]XM_ MDEL&G2T8LJTE&H6'NJ\EP:5GFN>4&79MDQMRM2(5 [6"*&2Q2(O4\?U0DYB) MZTQ.C^3=!.:%+I36ED+8'3-W $SK+ G-M>:]$1T#'@8>?$8\A6;=PF8("YT(DSEE<)P;*M68!B\+0R?RFB?.S-J!%Q]E[Z;A@-FT/B9* M>J:3==-'6RNW XT7-3YFB+1;9&P2RQD25[/$4KZYH,][L17=VXH1_-)ZG*TD M52G4)?O2RS>YE]H:Y(_.&729@1:4_<@.S.<,\8O'ZJ(@M,8L*U0 M=ARA&'AHN3Z8R;&[#KMY\68X6K*#W5'P8J%04&%"D0-[XE3\[[<8-L"T7B;Y M@3>9;;]D.K#IQZ@0,! QTOX5A?#,)"L2&.WF6DJFT1N7;!*9;;2@F3ZB1-D) M)0:I2+YQNHF0.0C434]KS1-/Q17-)BB%HK#^6)S*5#\<2W-I0:*,E -M X%F MC"JI++&\(V5CC,ML04[4GU2JSAG- M62XY;+)9!N+JY-/H0Q=SVO6XV/]#J1:YAZ*LNL9L2L$TL.732CK2!31/C['> MD 8>FMA1@;(9N/."Y"7$TK>!?<;_W$HUG/ YPAG+F+(<0S,G6_.Q7*$>8E/" M0$O4/25Y40HT_1NX]0J/,^H[0FGXHK.CI>7EOD K50SMY &C+*Q LEYXGZ5Q MKAJIJ@2:D6<$Y'B@TGR41!+$8:ZDD04YAE(SAS$E?F(R(I-HVDBL)H.N,455 M )21^;GQB _W?0SY?R9&;OPP^\!RTZ9UQYR!T9:?.#C*="2CJL-H"5?]JZZ_ M'9E4R?(W7GFV-Y-M U!<"T:1"DBN9M_69 CORAY&9E>"97L8/?^G9I)):0!! MW+XE%0.=6EZ4A$ @KMT]<#;Y$ 8?A?NW)3+P4W2EBP"($!<0VM$'^IYJJV[H MOAZ_3<*14 M(7:(M@VEQ; QD4V&R4)S33ZR3C/87/),LQ,+HY]ME (I-2>IWD8/)K\*V&&C M1)Y1+Q-MEE24F<\S93KEN" )3BBBCV\+!W32XXD3UJ,($P22+D!<,G39BW)I M@MBYSY1Y3U0UI@P$>U!)0&+!>=: : E8MK22G4W MZ3F3^X#B#%,ZJNI)JGJ(%:M![1^BBIZ+!=)SMMB,;T^:'SE"I+XHYT;V(*A2 MBXSE@<$D:.'K:WQ/G6.'9*A1&DDM%R.9JO]'[@#^D0*CR,:'#.#0DF8.S8SQ MQMFBBR[8"9..%=.G!Z!F3%ZK@1KA:?5V0@*U2;D.P"1%C/S=8U2;TOFZ9>! MP'(60T?6Y3@SBA_7H;#"@9@HZH;:2,B"V>F2@]%(\'3(JA)2Q2$Y!MBSP%TT M-.LU\S+(F.[@F!2"^\R< 6V"B,,$$$F*US- H,>(MYAGJV&,.NK=:19G\GK2 M.:E",W"+,$6I7G*(NN?),3TH@#/F0\8-\@YQV * V*0(*M$,Z\:HI8?B0"C' M571F;R,/S 7=C*/?FI4G>'!$NZ-5 +^=LQ_I8W-75A2IQD/^T#88!KFZ+LG? M\$&EPQ\HK]R]?M:1L6%\OT/9;_*:U*??ZEJ0>W:EY*MH,H:V5PE41:JU9@ * M3"+'KDHQU['GCX=QTX-:8_*?#V)BXY2^"$4LBD/:0$>Z:LN9JPAM$WW[D+TW M<-A*=4R2$BE?@?T0N@,\B:U-0\H\2;GND^1I&GEYQXRN(_J*VD3GWL -UJY M_=%JJ6^,A_LRN;2O-(-+LUYB&HQ&(>E\I]7=@:O<&5?Y5+O%WL0V8^88M4S* M/A/B0/WD0'?,F-)&_#I#$Y?4=S3R@"==52/4_$"&P$<%DQ% MFE*QO /.L 6+?\_UX(!-6"M!$;'+#^^H)/7=;V^>_/;F\LDE_M_S\[/_B5QR M&[J.5?AI*6A,:&Q8J)6JR*JD7QR[A[I)D-M#5;MI*L9=#ML)!Y$9RV:SY= AF^.>_6/Q* 9B MK$/8B4,X-E]LR$W7K-?(MX^QI#CJ!.\@B'5:K+1II64;-P-D1IRUA','Y ^C M:XOIGPT;-':=W(QFZJVO63Y84J$WZ+1 M6#R>UFQ"^J@F)8O8Q71JF\V&G]V 4J)R+(T\9^6$2=3TZS+##%82.7RTK=;A MBU_EKTG3R*D95=H2-T<%Y4@$BM*LV2267-#29#\.\\=&>?-@4W,F5AY_-CJ# MMC,$Q!GFB5A=)K6]PUX*IQAQ,^5S$9\H/Z;#BA"@H=@DL:&8J!H'BD4/(:&) M_LC)^3 2=ZO,: \@5 8WN MLL'"Z$^)3>/1-00_K&7*(VDA%TO"M>+6Q\%C39T=33AR$E,"=MK8A$R)R+ ( MG):%=P6L]JABIV9-I#EFJ?= 7,.T,3QM3'-R4OJ8>F>A8G%#3(46D";?[\@L M%]]\R]K<:N\ULU"['Z%EC1E>W+5NRHCAWLUTZ"XF"O:ARO4?-@<=;0Q]IQ[0MZ)8 >J#Q3.@4<+2Y-S;+/C_>Z_J"YF+A4K!DG?C19 M7_JP@5PV4)$]]O$Q.C G0+WCZ,FPJ@2C$HH03? F!K)K(_8C*35GA$4U&+/ M%)=((_\D!$PL]"T^!21"5[.4E&RI/:0PPGK)^&6B>,JI8PL7_Z779I7 #3&[ MI@IKGG19[D*/842_(K]V[ [I6XO\>H(0?%_B^=G[CTZ\&K?#M>%/Y^? MN=_7:Y1PZ?E3>/[B&+6F-N/G]S0+WR()J)K_*[9U^96<#Y?4AF>2;!\ZHIL: M<5!FT7U%)3A8L#W5@#]]<79Z?C:+K #^JDKQ9"1&087C\N[)X[E+_RKR/H_4 MS*:B-9JF2>K;TG1P2;^"I9'.W'$W"TI)ZSC_,-/[O*CD$K -"2HHNK!/J+J[ ML#U72LO/FM51%HO4:HJ@B)UYDHXO08F>A#B*,5$(Q#N>:U3)VD?!/-YZOMA4 MA9#R^["C, @Z63V!*EOS+4EU(->W-RFYB\M>7%P6)SJ8"J%,MN[K=7G3L"?: MP&:!P2T4T%&24ZD,,F=B*'1)"+D_J(>9%AR!H+8M\-C]O@"E\O,I;L+P/ZV0 M)^:%[3^_:)Z#U))?7<=R!P&0-GCG!A1\6JM9?E0:G'$)?13<*HNU$-X4SMD" M#=6QIQJ2=D*YBD^QX^&Q2N&H\I&ZV9\?[T7_J_:E(C[0\Q4('#"99&4/',V-1LO8 M6+DTI5*>7[7]27KR&V[!0DTH3*E.V';%;S *IQ'N@6\NJKY(EG53GW*^#Q7, MR$0I\#0Q\YH4??5"C_1=JMV,)?XJL7D 3QB0VE=@ MT>3;+NM-_+=L%EE)DR[[2-V'. N5,L+:Z+\BMA6[]@RCUS7LD+F-5MQU"1EY M.3,KO_*D/2/%]/32)D!42$=TP.>-;S9MN0,Z1A6\G$4KT.3"XJ,-$@V;,-A> M:&FS&Q(9_M,TT_L,Z&AI"@A+3HF<=WZ#2BO"IC(3;]59\I,ZY9+N1 IU2X/ M+C%S6;*).$V4-@X%Y*>X U=I2M>*W&TG-1'8G,;X#U$M=09UN1(^NPKJJ,1. M5Z*<'[_.Y'=<].DGF.GT4VP.EFR(2:G]]2,Z8^=\RCJEQ4Z64^*3$B]3-4H9 M+Q2R(&8]?VX6W>D%6>A49Q,P]8,N5)*\'XGR#E59K5+2_(BAWQN#'H?X".N= ML0R9&^'WDBJ?] #3G#-@?0>LBP098R1=R2*2F\E91R#[->$TA\Y(V^[V:*)B M"-(D2)!_FY-V "O6$E7A3/&USL]>/)0WG? M.?>^]F5%M\,E_JG:F,-K5YN&[A28#?CWJ)=!$5DSZ7!T#TN>#&+H)E7WS])5 M3]*$P'@0(Y\1XI;$P)8W.U,50RK>ME?H3RXD1#*Q58Z.6I!4!]L>X%*-J=O7/6U@;[$%W)4LB05B0W M$+P MQ@#;TD;M)_L>2Q,VS/E&4Z.9P!V=I&_D+37\XV[#T:V:#[JX&]Z!.E+T$6IL MA=0I-3,"RF3% NM)FRK-MN0&N:E=H6<%C0+I$#B8:$L!D:QG!F\'S8[:XSZY ME'3A-57981.-LBPXEE-,8FO$^#@Z-F^:-+$00]T-8'UEER7P65C@[+ M998T6P(^ND-BU[3[9OTW.>"$47W(GE._['^1 _Y^SY*0$B;8(36@_.8L5C^8 M/L]R!>I$JURZY^C8C='IGK.+XS>4_;5I5NBHFE+&'OCI@1K(C?Y\G]MQW>IE MPE)%4V=UF.1$S;R0HNM*[CDS(#?AE3OD,\7J&<]M(0\L,D_YP7%\)8KBO@\8 MQ ':-"+'*O/H$1$@F-(LY'&TVRI\IJQI9 H4I%?OK[U>:$TIW1KLIE(;K#[@ M.'DI-7,YYO Y@MXL%J<87WFJ?X(4!0;D70K7##)XLHBU$8P'00&<> M-9E)8!].VV; %KGHO%T]$OFE. M09QT?*,ML7Y;Z9WB<3F,XE)BVY&,G@:IA=$F'@';30!;W F33NXY7KY&'GWK M#S=.\.Q^&;1AZ&(@78'Y)J8F<\Y^U&A2*M]$TX58)15;5- -8YB'-M.;.F:J M^76>'7ER026Y9L1DBSI?T@[S1)+48I@!I'Y X47V!(8\$RN5^ J)9$#%)0_3+105;'-=NMT8<]PXR#8(4UF@!ZV9 ME/J4.W*)8'+ ,5&;+OJ[.'X]W\%T[[>"G9,R^&%CND-C#H(9)N3 [H>.6 <3 M)_=D(KN"4X&I(\6!)#3ZE!,XI>\=!INXD?=W3S'D='KQ_/2<"ZY<[(T]:M\/7-!]/GX^) M=MQW-J:* +MRK]^\_SV%?)#'3><)9^T-.2PVD?GZX%[I#F [.UPYP(%Q>.?D M\3Q_:SJ)M,BJ[;GZI@#\TJF8YTY>:K^)?'A@D"70G_]Q2'KN/;E M2MUI/7JM8A:8S0)/X\?>A'W+K)8&'S0CY+Z69*D.J8Q1" ,K+@[%[_OX;W/I M>]R]\43+-4P@D228G)ILH\/&-%K3#$/-4L.I.>\,O2IYCKL&N)7\8E/ >\&? MIV'%@)J\H->O^]JH/4!R\3U>4.I.J[6UZ#2+%G=\VW3;P61>TO_QD@9):=#K M8Y)F@[W=J MA8_I#.:EN"6VZA:I/12/W%IU(9&"4@!9!FI76')4XZ7*CB^,7 M$GV &4\YF2P&DG;X#.S3JI$T1.[,-RU\OFIX=VSX@6L>U8&P"F4K;;OD2@]- M&.)#QH@7#1*O[^$;:O,F?G@929W=LXQ?_XHE M1W.%N9I44%>D"X-BE-;H#:)I9E-K^T T66G/B'RT )/'?5/W"6W!]^VT7@]N@,Q&PTB4 NM/+Y:"RACN)ZH?9>CW:*_@ASR1K MQOB5CJ^CFI]VL@?D$;D-@&1:-["!35F9U@I1O8B'O_!W36QE:/HO"D'BF)S[ MK9=(Q+O^=!UQ+%43R6]B",FI,)B)2^7I[/GW<@W0L]FSBV>R*G.+UE'WRO#^ MJM^-@Y+R'P ]<[C'! #E"=1"C3[;#0BQ:0\2RE'*3]=%71R_X(EN43]E8^>U MZ8TY2>4/'LK9H3+-TO1H4!4B-KCA"CK ]WB6G5E=UKFSO"7%A]71,K_/F3QS M@S)-1A&9,EU?T#556 WN_.[PEG*-CMS73H.H'Y3.U-DB57XFU8U% MZN;77? M\Y?%B873*=]H;Q^=8%-N1/?[(9)44/83N@D_X3V8/)^R 21W\>"\&#:&M4W[Z_*PXX32D4Z[Q_6"*=E%'>:LK.1E&ZE/^9,,7 MDIEZ.=$+*'=NL)].D79P*[FFO6&*2TB);S92E'JW4J<,38);4:.[U HEV?L9 MVJXFV[9,M%!1++$+OQ]3'&/*\PNYC^_E[/GS2??RUS' 8VPIW9IVI=,,"4=/S3HF>=-#QW/C\8I?X-2=1JKQOV.W;@ #GUC&X$K/F)R$XDIB M&F&[\"L$V"+M8IEF7?.L&!Y*+[CQ"YJW(1%00J!RM 1R!^+BC'H\]FB:+H:( MDYA(3 M/;0L;Y#*@>@.TIC H_?Y9-6B>B52D]>6T56>6G# ):KY8(%N*VQ[8@74"%4N M3E5!%MF#K9,@D*6<++X6BROUY',)3QXCU'2-W,7Q"^#><3K5I_++ ;?40SYW M]/EA#Y3D;/7T5MH:)[Q3946\@CWF=8F/D/)MHC]/J]VIB$?=S,K6ADZ2EV%&E"';A-7;NY1)50H$OI?9)G2D'&CR'+[GTR7=[ MB0U1T)0YH<\RAL?[*5V,N8GO2>Y<)Y:ND:?)>W'2T9WR3CGP':-:@\G44Y1V MB73GLATFAQF3-2CQ^]1U["X5V^UV<,QR-WT?:T_S&Y7BC3!;3"$2N85]%65% MK!,/8FS8T"GG*5$$"&YZ: MU5J)<:'[%GWQPTEB;LV&^D>+\0JZH+3T$1QU] 7[3;D^D9EB+"\!1^T7&NP&0GGC04 M@0F6^R&MS8QI(2JEGNC%:.H-.FB.KCRU)XJ+7?G3!ZQWDN=.]*7.]I!692X? M^^!K:>*D&9PD_:,OW"1)DGJH[D^,$"<63A[U"EL1T&TH[/'7'P<6-142I^C' M;XU-CG8[6L\=9P?I%?#F.J1,RD?';ESNOV//_O7R\D/6L\<$F)K:G AS%MWG M,G(:628Y+!6<,UON0(ER>-);O=V'KZ*J&G9SD)3$.FWA)K_7+EY??7%!EXA^ MQ];&U=O7JLA?]>5Z;4,]K_95A3<\%8].KBY?%>?G+T\>JW\K!LKLSO([SMQ0 M4;@FC0T]@O-"!C1=:#+5*%J>E%T7D\BD@%G\=;&*/-:>R?!P0.62#&"Z1XX. M,27KV][X[-:/JT[7R(*,Y7;/ Z>"K'O&O<;94-L32JWCA8X)I5RV_88<3UFQ MQJ7<'6OZ=1U8C;78Z=(T4K,EQ9IEVC)EJ\9!2*.*!:6&AB;/1>JS%3J8P<>B M5%68)#C*PC1*U%R'&;XN\$"XN3(US4%_DJ9$L(H[;",_+6+>K0VL@:01#^PR M#D_@'C(!+5E0S-[T1V52$?A3[3SCQ/H X5J5M^;J9G-#<-B"!H0>QRJ[PB=B MZHA"_D%W&!]0):GY_,0!I"H@*E%RT6PFO9)[URSE+G$)&JA&O<)($O+G78F1 M0%8L(@_!S89+!PJ;_G"BZ2.W0#"'RP7VG<<@VT MR VM4'NK2K[!7,ML?7>L+1U+N53'4OL-9R]X2;9V[).3WM*A+_+N='P*').8 M.JB2,H1[Z^=J\WZVXT,*8E7\<]^&;A66W-#L'5:PD%_MGCF'G:TF85M,P58# M4B&'0'ZIHYJ.0RR8WC]UO9BE_H_1,%X7;(9BAT!TOF+YCT7+KN,O9=FZ:?[%R* MU%'BWS@8!9!88W)QC+FDAH!!@>IC\B6U9;DXWD3E5RSI^ G?Z45[J_9=4_1 MLDGI0:J=M7IR-%(U268E<#%]E-Y:3%(=_'B;%:>&%?# GVO2^YZH:NK$GL1.96U2'6X\< ET:F)FYL=WT-*R!8W99_\'5/D8; MM(7'FU#1?#BV,_LR2^G"-F#_;.0U$\NF:,C.9.4#*36$"&C>=C%;51SWJ9 S MK3AQ&IN!#;'68QG=1-L*,[C-F,9LN2/ '2^>/0]!067"&$ MJ/FVPLK;$XTPD);X0-OZA5F6#,@3AC8JX!TEXY[&.8Z12VK[<7&\4&XUWN(-1I(-G&*G./CI)W8LP*WM0NXU\"*BJW://4JO" MU8U -"9A5A1_A(Q+._B<_ 4D(%!NI-1]*=(CRWS\&5_"BM-*49ND>1J'C.2T M1MW:R3U%5?2R3R9/,$$1UB'W;^/]1E6T.OG70<$)F[GQ.BBVJ&O5A@"A'2.T MI*QSIY\414D8KXXC)5#)RSID?@X"&OHJ@XRO2$P)W^F"&FR4MBDKV^\U3VC1 M7";M]WVXL=R[6,@WZ ]N>V-R8]K!.NB.CH0O^=KSL4A<'K'"Y;A[Z>Z./*:I[,0Q0H?KJVW8V5]+.'+W_RMYC"NL#]_VQ6/3G[[].;DL3/Y M@Z2: W>-O1J$<\8(?S:'1'+^2M6'TOK&3W:$&I2L:IBPUTVX.&>KS+;49'<$J=/&G5N_).[O%H-92 V=.MET)W)G63A"[L MR?J>.>U28_;4 #.%)'Y7SU'%W5&NT8&_8F^(^8'J+T>+G8Z2RO$2]41&@W$. M8'1<3I2!,Y6 Z\G80*W)L4<6K[4WLDW1-]C"1O_EX#AP-5$'\:/25-6+UJ(D M<#8SZ["#-8QZ=Q.RR7VC]I[Y5))W97+FUJQ.8F@"SN%;;<+UZ UE5?2/CW&$ MIZD<]>GQFM)/9DV7<4U3K.#A [DT$,GWF(,P:J-T("N9-"=J(DJQR]AC(K0' M6*VDIK9X/13?D@ 4Y&2T-T1!Q!Z^P2H-2D ^/(Z>DM+B'_.KN8R!/.:;$Z2' MDS^ND-7D"CSJ+"^Q6N1$^&+Q6M'^/=WIU9T8FQU6H[?CI%ZGD2D8-42-LH@< M,[H8Y0@EF2UHIIX0049(,\9AQC!V;2%F'1CB&HS;IL48KTM4*$0582@9!.,1 M4/,06R-;0W1UJ4GQ*:/K R0C5]-(VSRF'RVYV (:7&,&=;)"J9+\<;Q/51H, M*PU'"I-B\4>KAU!8JD)[>E_%&,5^313J0]O4S5XNG9H4NP\:TAT<$LW]%!VC MU$($,66!BK)X>?5'\5LS=_CKZ?G%K+@"1; *ZSLU\2ZSR%=A\Y/H&K.==']/ M;!DV@ZS"^@%"#0 MC#:!'9+LU(F[/7^NQ9HIO6$06,0Y@#SK>?$6FZHY,CE,T$/7)U7 8+ST/FM\ M&S\P04NZC@'K[.,L*0@VR6O((@6%U-WYWIJ68V\]DVYU-_01,G@H58\NWXXF M-,*/_*DT1Q-O?#V>I3V)[4](NK\I^_+GG[8>1.IK7U6DGM: F4@#\2D&#+%% MU0^7%R=/X,OT^L\_[8#NWX-$1L6J\FOX]&S^W?,3+BK4?X!%AT-BX57?;.E/ MK/SR+;X OZ\;,(CE'S@!EFS0\G[^?U!+ P04 " *E]U0N4#2%D8" #D M! &0 'AL+W=O=7$#YM MP% [3M(511(@Z3ILP(H&S3X.PPZ*3=M"9/DA,O&Y)<;(GB>X^D M2$VWQCZZ"I'@I5;:S:**J+F.8Y=56 MW81K4?%(86POBK2UCUU@4>0#5*DZ3 MY#*NA=31?!IL*SN?FI:4U+BRX-JZ%O9UB9%F1-\3S:2-*7"-] M:U:6=W'/DLL:M9-&@\5B%BV&U\NQ]P\.WR5NW<$:?"8;8Q[]YG,^BQ(?$"K, MR#,(_CWC#2KEB3B,IQUGU$MZX.%ZS_XQY,ZY;(3#&Z-^R)RJ670508Z%:!4] MF.TGW.4S\7R942Y\8=OY3M((LM:1J7=@CJ"6NON+EUT=#@!7R0E N@.D(>Y. M*$3Y09"83ZW9@O7>S.87(=6 YN"D]I>R)LNGDG$T7W>7 :: M2RU+&0F-,$B MRTRK2>H25D;)3**#-U_%1J%[.XV)A3T\SG8BRTXD/2$R@CNCJ7)PJW/,_\7' M'' ?=;J/>IF>);P3]@)&PW>0)FERAF_45V$4^$8G^(ZE^W.Q<62Y:WZ=$1CW M N,@,#Y59AZFO%7HZ]Q8'BE+KR!T#OC4RH:;G(Y5]3SGK2/);8DY?)$%#I:M M5#EGX *O0F[5RJ@<9,V"S^@U'$S@-TR2P9W(*F:S_\40CH?)X+[@-L #^XCM ME\?*$!]T7HVV#//E(%2S:\+>VH_PHNO&ULA51-3^,P M$+WW5XPB#E0J)$U26E!;J85%RP$)P;(<5GMPDVECX=A9VVG@W^_8:4-7@NZA M]8P]\^8C\V;:*/UJ"D0+;Z609A84UE9786BR DMFSE6%DE[62I?,DJHWH:DT MLMP[E2*,H^@B+!F7P7SJ[Q[T?*IJ*[C$!PVF+DNFWYM9L!A>+5-G[PU^D8.+U/"^']H6MLD#B"KC57ESIDR*+EL3_:VZ\.!PR3Z MPB'>.<0^[S:0S_*&63:?:M6 =M:$Y@1?JO>FY+AT'^7):GKEY&?G=W*+TBK] M#J<_V$J@Z4]#2[CN-HN!ZT96^';<8(;E"K53>J?/ MDM4YMYCW>[=<^%J''&Y5FE58;&4&,'Z>70 M'1?CB]XC:VBF+&K.A('1>)!,4G=<1FEO(8BW3&8(M $^:H,M$S5KB25S4"NC M:'@R=(;48 .GPW%,. GTG9@,DF@,_5[W)08@:>.&ULA511;]HP$'[G5UA1'XH4-8D3 M2$" 5-I.F]1JJ%VWAVD/)KD0JTZP%WSEWW_?=F;O95JHG M70$8\E*+1L^]RIAV&@0ZKZ!F^D*VT."74JJ:&735)M"M E:XI%H$- S'0&SOT3^YVK&6-=-P)<4/7IAJ[F4>*:!DG3#WI>,?LV;_F0ONSX<)63A!PETET"=[I[(J;QF MABUF2FZ)LM&(9@U7JLM&<;RQC_)@%'[EF&<6*X7OJ\PK84U!;GYWO,6.&W+^ MC:T%Z.$L,$AB0X-\![CL >D'@#&YDXVI-+EI"BC>Y@O$'4$L#!!0 ( J7W5# $KJ6P 4 ) 1 9 M>&PO=V]R:W-H965T07E3.FT;>RJ-3Y.->Z?C6=JC1G)5434;,*OBR$+*F&1[F75>'9FW]W)V9E8Z8)7[$XBM2I+*I\N62'6YV,\WK[XQ)>Y-B^FL[.: M+MD]TY_K.PE/T]9*QDM6*2XJ)-GB?'R!7UUB8A2LQ*^&17K"B,)=C'UXW1<;NF4>S.M];?6N?!F3E5[$H4O_%, MY^?C>(PRMJ"K0G\2Z_=LXU!@[*6B4/87K1M9/QRC=*6T*#?*L(.25\U(OVT" MT5&(W3T*9*-@ S%M%K*[?$TUG9U)L4;22(,U,[&N6FW8'*],5NZUA*\<]/3L M6E3+TPF1*0\"U0L M5!G+=O6GL+=V@V2[P4LR:/"&R@GRL(.(2]P!>U[KL&?M^7OLW0.NLU7!D%@@ ML:Z85#FO4N'DB_AUKP$=;>T8@FV /1S?"=QELNX;DKCH-)G(#@=GSS=<7!TXW*)^/7 MCKR')R$&N>VX(S\ ![^%@W\P'-@W#1%&.F-:?Y0=8;__2"()@7E^)LJ;5$X)"C#A0=+Y2L*0Z$ ^W JF:I7S! MTU:SV08$V<#U!5R\K+\/'U N"SJW3_!ES76^XXX64$,?H3G4B%892D59 F\X M+?B?#&5RM53].+H6M(((+J0H=Z-FK-12//*,F1TJ9KEGWF[6,2R")E2#*1@A M,3QE/<#[U_M& ^@,6G0&!Z.S,)5:FTK-VTK=A\M!B_VX[*]/HUM1G4*K_L*T MZ09=;G>;A8,J.#P&9&8@='[FBGG/S-JSTES"&![Q _ M@IGGA8[O)SWX.46GHP>[[A'R'!*"ANO:N0?S$&KZ #["%A_AX=6K<>49'+U5 M:]C>0RZ!0MT./FI[T*B;XGO(5'?5L@E@R\)"* 7\.T+'D>OX&*,3,P]#"$* M3@8\CUK/H\&=MIGY_<8"]H\!FW%K,SXXFG-:T"IER)ZL>B,Y:.L?\:P;V*N5 ME*9 74#\M D@H,T+'-?W[-P+7"=RL:%FNBL9@5P,H0Y@YH.4ZY'6V#6G2Z*#,XW/V_[<&@X[(21 M![,PA/W%P1"NDS83R<&94!IZ97,L-4"^A7JF:&'QBR%> MV/ 60V'Q_-$["<@V#6;!->0CB&+XC6-BE0SJT;%' B<,"$#^V',C2(2/.H39 M,,,VK@Y7X7IB#X.FIT&'-RUV:1O.+L&>Z70(F;#[? MP!V/3U*\#N(0[%PO\ M'[+I!6,_Q!POG"1>"+.8F)+=0QHH) X41CW\L6';V$8P7($>L=^KA G MAFYV^AU-7C,X,0%2C@D!@D:121P.(R7KAPATM*', MG:5,AR;$\"8Q 2$FPN1[DOPH1:#Q]I:@:>>2#&>UI?TK0"%KLKDOMV_;OQLN MFDOVLWCS7P6@<N>="PP7>3G-& 1)& +XO M!!QQ-@]F@?9/F-E?4$L#!!0 ( J7W5 .IN&VF0( #H& 9 >&PO M=V]R:W-H965THRP5W!EFUU4ES-L,I-Y,@CC8'MR7JP+=030=UV(%#X!/]9VA7=2Q MY&4%RI9:,0/+27 5CV8#%^\#OI6PL3LVR@/:,A;$@ZG,Z&>V8T6RK*31[&08$_'$1*QK[TWU7^N%I8-/0R_#S"V^]X^YZW?X#W@7HD7TM@>LELH0V>(9B*7A.Z3M)U M^Z0\RNAZ<&1KD<$DH":S8%X@<')DA=?C&C*H%F#V),J M$7+FJ_W DOXP3 ;<60,>#CCOS1]G\\9[<9&$G'-:AV[=$GA?[$Z\M[-ZCQJ% M)*8XO(QYR^KLH>-E1Y0<=$H.WJVDU&KU#B&/$OY/(=,P31-7=J[ 6M' MU)O&@$)6TU-WXV5_WNRD 9^RDP;-3CLMS_QOGW;13C]78%9^:EF6Z;7"IK6[ MTVXP7C7SX$]X,U6IXE5)K[V$)4'Y^4=2S323JMF@KOUT6&BD6>/-@H8[&!= M_J76N-VX"[K/Q?0W4$L#!!0 ( J7W5 FHJT&PO M=V]R:W-H965TV:O)KN1*6AS_^YZCO; FQJ5)^H!7EW.^..%I)]45G MC!GRM*D93RU3D@\#SAH." M.[S0+-WR1&5P8G!PMZ8+=,O-Q M.5$P&[0H*2^8T%P*HMC\V!G[+T\3I+<$GSA;ZD;$[+ MW-S(U5M6VQ,CWDSFVOZ2544;)PZ9E=K(HF8�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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 360 409 1 true 97 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://metuboutique.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://metuboutique.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://metuboutique.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (unaudited) Sheet http://metuboutique.com/role/StatementsOfOperations Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://metuboutique.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) Sheet http://metuboutique.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Collaborative Agreements Sheet http://metuboutique.com/role/CollaborativeAgreements Collaborative Agreements Notes 9 false false R10.htm 00000010 - Disclosure - Inventory Sheet http://metuboutique.com/role/Inventory Inventory Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://metuboutique.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Long-Term Investments Sheet http://metuboutique.com/role/Long-termInvestments Long-Term Investments Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Notes Payable Notes http://metuboutique.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 13 false false R14.htm 00000014 - Disclosure - Bank Loans Sheet http://metuboutique.com/role/BankLoans Bank Loans Notes 14 false false R15.htm 00000015 - Disclosure - Notes Payable Notes http://metuboutique.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 00000016 - Disclosure - Short-term Loan Sheet http://metuboutique.com/role/Short-termLoan Short-term Loan Notes 16 false false R17.htm 00000017 - Disclosure - Related Parties Transactions Sheet http://metuboutique.com/role/RelatedPartiesTransactions Related Parties Transactions Notes 17 false false R18.htm 00000018 - Disclosure - Equity Sheet http://metuboutique.com/role/Equity Equity Notes 18 false false R19.htm 00000019 - Disclosure - Loss per Share Sheet http://metuboutique.com/role/LossPerShare Loss per Share Notes 19 false false R20.htm 00000020 - Disclosure - Lease Sheet http://metuboutique.com/role/Lease Lease Notes 20 false false R21.htm 00000021 - Disclosure - Business Combination Sheet http://metuboutique.com/role/BusinessCombination Business Combination Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://metuboutique.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Inventory (Tables) Sheet http://metuboutique.com/role/InventoryTables Inventory (Tables) Tables http://metuboutique.com/role/Inventory 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Tables) Sheet http://metuboutique.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://metuboutique.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Long-Term Investments (Tables) Sheet http://metuboutique.com/role/Long-termInvestmentsTables Long-Term Investments (Tables) Tables http://metuboutique.com/role/Long-termInvestments 27 false false R28.htm 00000028 - Disclosure - Bank Loans (Tables) Sheet http://metuboutique.com/role/BankLoansTables Bank Loans (Tables) Tables http://metuboutique.com/role/BankLoans 28 false false R29.htm 00000029 - Disclosure - Related Parties Transactions (Tables) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsTables Related Parties Transactions (Tables) Tables http://metuboutique.com/role/RelatedPartiesTransactions 29 false false R30.htm 00000030 - Disclosure - Equity (Tables) Sheet http://metuboutique.com/role/EquityTables Equity (Tables) Tables http://metuboutique.com/role/Equity 30 false false R31.htm 00000031 - Disclosure - Loss per Share (Tables) Sheet http://metuboutique.com/role/LossPerShareTables Loss per Share (Tables) Tables http://metuboutique.com/role/LossPerShare 31 false false R32.htm 00000032 - Disclosure - Lease (Tables) Sheet http://metuboutique.com/role/LeaseTables Lease (Tables) Tables http://metuboutique.com/role/Lease 32 false false R33.htm 00000033 - Disclosure - Business Combination (Tables) Sheet http://metuboutique.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://metuboutique.com/role/BusinessCombination 33 false false R34.htm 00000034 - Disclosure - Organization and Description of Business (Details) Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails Organization and Description of Business (Details) Details http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness 34 false false R35.htm 00000035 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Collaborative Agreements (Details) Sheet http://metuboutique.com/role/CollaborativeAgreementsDetails Collaborative Agreements (Details) Details http://metuboutique.com/role/CollaborativeAgreements 37 false false R38.htm 00000038 - Disclosure - Inventory (Details) Sheet http://metuboutique.com/role/InventoryDetails Inventory (Details) Details http://metuboutique.com/role/InventoryTables 38 false false R39.htm 00000039 - Disclosure - Property and Equipment (Details) Sheet http://metuboutique.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://metuboutique.com/role/PropertyAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - Property and Equipment (Details Textual) Sheet http://metuboutique.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://metuboutique.com/role/PropertyAndEquipmentTables 40 false false R41.htm 00000041 - Disclosure - Long-Term Investments (Details) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails Long-Term Investments (Details) Details http://metuboutique.com/role/Long-termInvestmentsTables 41 false false R42.htm 00000042 - Disclosure - Long-Term Investments (Details 1) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails1 Long-Term Investments (Details 1) Details http://metuboutique.com/role/Long-termInvestmentsTables 42 false false R43.htm 00000043 - Disclosure - Long-Term Investments (Details 2) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails2 Long-Term Investments (Details 2) Details http://metuboutique.com/role/Long-termInvestmentsTables 43 false false R44.htm 00000044 - Disclosure - Long-Term Investments (Details 3) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails3 Long-Term Investments (Details 3) Details http://metuboutique.com/role/Long-termInvestmentsTables 44 false false R45.htm 00000045 - Disclosure - Long-Term Investments (Details 4) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails4 Long-Term Investments (Details 4) Details http://metuboutique.com/role/Long-termInvestmentsTables 45 false false R46.htm 00000046 - Disclosure - Long-Term Investments (Details 5) Sheet http://metuboutique.com/role/Long-termInvestmentsDetails5 Long-Term Investments (Details 5) Details http://metuboutique.com/role/Long-termInvestmentsTables 46 false false R47.htm 00000047 - Disclosure - Long-Term Investments (Details Textual) Sheet http://metuboutique.com/role/Long-termInvestmentsDetailsTextual Long-Term Investments (Details Textual) Details http://metuboutique.com/role/Long-termInvestmentsTables 47 false false R48.htm 00000048 - Disclosure - Convertible Notes Payable (Details) Notes http://metuboutique.com/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details http://metuboutique.com/role/ConvertibleNotesPayable 48 false false R49.htm 00000049 - Disclosure - Bank Loans (Details) Sheet http://metuboutique.com/role/BankLoansDetails Bank Loans (Details) Details http://metuboutique.com/role/BankLoansTables 49 false false R50.htm 00000050 - Disclosure - Bank Loans (Details 1) Sheet http://metuboutique.com/role/BankLoansDetails1 Bank Loans (Details 1) Details http://metuboutique.com/role/BankLoansTables 50 false false R51.htm 00000051 - Disclosure - Bank Loans (Details Textual) Sheet http://metuboutique.com/role/BankLoansDetailsTextual Bank Loans (Details Textual) Details http://metuboutique.com/role/BankLoansTables 51 false false R52.htm 00000052 - Disclosure - Notes Payable (Details) Notes http://metuboutique.com/role/NotesPayableDetails Notes Payable (Details) Details http://metuboutique.com/role/NotesPayable 52 false false R53.htm 00000053 - Disclosure - Short-term Loan (Details) Sheet http://metuboutique.com/role/Short-termLoanDetails Short-term Loan (Details) Details http://metuboutique.com/role/Short-termLoan 53 false false R54.htm 00000054 - Disclosure - Related Parties Transactions (Details) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails Related Parties Transactions (Details) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 54 false false R55.htm 00000055 - Disclosure - Related Parties Transactions (Details 1) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails1 Related Parties Transactions (Details 1) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 55 false false R56.htm 00000056 - Disclosure - Related Parties Transactions (Details 2) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails2 Related Parties Transactions (Details 2) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 56 false false R57.htm 00000057 - Disclosure - Related Parties Transactions (Details 3) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails3 Related Parties Transactions (Details 3) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 57 false false R58.htm 00000058 - Disclosure - Related Parties Transactions (Details Textual) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetailsTextual Related Parties Transactions (Details Textual) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 58 false false R59.htm 00000059 - Disclosure - Equity (Details) Sheet http://metuboutique.com/role/EquityDetails Equity (Details) Details http://metuboutique.com/role/EquityTables 59 false false R60.htm 00000060 - Disclosure - Equity (Details Textual) Sheet http://metuboutique.com/role/EquityDetailsTextual Equity (Details Textual) Details http://metuboutique.com/role/EquityTables 60 false false R61.htm 00000061 - Disclosure - Loss per Share (Details) Sheet http://metuboutique.com/role/LossPerShareDetails Loss per Share (Details) Details http://metuboutique.com/role/LossPerShareTables 61 false false R62.htm 00000062 - Disclosure - Lease (Details) Sheet http://metuboutique.com/role/LeaseDetails Lease (Details) Details http://metuboutique.com/role/LeaseTables 62 false false R63.htm 00000063 - Disclosure - Lease (Details 1) Sheet http://metuboutique.com/role/LeaseDetails1 Lease (Details 1) Details http://metuboutique.com/role/LeaseTables 63 false false R64.htm 00000064 - Disclosure - Lease (Details 2) Sheet http://metuboutique.com/role/LeaseDetails2 Lease (Details 2) Details http://metuboutique.com/role/LeaseTables 64 false false R65.htm 00000065 - Disclosure - Lease (Details Textual) Sheet http://metuboutique.com/role/LeaseDetailsTextual Lease (Details Textual) Details http://metuboutique.com/role/LeaseTables 65 false false R66.htm 00000066 - Disclosure - Business Combination (Details) Sheet http://metuboutique.com/role/BusinessCombinationDetails Business Combination (Details) Details http://metuboutique.com/role/BusinessCombinationTables 66 false false R67.htm 00000067 - Disclosure - Business Combination (Details Textual) Sheet http://metuboutique.com/role/BusinessCombinationDetailsTextual Business Combination (Details Textual) Details http://metuboutique.com/role/BusinessCombinationTables 67 false false R68.htm 00000068 - Disclosure - Subsequent Events (Details) Sheet http://metuboutique.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://metuboutique.com/role/SubsequentEvents 68 false false All Reports Book All Reports abvcd-20200331.xml abvcd-20200331.xsd abvcd-20200331_cal.xml abvcd-20200331_def.xml abvcd-20200331_lab.xml abvcd-20200331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 85 0001213900-20-016186-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-016186-xbrl.zip M4$L#!!0 ( J7W5": H&UL[+UM=Z-(LB[Z_:YU_P.GIGIV]UJR&Y!X4?5,G26[JKK=[;)]RJZ>,_=+ M+2RE+'8CT "RR_O7WXA,7A($""20D,0^??9V28B,ER&9 MN)[IV/]\(YV+;P1BCYV):3_]\\W7^[/1_>75U1OA?[__?_\? ?[G'__K[$SX M9!)K\D[XX(S/KNRI\XMP8\S).^%78A/7\!WW%^%/PUKB)\[_O?AR#?]D[W\G M*.?]L7!V5N)E?Q)[XKA?OUQ%+YOY_N+=SS^_O+R*X?WGG8Z?? M@2[IY__[^?I^/"-SX\RT/=^PQ^1-^"O+M/_*^ITT' Y_IM^&CZX\B8.'8_1_ MQJ\?#2]^,Q)8\/P*)?#MQ(]^P#^L_,R^3#QJ9CZJLD?-\-$)23WGD?'YD_/\ M,WP!STO#,U$ZZTOAXRZ9YI*L_@S?A@^:GC.0):V(/_9$^(.E=_9D&(OH!U/# M>Z0/!U]D$ /?N(Y%O,S?T&\R?F0[MKV<9],U\=V?_=<%^1D>.H.GB&N.H]^M M_U'R!T #?IQ-'?TF@[JQL[1]]S5;)<&7^#,M];.EZX(UR?M=\&W&>.3[>);] M(_PF2WR&.?:R?T&_RB#.,\?9/X O\'$I];CKKXH,/LP@AEJ7Z.$Y\9>/SM(W M_[,D8*_F/X=&YTUH3G *OO/H1/]"I@*=O>]F%-/T56>QF?(F;X+O457_?..9 M\X4%<_'G\%W,OHP=VR???<$$,D;>[11?<";VS^)!HT>)[9O^:_1I]+DYP6^F M)G$%2AI)P"R4U>75'V_>@WF3) WHZ__CY_2/X^%^SAPO&&T!$'4F&510:^._ MCQF(A@B^2;\_\:;PPT >ZX2$$!F>]<5OXZ7G._-OE\Z$/!/+66.38#6H6)"4^R)3ZP6^\> #^WTY'K M&O8396OTW?3>O*> >U?$^#]^SAR#I^_G; *WA4"HGF8@<,G^_C;ROMU.O\GJ MM\_&ZS<<]$$4O['_'FYS/L^298>>]J%'.9/5)@U(:*1" W)A.I],U_,O'7?A M@&\,,CP._7\A%CC+DSO#]5\? 2>,4;F>!3D\KX_"#2[AGQRG3D; UT'WSG8 M11>$XOJX&7H?LQ.I)/INY6>P8^-^Q,LY_*9..4LZ+@9,SNQO6+<#>(+IM2SC MD:+NF7!6ZC@F7X[Q#;\N9G[7LX\'4ZBS2F *E=L,F,)5_Y(9;''P[1-YQ.5= M32S[HI[U>>:R?S\S7/(1MBGXZ2A<_1[ GR='#3]F]==ROU?\J6>B?"8.JN&/ M_4C?#?ZDSNT\!K%:U>BEOM8DE-,M5Z3S7%GFN!^&(%:'HRQ.QR2E" M*)OQ#C\YCKS".?+P]S#$SU<;E+QTR026R6?B^N:C1>[@5Z;G.>[KC>,?B4MU M/W-<_X&X\P_DT<=%CL=262'LV[.OOL8%VFX&74%(MT/4X2"*"]:EH+&+8%T' MC8. QKZ">!U,#@ F!^'QE-EWC>"?KF&9QG& J<*N*\5YAZ _"F70 MF9(RIJ2#4@;-;,\*2 MB(/CI@KYWMI TS5)UOJ'CHV#S:&HGCFF-9DY%D5B)#D^O82_Y4%W?:"M* J4 M537B0K6ZDV6IRYMH0][$SF\= W)-#(_,'&MR-5^XSC.53^"^??-<_]MGTS;GR_EQV(T[UP&9 M^J]W%H@;F$>GED+CXC4=]R\IH_4@*D,?"/K=%YKG3"G ?R;DWNW FD2X\;U# M^#X0SLN]0WC50-5G8SR#+;?[RFOYI UW^'"!9#IS?:!@/CD;O5%VX?(ACB H-E]._)?F JR.$[%0+ M* =\-RWGP9D[]5U*S>RUU$7+ADAI)\)E?VV)D? MR\76TEC(YK\+/-8&I;ZNJ;*NZ$KTQXF Z\:Q48:N8UFPR%R!-%WBM2"#MX7X MRE^B.O/4!O.T?U>ER+:HXOYBQ[L%Q(-+#&_IOIZ ][(Q%$X-$VU:9O9\)M*M M%ZU;+_82\EQG)"3U1 #1JO6BI5 X-4RT<[W8=T7""].Y-GWR8)@OQNE<%Y(0*JI;3"L(\E]%Y4 M1S";Y6-=:G+4_G!Q>2KJ3K!Z8FJF4+^PC9-0=(K98U5UX *H6#0T< 'HW[*> M9=2O'<,>'5>=DM+6/8/WO3H%@V1F'(][@.;G'J9Q*&F#O;U#K;E [F#BO? M5 UTV^C:UN&GK?A)9I[P0&@J+:D"$+JU[037MEW $-9/[4P:\J<,"9$?R[6> M=><-64SOUZU!M32]9=>X+7L'@Y; (+U)US;9I//H:22?0>,.,^C?DMRAIX7H MJ7Y\$6BSZ1!/AYB6(":Y[/"JWZ?'<5H>[\90.!)7MU%_IYK-Z8!W8L!KSN+% M5>"BU$_ZMZ1W"U\+%KYT;;OJZ9^!-IMTM(M2SKOH86NBAP>1A%Z(IMA9N+-Q!?G8>8L/<.>/) CN7G9R$6Z\L$> M5#0_XAII=]C>^,9GA^<.SZVXK+@A,$\KSGYX0#V. /].+G9JV![K;F\Z#&&R2!S%HN+9#.;0<7_N[O=G*MO6[2YY$\G!KZ@B\+-R.J5E= MJ^"VS^YTNX7;2H4LUS!!%C;Q3._"='PRGMF.Y3R]7CK7_I&THLHI?.1=O/+? M).H@E9#*2#%2\==.*Z!XC]5;*T5R>D: MHPXM[4?+09HA$-YOSH+\ 4:]P]2[(FF*8/UV3TB&@,Q?Y1ZG),OFL M<].ZM>A(8=3Z16?3DOF)MDX-H4@2X;\014"DW*&HO2BBRJJ,(M3JKFW1WD!R ME+,U+F&LGB>4L$&M'EO[-LJ5&KHOGPI0_?H86\[['\^) M28WF4:E<1:(.%&T%1;I ?O7Z1"DL-56?*%F06E:XEFZ693S2%?"9<$(_:BS% M+1Z+F-\KF#:O2!V7^FP$3 JN@@&8E-2NI#-,K31,@M^.&\ M':7)WL.QMZ-SWH[>@:*-H$A[._HFWHZ^Q]N0'99:B:46AF"S3VQ&X[&S!#;M MIWNP@1/#G7B7S@1T.3Z"X%EP5ZJ8Q<2UJC+2.-W#G7\O#9J7>HK1U5S>.S-3 M$44CSSQ=&.4SW^&H(HX^+E&.OZ,\3P8^*SQWJ*F(FC_(Z\(Q;?\ANE5Q,N#) M8[W#4%4_R/%FINT\+F\GAND:)P.@3+X[]%1>MUP'W8 K^YEX/MVXVI-/IFW8 M8^H5'/O-M^1Z5E(6'D"O<'1O!/ MU[#,TUGC+ MW 'B3,]SW-<;QS^2ZV:%9;"XX(/I6^"T7-D3\]F<+ TK%;>(F-SKNA(HHMJZ$FBL M4?^D&"'7YJ%;BS(0B;GL,)+ R"7[^]LE X0L?OMLN-\PO_-!%+^Q_QYNO\G2 MZN>'?&M0Q7V!7/%V)OM10TY@2A'BX-LG\KBJ")B[&9]G;>J^W<\,EWS\/I[1 M4JTGE!];Q/A>I[]*9_*@,NIV-OT;0]WML13'V !XMVVHC7'"V'MX<4X6>Q'O M'?;V@KU/SM(]6?#%S'?H*T2?E(T^2F*C,^T,_\/'.AS!/_:6P1UG*_;_SU-S%F.TO3ZPQ8ZPS8;C-U\$RE M?R;K)Y=47FA56IM.GCP,0\7M$AQ!(K1I/YU2^#.7Z]-2_NE=!"BHT-NB>P&[ M0D7HN8Z\;[?3;[+Z;;1\RCC8ROR\'P<>2F2*YC._S]UP"S..\]O]W6&WLE/" MS"K31[_QS>P;T-U4W/M-Q71V^"YN**')_/5$+Q;D\GZL%J#$K:4'EQC>TGV] M]YWQ7\>!A'L?@("_9P=_E\Y\X=CP3R\9#B>F#S(7VL-]C@6)GRW72.0K)8M'SH M)7%4)((.4"4!=5U/C%.N MC]6Z\EBM/;[HD--"Y.RW2N>%Z?SF+,@?L-RM2&*@Z?VA*@Y/ U%8C@M0%P_ M/GWUC%/*@DIQ?-SJ3J= =>K>WRELHRE/ZPNK=MEO>\Y^:WE)U?4[CTO#GQFO M%[9Q+-&FHEJ9:6:['49.4D]W8MN&$]MDMD_C;D5WW-KRX]8]XZ$[*]W[6>F> M$= ==+;DH'//..A.*4_7*^B.&%MUQ+@?-!S8^>#NA:2>]<5TD(;:C+NE.YX9 MWDD5HBXC@/W.&U17TY#0ST2E@\3!0 +5U7!8E]8K#,.ZXIFT H]3/-3-Y7W/ MH=U$<35.UYF+#,^0,#_PWZ&!R #!)&Y[A)H9GR/48:,KP M=(@Z$$0E#0\/C5WDP;'C_J^V"5N.:\>PCVR#72+5(9?W_0%A%R6"BE*FNF+( M[6D$U]:$*2R2$.%'Z_#35OQHF^!'VP%^"NQ/6*/^E-"3PW-G>RK:G@X[[ZW^[G4[-,3GP%I\%E1_Q MJP2/>PRD[*&'3,#Z_HNB-J=A-OO3C)ZDF@^^!4=9-;>AWT:C:LX[""[NM^'/ MR/75[9B1WTWC:"['%J(FQ6N' ME9)8.;#+4RV7,Y^.>G"R32=F-IP6DU4Z-FR#A!=Q[I>/WM@U%[@ ?"%C8CX; MC]:!Q_Q*WNT,^K*ND\*^C5S+*IMF%R3KL-1*+.VV4V-G8 X-%#NX&IW.T.U MT7)0[*2>I4K/0 [8=PL8:-1WHR:;3]*0-2YH>FWZY,$P7PQ[9$\N9\1^NIR9 MQS&%RMT9+A# GM,WI.H]V@+]-KHQI0>/$9X0OQ&>?O.65(C.R\D@*,WRGC%# M55,5,U2'36*FJ(YHAYFNFFA5S%Q??/AZ/[JZN3P9R*0X[A!3%3'!0?OI ";! M<(>7BGAY\);VT_W,L&T\J9B<#&PR^>[0DQ,35[B8N,+YP7BLGGTN&CYQ\W R MD,H7QGI>9QL+4<E5\ZDKE%(6QN%5#]<>&0^8,!W\XU76GV[.AJ'[\ M%&BP24.1#M30:]S'#)S+$FQ#V2-.D2*L_A_+C5 MWSF1+7,B5RI0RXVJ7\>:CXE&&)TWN'=OD*JDX3B4Q->3D3H([!\"Z:2DC6K* M2!QRFMH^=FAI 5J2VT>I70;C! _?-H)$&1H.XM2M?>8J+^PAKKBZIP11CN$# M#7J(S49'.XSL$R/)S0^O[$8V/]I**+Q3]EZ4K>T@ *YQMS,ZQ;=F)= VN7VQ MFT*])?%RFLYN)?P_@JX?N&<+A\-CM)9;O!?9X^<^2 M?"#1[=%4WX9\171@K^RW=0#O -XBIU,DPLC>, M)%T27MD[Z$$-?R>KS'>*WU"QT!7/1 M7>)+> "5E<"^H55]*QRHNNEU9Q,X2:HBZJ(TT#M<[7>M4ILO*Y.J/!P[*;]? MC6Y^O3\.^U)BI>+9W;,QV;2J<+-.;/J^;Q=[W9-A:/9V;UZYF#BUO;O/?UAE M89JZ^+"^1&=7$F#/)0%:7J8S>V'I-LE'O+ 4F8O.X^P,0\H)D<0S60F<$/Q[ M>&J1D?N9X_H/Q)WC5A93$P]A$YMR7*@2JSHN5-L-G]AUB#H41"7.]Q+0:*JT MU>!,5**TD>_C&98=CM/0@\SK0*;?L,$7^<\2OOGX#/_KL($25%JFO-HD$37+ M$\1Z.%1":%*:,49S'M@W)$.X-.TW#3B_J8-G!\]*'E[E!/ TJIO:^@VXK)D. MR1V2UQK:9G-[5@UM!\\.GLT;VJ;2$]>'7;I&O:ULU'L8(9I4LM.:DJ"G>U7U M9,N[;99TU7AZO\;AEOXMJ]W!]O[QHFV"ET!_NSRCNK[X]>O]Z&00PK-[NN=3 MG6'H'*#LVX:2$M\VE)4T7DZQ45\N[_M>7E!9E9>7(7> M0,WNLO#; %6-G1= MFZ_8!H3IW)9+YRQ.=X;9XC/,-+KT339&>M.6:*4D2[RA[]!U*.C:O'A+\[?J MAQRZL!Q$5';/\&<&%H2#!>+:,>*:;R< JC6\[QM+U2LT!+IM.'^GPT\[\9.\ MC<\#H:E.9!6 <&PQZ&:!<M/K5QG5G];"M3$4CF?%:AIX+*@N#=<"[RC3 MFP[4(H5*V^4A6 >2@P!)+0=F/+::.DDOA:?4:M?AZV37PEV8O-5ZGXES_ZY5 M[;X-VA:5/YL]CRO*&,%;W7N,/-,X&9 D M&=[C)DMOLI-/=N9@I^P]>A'-90\F0CDK78"[#+ ]9H"M!%6:;E>5HJ?A8X<.H:>*T'11#:FA"@8Y M5R@2DNZ@=22.T.IA.([7.44M,*%57)Z6J\)YA\)NZOBT(=\1)DH&E/ M$<88A%/P 66!B.R4QF,O)QWT-"0QKT/7,Z;' R)]?$\&C5]*OYPG6>CRGY%59.D)K_>F>!0(%5]-X6^+Z+U_3" M6U(B^PT9[0PFH0]_;=B3$X)"^'#,]HGI^[,QGIDV<5]Y"9T@ KD<&*(N)U. MS3$Y92QD2N!$4!"Z"ZX!2R.QB6=Z03=SV[&7I MV(^6"F# ,7]:6C^UD^EB4]".@^J6(D(9RK(D#H\4&!T2LE>$4S$,*ZO!R2@_ M^S985A784\1":VQ!+3?#=I%=D(>BSIQT^*F(GVXY.B[\-%\IM@ _W2IV)*O8 MSA(:NKRX \B+VZN;W,'D4Z9.6H_>'B\E34G6#UQ-1,H7YA&R>AZ!2SIZCJK@Y\V^K [P(("1^Q T([ M@;"3R^=Y&X<.%*T!1:44LH6#V/ RE5^F!% M3!^KEP1_-,UK!/J;Y;#^7CQR4"RGY.7G,W]Z M(/CU1+W]7-Y/"P*XZ;%/><>7S?QI@0![5)TJ!G)Y/RT(/,S([S@9CN2HN(3B M4QR?EKK_,.[IF/(NK M^'1>?2M?8U# M22GJ4-,FU.S^AJS,&9#CZ!%!']=LJQE;X%4,3\7FUVH+-J8 J4VZ3-3ON$IU9MIP45=F(KG7;S MFK+2"F>EX>_^@5MI91,KC7PW:J55U&4@9_JW?&C=QA-R#MBI)N> [T;EK)Q) M8BAG^K>TOQRV&N0\QD MO LOE' T.LSL%3.[I"T <40&S\;"J]1M PVL?YPG)> M"3FQZ&&*[=-:'SK%MT#Q>SN>#&.9H22.J9C%\M$S)Z;AOMX;%KF=4M:20Y2/(WS_6_?39M M<[Z^OBJ2\;Q]* MDIOTH9(0-+Z?, 1YYCL([@&"QPRX#@IEH:">R>J!.1M)(2$#37MG"N>=*?SN M![<*Y#]+H/_C\_&9BD_C6]ZSD"6M'?P3/BR\*OD$/BVG/?3?$4O=XA 7O2AC<< M^KX!Z]_N\34K0TW,9T#2JGCQYS?+.8'ET\GPW"J((4UFUENY03\0VYF;]KIA MUXLF/6[6B\/O$U(H(=/%,D.42=+PD?(Z"Z<6#4=R;HY)O,NEBW451_8$2VVR M?P@!;+^0:3J0_T; ]](O$+W"A(S-N6%Y_WPCOGFO24H?2:6L\!/C%3^7)$0^B+] MG[U((77H4C*%M(@;213WR,^*5D?+)]2>FM9JQN3#TC7MISNZQE%3[]V0%_J5ER"RQ"' :N.3F)5@Q>*X MN;KY% @^9J<<7;OBIN3>+35QO M9B[@'6.Z6I*B52E4B6N8]):O9WJ@'I^,9[9C.4^OE\ZU/UEAC/I$:;;$<]BX M:#%7I>EKDC$L2K7 $L0!5ZM7N$MPIW+ MDCA8SY6D\(ML*[CZ@C.JK%;ZDBKMC?ZD;P>F^A-Y7/7MLC_/].VH[?KX?3RC M9P>AQ_[PXI05AS;4Q#VK$R\(Z7RWL$R>LKS5/)[V/>U6*M8>B]G/*K=_^&:_ M2H'A@S#[:88.QT 6%_S>0!MU+5=!.M,%"')J^AYL(:F9NC \,L'N'<3V*%TE MMU*%.UG>()<=MTZ"LQSQQ@F&I?$9M #?!/ED'TC4*#%S#;UDV! '32VB,_@C M/'X0SV6EKYY-'?>,FQQ%-&_,7Z #G;O@R/X>AM/AJ^V1,?#*_DXD0$R7:8O/FI M)WC+Q_\F8U_P'<&8_/>231'!<84?37B;+OX@.%,!WQ&_TIE.">ZGA 6^)!AA M9/G$M6F((&,<&8.TN@AGP?$S+! MI]XJHM@3@4%_9@"58Y"+)[S,B$W?OC!H*S]/%< M U^4P[,070.W^#"G(>,^Y< 5CC<>..S%L8/[%A$<_C>XOA-']I3#0Q#-9 M["4X<;+-_P&>;<*ACK()% P/W_6!C-GQ5%_J"3BOZ4,(KG/AUA9^-^REX;X*,OT6 M2>9>0V@+J@F2",(1;/(B1-%A)G@<%S^F SX2 Y1@!GVK!/A:!M0@7 S;7L[/ MA0=.&H @RP)%O:+@4^3'"@?6QH8W ]D%S*+N\8><"A%]]MA<@)#P!: 3%W;Z M].^EO3#,24R2PR3U\$(L0.>/DOR3,( ^"9XQE%%B=1D4I4HF(> 8V6H(0RYF&1%+*-&*<&B1,UQ18_+!.E M\01//"%UG 28W!;6THLD$;%/OJ,9)O -H.=M7QGT-%GNT;?R%-&!)Z@7E $) M%?0;*P9"M1.-#'*1AG)/TP?,)GBI^?M?&/'!$([@H?%C@[T8:(EADL&;8?T& M?CU2Z37G.[/%ZIDLA[88_M8Z6[R-+?Z#O"X<@.-VECCQEO;9X223&UKAZ"4[ MM<'1J"VWP"&=.[6_T:"U6%\9S)TNJ]M;7V78DP;*UM:WPFMV9'V'&!Z*=R/Z MF:QO:'W/E:V-;R^ROEJ-UAG)=;AS8)24OEC2H,#J'DCZ+8U4QG.BR-BL#,&.^83[ MW9J7(6=>X+]!9UXZ\[(C\W)Y?@W_;S<6AHU5CY'1A[VA-MC>R*AR;RCJC1J9 ME2'V8F0DP)82%H^ OS>-YG5&IC,R58W,-2&\A?ELP-0(S(LL[BZ&HG/Q;/#B ME2Z&LDT,Y79BF*ZQ702%>T?[4 O$N::Q?FE<#9K<8FT"8[C&3*9!6_OW$$;T'&)G L/"X]$Q['Z6-1I&'2XT'PNC[1^$@8+PN--2'%2CES/#=.>&?1!,A:DA#Y$M#GFC ML:. %517E&%C>@(3A4!E\5\>[%M E^[Y03#\;PO*6%U5V\A-]PX+Q=PV]& MKN_A3MO!%W"]80^<-03G^AW#"6T1KB\^?+T?7=U<=EL##OV_-*&QFZS^ZY0+\ZH]^Q93B,5U9UO:C+0OW7( (4+OG4E?EX&SX> MU&:@!Q3X=K!.Y_29\(OH WPZZ1$9PIR%L>!=CX[A3O"/2;#BT@!0B'CALW]D-A@9I6F*V8. MZ> ]'QP4/\-7(=U)NCS'SOX)U5- )Z-J;ORWXR*DUZAI WHO,:QX]CNQDR3G MB],S'REZ0DU.LAVC<\KQ9V)RFJ(O7]%?^LV'X2:BC;C#[3L_Z7XECOM$DQ/8 M7(F<1M[M#]3P%WG-1&7TXL.00U['H)&=O5I_2(GI9>;0R";&N5>%@?_.!?(? M*$$ \K9RBLHKD4?_RO9\=XDN\B=C3$8LS)]QG7?3^XOK2XYQY9YRZ-F"[I)Q MVD(JU6&B.%S]1&)W0I5+B;\T_)GQ^A5((I.L-JA%U,H#75::E6E% MZ-IG(=T[P/>F]\F*Y8V>0./X5LZDM3D8A>5X=X5F>1LJI=T8BTV,G*0JHBY* M [T%LV^S"TO[I_N@MFK5R&W?WH%-QWAGOXE/KJIR6^BL)&!Y5YZM5&8W4=Q+ M9<_R+\U%2OY;<+43[>0M1]4"AKM8D+*J0U8-:_;[\DXW/E4-MK2IQD>>1_RP M4\"F34%T41[PE<<3+]UTQ"V!)?<5<=!OB*8-,"3UU6%?K8F>4ATB=$V7^WK- M(Z[5BC*494DRP23154<\+&Z MAHC<9"V5Y*%2B3)Z=8?E-7BLHO&F$P[V^'TUT35G]=U;C;[=C%/[HJ3RU=P; MHFX#K9W)LB9K6NVDE9IR9^ E#M5!8X/7,N54597ZNM(XD9LH#U UE/4JI'TA ML-)D#1X1S?,)7;SGDMNZA)(F-T51.1]\]\YUM6O]\ TXZ>2/\7&'P MRB7+94F6!_)6#&?V*]I."6*_/VB,IGJ4\*OK>)A5/37]6N;"0)A3:4APS2,N&=[ZC&4"P(O!=MTYQ;@BA_*7AKNA$"5([!4OM1."4Q-"JG,X='[^ !G#P3*A?'H][&%;)RV(E.\ M7<93,(D&8!-V@M$!A]$!9XBRN8AMT2[(&W)SO&2VP?MXA[H3^E+=7U?H2XI- MW@4V)913K-7,D$*2+.6,WP3L#&P);>*J=_'G5=+.8!;,3M28+-I63!B3V(X( M2QG :'J&5__2MF\7"T?*?>$7CE6R@J5E-^M9REJ46L\"N34_ =)K1@VY! 'Y MVH;RY;HZLR[,HZ4_U#Y[!>JKZZ@ZI6HTC MMT!63(-@W3S7__;9M,WY.R^U*>;. M<&_=>UID[T\L-'='7/KKTJ=&WQ; %/U)=EO:3 +S1JV'4+3[?6YK6+YJ1UG. MI',U6_*[92RHSV':3X7I+^UGI*C:R*&P@E/]=CHUQ\0],,H#)03$9S73/B3Z MLQJ>@I?8T\]RYA81&RV[%1;9I;E:/D/&8SO4(6ZT75NY11)\K'(R< MO7EO_B20Z13K^AJL>+C@LG<)'GU/4+F>KYL?>*G^"46&\8:Q+ \L1\:@5KPQ2:OF/1(\"N7 M3"U:Q!@^3M#.:L9?T)(&Q@*+OP:T<%RL_(C6" 1B!>?1-\#%Q.H;]+>&M5JA MG2L1XF%==ZR;3ZLIWQ-:]D#0]'-9U/"'-^39F!@XENG!N B)I4\\KKQN"0C4 MAYI!W$X&@P?]H,1<(%56']D0QG@_ TQF4/>>Z@==B+! ?BR)?(4%!:+#G[ZA MF@[PF2W]L":S2_R@*P&=0+$4F6*9>X8ECJ_L"8;17N%=3TO+\!WX,W!M_5?A MQS>?KFZ^C&!@TYYBC#+'P<3;]HEM)Y0>?J;N%QR?X.>Z/+(FQ, MW-7>Z+*T^CDLD:C7_KDTD/8!:;I0QL<^=-&LBZ25;=,5,VM;A1B& UV75+U@ M<\9&V9R8.O8X.=0K:_:5=9->9A>30^I EW%"[AN5T F=47\9!L=ZL5@AQ##\X6W2M1&XD?#%K VFBS^$F2. MANT)@RX7]'W@%/Q[21V+?Q&3=43A%K#U&JA/:=OWK3\EI24[RN])9=S1 M5KEL[*2./'"-!$61J83CSE1I?7"%YH7+%6__XK<_P-T&G=$>,1XHWGZBDD95 MWSR\E94>[?T"FRK<3;P5SW6YA\X:?->7D]])YZ)"O_-?G%19NM_^H)-$5L#% MGIC/YF0)%@Z<X))N\3V6-?,,FTC43-&0"%M 487 MY'T N);.D@_)A9MU 'PKJ;&Y>CMDO>$R#$/877#+3JWXFO:V:0V93'9GQ=BE M/.2,VN]+L(+!![UJ,R,28]:T"$DXP7D!B 4(^:]WED$C:VCZ:%.YCQ[(%S)OWBO"*<(]9JT1G M:YGD$V8PL-)^+L-,N,_&&-8^XK[R+SYH_97F+*DTZ8"4QF)])=35/PJ>DHI2 M:^&)U8VG)O4"76\TS,3VZ%[ED^/>P Y@OK"<5U+/+6E%5L):]:7&K(?,RMU9?':"P*^<\GS/7'P[1-Y7#W?$_6LSU\7L"*.L(TY:[,\^FYZ M+!TB[)<;G=A7%;T?2F$M2X<@@?+,]VE:[U$Q7^7,YAB57^5$ M2!H.%#DV54?!_R=G6?I8454&?4D:#/8B "E; )*6\3FN=3?&G%"^65CCRL9 M$ZQQ^%W%,\!ZN!U-80>T;[17,?:2JLI:?RA+N1)(L;2% '(ON>E M]H$L#W=!>=M6*>"\KVM]33TBWBLL4KL$;0O7*$GM2\IPJ,A'Q'Z5)4H6%5BF M93G?26F._WVL4)*BB4K^$K6&V3"B=CL-A?Z%YAGO>VEZ+Y[+2E]EN98Q"8I09XF/<^, A)YC&5%_^EX]/C.!&+G MMCE]#7MN!JEW&)J/X_1XEB\I(HWRSV#R1X'[Y8*>4_;I"0)^2^/M[,B2IJ_C MUW_ M'HUYD8JHIS,8V>Y"NPE=&K18RQ*+*.!?,@$B H\#76=Y=,,F[.Z MK^QP$G_WV;2 !.+Z^)K(=\"35F[!HZM2?,I9; M;!$\5[DEJA>L45S^C[VDV2[PK*+*/25*_>EABLS"MFEL(WAH3.71_1 MS^04)(*;;%)OH.H]38GRH7Y\PR8FNR>7[Q[T4'3",UX!Q*0H492"5$D^-<9) MHXX7';N-99BAIN^"]*T8//3$?B*,ED^8'R.K-%U)#<:YOQN]^8E)^CZXN 0> M"OE.Y@L_/O,'#)A8D(C*R<5<+9>=O8;6QBP/C! M>(D'W_S42S 37-2"4?[^-TD5?[G/>?\""%M:3Y0O'V?&$EW3(-$K% #=^QV M!:\*)8LY$!3V[&/LIN0]ME@.T6_Q??3^WW=ZL&6]"F_E7E^A22;GJ(,$ MM-=:A O7_-.D"0<>>*'6A":6@%M)EQ,Z/5GV%/5&0Q<5DZ&R;EG2NW)$MRH:@S MV+*$ M1WBU,2'@00=9*\P,7-U\P#Q#S-Y!/ED:"DYF^J$?3&:6:-?0;-:XD!_]6];3 MN4,!)32C)7#/N>E')?M659)ZH/E%2D^//Z9;SQ'597#/=Y1A+Z2 PN%2M1^*_8!)/^OIN M* IX!#;A[A(3CX+KC[VB;=",6+3W>,J2(0 0F2!HO">)V=28@;F$MU)L>Z$X M/;SJ25$)I!.6/OCCA( ;9?H_E<)*E,.S]K*,J"8K5](46LI&:%RK7S>3=47C MKQL6W:593R#>E:F90&F@B7(M!+)">C&!*_&7J@VEWUDD1P@F4T*F)8/,"'\]=:M,(7*!?\ "\)ZI@=P\$8%K(.)3DUJ3=./;<Q579_F&;-QH2!;%X5")S@-* MC54O>94F?&$!_;XHM8"/]6:@4!_\N>P^M5%D'0K#'$-=[*O[8*%4PQC@5)*+1$K3VYJT_NR.I#Y MV_DY[]^>C&T[[2@#>:#MD,YZ.@R4'[^42>KWU8'*5XVM70PU=V@$>@>[)+>) MOA#<_2P\6O?P@@9_?LQVIAC->'#-IR?B-M"S).=$6U+TW!+"EKQ36:BY' M!'U)S:WIW4(1I,Z"JH'W^$70MKG 75%@80Q:SK!D#8HUW8ZY$\_T )6'+[SR MLB;#I'#!"8LI%]/)2SW.+@JD3B:Q(EC[:*E$??IU[76*J!YJNIIJNE.&JCJY M&7)':_1OKBLWO&SD^MAJ:^X@PJ_LL3\CUU>W-T?!VZ_5._'*NC@.E>/KKFMP?[%D!K*Q0M'Y+6RP_+3%G)9L<%;8C'O;W/MO+]T4JY$168.M\ M()QP69_!0/%)74X5^O0]X*$FI?OY[0&"I1LT%5IG79/Z^W=Y2O9T*M3*_M?. ME2Y0R;6S)".#'2V8_ %RO9N&O-3C_E"OXK(E"*R?O9IV$4?![+IM1=Y56TE2 MM(-@LLPVHV1Z2XNY++/MR$LOD76ERIJV/R;+;$-R)Z4\. Q-YN]+\EC31*G2 MAGCWO)6P)T-55%K$Q,;[EH.QEY7W,3F<#8?5O*^&.=MD7Y-W>V;8UUID&!O; MY^2QK_3%*ON#YB&[P;XGSV8.)%%N$6HWV0CE74R4!OWV,+;)QBC/A%:+_F0R MQLY;HF8_42.A-7< 5K"7U^/H,MGC*'I_N59$/>Z"0]PNB.L5Q*Y'8-%<6K!T M$5V?>G'Q"H(MV+!G&0=E-RNW-%J]@I+'3K*"+B-U2>_5&(4=B,*2OSFMO+++ M0O?".T[1I:?X8EM?TGL#7>G)BISSIH*RG2^$7EIB2=OL'H&D]=1AOZ?*2JE; M%SOMW50"NRN7*(/[;\%1[,B>_,O @TK? Q+NB?N,!?5OW4O+,.>9%>@*6@!< MEFL&FCZ^T77>6ZA$8.W<:1QW6AW<*8/V,%>@NO#>?A766L-7@=(VX2MU\-9: MWNC5_RJ,#=O$6 $8*S-6%U.YN2RQ6T%S5Y)^#7^=JD*+4NT\O4DJ-72M-%=- M_V@].]6.$UO.3H7CQ)9S4N$X\9 YV> XL>7L5CI.;#\O98\36\Y)A?/$YCG! MO'$;-Y"P#S&]&9G\ZCB3C>])# >*R$78LE^^,0FE%72GV6[A?+F#+2C:6 MAZ+U]4$&,3G#U$!6*1DIVE#<@*S@NJEE.2_HJH)C&OT2DWUI9 !^=OOH.1;L MY D\<^UL#B9)D_MQ">S*P]9/=2G92EJ_+VI;4QWJ9N1YQ/=N''N\=%UBE[QN MN4$V*@I[("DQ*M(CUT!9NW-AU;HO ML.9\H"5X[F@'T9RPR]:=DM?7?]7S_,H\4FME<.NNPJUF<"69(BX'61^#Z9/0 M'3,XY!B$_P;'QJ DGLE*>"T/_FY@#NZ3P3JZB;9]#F[=;;+5&@2F-. K9% # ME+:1P;"B^(,S&M,:@SB\]X6V[L1B#\VO@'DW.;EN9FMHK(FG&A>]C&" LGN> MZEWG,JLL[8.G&I>V+#UIRNYYJG,U:P?VZEW VL%3O6M6:WBJ<9FJGR=N;%S@ M2NRSZS)M23N0HJ,ZF>EM[%[(3/L(8RSQ2D:LHW/H,E2LAE(/(YHFJFJ^,Y-) M:)W<#3CN:BV9FG$ZTI<4?= :7FNLM9H1WY<4:;@OO195;ZD%M9(NZ8I<*W-BZ2]2TCC) 1+:^3673Y<7"8(\9JF1.4H4;E\A-U24K2.\$JZ M,.R_D@DAHX5K6@\ST_5?'UZ%LTHXCMD +!%&D^6"U;R0JKI9JKHT MK.=-X@]B]\N;AMY*O.7*L1?8(>NS:9OSY;PTDZ*F'2"3QO=*3$I26Y@LFGB; MH526"[RPG?-6@RTLH4ZUWQ*6PSYAQZC.(MYVO$:P-)[D3S\LR0>\1U:S?QYZ MTV+43SISV TIV\91C_VP)BC;QMUC4[\T97'&&U/^R)[@\S7V!E0RNO(E1ZF5 MENJS/ZL(LZ;OA^@\W[DX9L6G@]5,;>5&C'(RO7/'^KZPC55;F*E@OGC>#F16 M#RS[>R)Z(UBJ8G-(6"_BDD@8*G)&W])L*IDY96<$@?980[C<*PIQ-::*JE82 M-817ATR2]#'L%YU!3UX1 E&OA[;4V&E9X9UT-Y$$L/8V?JI80J$,Z45]C))B M@\KQ,N@9".^U">M:%]W-QU]S'3 ?B>'BM6YLMLKBMBXNQJPE94"V$,5TD? W M/V&7.<,*[\][2]K-#]LE+IB3)/PH_? 3O2H>-.N;$_96[(>Z?+3HG8.P?=V_ ML#/BO0_T^,+OSM*UXJ1%C/&,M MR8,* 6$O/HF5%U@M (!B2U[V9R_&3I/X*7!D8I-,[NH]\&2/S05V>[267D39 MTEX8)D=@T%_PLX%M!/U7@?HYR,X<7KUP"8ZP<%S6=] 5<-#@*CY5Y2.9.C#P MZBM0F4 .R!NDY;^>"U?)/I<3,C66%O8@M5,SN/9603R+2=$T9*7.R&BX@W??=9I-6,"1!/#,X!Y'Z-K6"1!8QCRPG(5 MIB=,EK2YX^W8=V $H4\!)8OGPFW8G3/\*%4ZHM'1JTD_-/"WH& #;_Y?XXG( M%_-IYM].OWJ$IH-O>BUC,!BJ.K<++ARD+HJB@'34Z^P>9ZGA3KQ+9\(*>Y3+ M[E8T3><=BT;)+W<;1QX,!DHM%(79W:^7:Q/DU[BULB;EDI0>I3::ZM-R7Y0D M<7<,E.O-(P[D@5XS3:4N0ZRYL#0<#@=KR>G;.)=?N!.L>T?%*-64;\+=L#IWYT61BXOL,ZPZ\ MV"O[TEB8OF&5*G@DR[*NRL%@<$2(J+@,2+JN'!7S M"Y?,B.V9SP0&<>9E4N]41=&5PS=]ZZ70!Q,/:YVXQDH.I=1EC.,72#G)]"58 M(@]7+EDNXT;31>N+1^0OK4.'I![W=-E ("4E UM$/AOJP.02G4EMN+1JZO" MO:LT\UMXFHJJBZIV1++8R-/LB]@&XKBFPR:KQT <](?'(X4'O)>Q=%_+FH6# M7RY6))#]RS*AE[XR5 _?+*P).2BRVC^ʨ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end